

University of Pennsylvania

Philadelphia, Pennsylvania

Reports on Federal Awards in

Accordance with OMB Uniform Guidance

June 30, 2020

Federal Entity Identification

Number 23-1352685

**University of Pennsylvania
Reports on Federal Awards in
Accordance with OMB Uniform Guidance
Index
June 30, 2020**

	Page(s)
I. Financial	
Report of Independent Auditors.....	i–ii
Consolidated Financial Statements	1–3
Notes to Consolidated Financial Statements	4–36
Schedule of Expenditures of Federal Awards	37-103
Notes to Schedule of Expenditures of Federal Awards	104
II. Internal Control and Compliance	
Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	105-106
Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control over Compliance in Accordance with the Uniform Guidance	107-109
III. Findings	
Schedule of Findings and Questioned Costs	110–112
Summary Schedule of Prior Audit Findings	113-115
Management's View and Corrective Action Plan	116-117

I. Financial



Report of Independent Auditors

To the Trustees of the University of Pennsylvania:

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of the University of Pennsylvania (the "University"), which comprise the consolidated statements of financial position as of June 30, 2020 and 2019, and the related consolidated statements of activities and of cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the University's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the University of Pennsylvania as of June 30, 2020 and 2019, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.



Emphasis of Matter

As discussed in Note 1 to the consolidated financial statements, the University changed the manner in which it accounts for leases. Our opinion is not modified with respect to this matter.

Other Matters

Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2020 is presented for purposes of additional analysis as required by Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. The information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 7, 2020 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2020. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

A handwritten signature in cursive script that reads "PricewaterhouseCoopers LLP".

Philadelphia, Pennsylvania
October 7, 2020

Consolidated Statements of Financial Position

University of Pennsylvania

(in thousands)

	June 30,	
	2020	2019
Assets		
Cash and cash equivalents	\$ 2,117,979	\$ 1,375,469
Accounts receivable, net	507,039	398,058
Patient receivables, net	726,081	830,935
Contributions receivable, net	478,150	488,450
Loans receivable, net	63,398	72,362
Other assets	872,383	385,798
Investments, at fair value	16,870,116	16,499,386
Property, plant and equipment, net	8,778,085	8,028,992
Total assets	\$ 30,413,231	\$ 28,079,450
Liabilities		
Accounts payable	\$ 313,884	\$ 346,986
Accrued expenses and other liabilities	3,646,811	2,495,808
Deferred income	189,920	192,302
Deposits, advances and agency funds	220,114	190,078
Federal student loan advances	51,822	71,265
Accrued retirement benefits	1,968,251	1,651,685
Debt obligations	4,456,160	3,706,493
Total liabilities	10,846,962	8,654,617
Net assets		
Without donor restrictions	11,366,361	11,392,252
With donor restrictions	8,199,908	8,032,581
Total net assets	19,566,269	19,424,833
Total liabilities and net assets	\$ 30,413,231	\$ 28,079,450

The accompanying notes are an integral part of these consolidated financial statements.

Consolidated Statements of Activities

University of Pennsylvania
for the years ended June 30, 2020 and 2019
(in thousands)

	2020	2019
<u>Without donor restrictions</u>		
Revenue and other support:		
Tuition and fees, net	\$ 1,176,737	\$ 1,155,894
Commonwealth appropriations	35,144	34,518
Sponsored programs	1,074,494	1,022,338
Contributions and donor support	210,894	188,805
Investment income	744,911	675,865
Net patient service revenue	6,803,782	6,932,160
Other income	1,203,185	931,484
Independent operations	60,819	77,047
	11,309,966	11,018,111
Expenses:		
Compensation and benefits	6,313,668	5,991,191
Depreciation and amortization	535,003	540,235
Interest on indebtedness	87,760	94,810
Other operating expenses	4,008,255	3,872,702
	10,944,686	10,498,938
Increase in net assets from operations	365,280	519,173
Nonoperating activities:		
Return on investments, net of amounts classified as operating revenue	(114,855)	103,711
Pension, OPEB and other, net	(374,803)	(426,535)
Contributions and donor support for capital related activities	98,487	42,911
Total nonoperating activities	(391,171)	(279,913)
(Decrease) increase in net assets without donor restrictions	(25,891)	239,260
<u>With donor restrictions</u>		
Contributions	478,490	598,622
Return on investments, net	231,372	464,755
Net assets released from restrictions	(542,535)	(451,770)
Increase in net assets with donor restrictions	167,327	611,607
Increase in total net assets	141,436	850,867
Net assets, beginning of year	19,424,833	18,573,966
Net assets, end of year	\$ 19,566,269	\$ 19,424,833

The accompanying notes are an integral part of these consolidated financial statements.

Consolidated Statements of Cash Flows

University of Pennsylvania

For the years ended June 30, 2020 and 2019

(in thousands)

	2020	2019
Cash flows from operating activities:		
Increase in total net assets	\$ 141,436	\$ 850,867
Adjustment to reconcile increase in total net assets to net cash provided by operating activities:		
Depreciation and amortization	516,878	521,795
Provision for bad debts	7,925	8,040
Gain on investments, net	(372,476)	(739,519)
Loss (gain) on disposal of plant, property and equipment	1,824	(10,915)
Donated equipment	-	(531)
Receipt of contributed securities	(134,329)	(75,188)
Proceeds from contributed securities	26,350	22,816
Receipt of contributions designated for the acquisition of long-lived assets and long-term investment	(231,406)	(213,867)
Pension, OPEB and other, net	374,803	426,535
Changes in operating assets and liabilities:		
Patient, accounts and loans receivable	(3,700)	(17,451)
Contributions receivable	10,878	(209,992)
Other assets	(49,605)	(27,718)
Accounts payable, accrued expenses and accrued retirement benefits	685,623	118,862
Deposits, advances and agency funds	30,310	19,167
Deferred income	(2,382)	(14,134)
Net cash provided by operating activities	1,002,129	658,767
Cash flows from investing activities:		
Purchase of investments	(16,043,267)	(13,267,225)
Proceeds from sale of investments	16,168,730	13,369,735
Purchase of property, plant and equipment	(1,397,560)	(1,232,647)
Net cash used by investing activities	(1,272,097)	(1,130,137)
Cash flows from financing activities:		
Proceeds from contributions received designated for the acquisition of long-lived assets and long-term investment	231,407	213,867
Proceeds from contributed securities received designated for the acquisition of long-lived assets and long-term investment	107,643	51,913
Federal student loan advances	(19,443)	2,579
Repayment of debt obligations	(598,091)	(139,692)
Proceeds from issuances of debt obligations	1,290,962	287,000
Net cash provided by financing activities	1,012,478	415,667
Net increase (decrease) in cash and cash equivalents	742,510	(55,703)
Cash and cash equivalents, beginning of year	1,375,469	1,431,172
Cash and cash equivalents, end of year	\$ 2,117,979	\$ 1,375,469
Supplemental disclosure of cash flow information:		
Cash paid for interest, net of amounts capitalized	\$ 83,526	\$ 95,392
Contributed securities received	134,329	75,188
(Decrease) increase in accrued plant, property and equipment	(53,778)	51,392
Operating cash flows for operating leases	61,093	-
Right-of-use assets obtained in exchange for lease liabilities	497,406	-

The accompanying notes are an integral part of these consolidated financial statements.

1. Significant Accounting Policies

Organization

The University of Pennsylvania (“University”), located in Philadelphia, Pennsylvania, is an independent, nonsectarian, not-for-profit institution of higher learning founded in 1740. The University Academic Component (“Academic Component”) provides educational services, primarily for students at the undergraduate, graduate, professional and postdoctoral levels and performs research, training and other services under grants, contracts and similar agreements with sponsoring organizations, primarily departments and agencies of the United States Government. The University also operates an integrated health care delivery system, the University of Pennsylvania Health System (“UPHS”). The University is a tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code.

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include the accounts of the University and its subsidiaries over which the University has a controlling financial interest or exercises control. All material transactions between the University and its subsidiaries are eliminated in consolidation. Investments in subsidiaries over which the University has the ability to exercise significant influence are reported using the equity method of accounting. Other investments in subsidiaries are reported using the measurement alternative – at cost adjusted for impairment, if any, unless an observable transaction for an identical or similar security occurs.

The net assets of the University are classified and reported as follows:

Without donor restrictions – includes net assets that are not subject to donor-imposed restrictions.

With donor restrictions – includes net assets that are (i) subject to legal or donor-imposed restrictions that will be met by actions of the University and/or the passage of time, and (ii) the original values of donor restricted net assets, the use of which is limited to investment and can only be appropriated for expenditure by the University in accordance with the Pennsylvania Uniform Principal and Income Act (Pennsylvania Act).

Expenses are reported as a decrease in net assets without donor restrictions. Gains and losses on investments are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by explicit donor stipulation or by law. Donor-restricted resources intended for the acquisition or construction of long-lived assets are initially reported as net assets with donor restrictions and released from restrictions to net assets without donor restrictions when the asset is placed in service or in accordance with donor-specified terms.

Expirations of restrictions on contributions and investment income, reported as Net assets released from restrictions, and the corresponding amounts are included in the Consolidated Statements of Activities as follows (in thousands):

Net Assets Without Donor Restrictions	2020	2019
Contributions and donor support	\$ 137,572	\$ 118,068
Investment income	306,476	290,791
Contributions and donor support for capital related activities	98,487	42,911
Net assets released from restrictions	\$ 542,535	\$ 451,770
Net Assets With Donor Restrictions	2020	2019
Net assets released from restrictions	\$ (542,535)	\$ (451,770)

Gains or losses associated with investment activities are included in Return on investments, net. Gains or losses associated with property, plant and equipment disposals are included in Other income or Other operating expenses, respectively.

Consolidated Notes to Financial Statements

Gains or losses associated with all other activities, such as debt retirements and pension and postretirement plan actuarial valuation adjustments, are reported in Pension, Other post-retirement employee benefits (OPEB) and other, net.

Fair Value

The University values certain financial and non-financial assets and liabilities by applying the FASB pronouncement on Fair Value Measurements. The pronouncement defines fair value and establishes a framework for measuring fair value that includes a hierarchy that categorizes and prioritizes the sources used to measure and disclose fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The hierarchy is broken down into three levels based on inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the University as follows:

Level 1: Unadjusted quoted market prices in active markets for identical assets or liabilities.

Level 2: Unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable.

Level 3: Unobservable inputs for the asset or liability.

Inputs broadly refer to the assumptions that market participants use to make valuation decisions, including assumptions about risk. Inputs may include price information, volatility statistics, specific and broad credit data, liquidity statistics and other factors. The University is required by the pronouncement to maximize the use of observable inputs (Levels 1 and 2) and minimize the use of unobservable inputs (Level 3). The University considers observable data to be that market data which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary and provided by independent sources that are actively involved in the relevant market. The categorization of a financial instrument within the hierarchy is based upon the pricing transparency of the instrument and does not necessarily correspond to the University's perceived risk of that instrument.

Assets and liabilities are disclosed in the Consolidated Notes to Financial Statements within the hierarchy based on the lowest (or least observable) input that is significant to the measurement. The University's assessment of the significance of an input requires judgment, which may affect the valuation and categorization within the fair value hierarchy. The fair value of assets and liabilities using Level 3 inputs are generally determined by using pricing models or discounted cash flow methods, which all require significant management judgment or estimation.

As a practical expedient, the University is permitted to estimate the fair value of an investment in an investment company at the measurement date using the reported net asset value (NAV). Adjustment is required if the University expects to sell the investment at a value other than NAV or if the NAV is not calculated in accordance with U.S. GAAP. The University holds investments in its portfolio which are generally valued based on the most current NAV. This amount represents fair value of these investments at June 30, 2020 and 2019. Investments reported at NAV, as a practical expedient, are not included within levels 1, 2, or 3 in the fair value hierarchy.

The University performs additional procedures, including due diligence reviews, on its investments in investment companies and other procedures with respect to the capital account or NAV provided to ensure conformity with US GAAP. The University has assessed factors including, but not limited to, managers' compliance with the *Fair Value Measurement* standard, price transparency and valuation procedures in place.

Cash and Cash Equivalents

Cash equivalents include liquid investments available for current operations with maturities of three months or less when purchased and are carried at cost which approximates fair value. All short-term, highly liquid investments, otherwise

Consolidated Notes to Financial Statements

qualifying as cash equivalents or restricted cash equivalents, included in the University's investments are treated as Investments, at fair value and are therefore excluded from Cash and cash equivalents in the Statements of Cash Flows.

Investments, at Fair Value

The majority of the University's investments are held in the Associated Investments Fund (AIF). The AIF is invested in accordance with the investment policies set out by an Investment Board which has been appointed by the Trustees of the University of Pennsylvania (the Trustees). The Office of Investments is responsible for the day-to-day management of the AIF including identifying, selecting and monitoring a variety of external investment managers to implement the strategic asset allocation set forth by the Investment Board. The AIF may include marketable and not readily marketable securities that it intends to hold for an indefinite period of time. The University also holds other investments which are not invested in the AIF due to various restrictions. The majority of these investments are in highly liquid short-term and equity type investments. Changes in the fair value of investments are reported in Return on investments, net in the Consolidated Statements of Activities. The following is a summary of the investments held in the AIF by asset allocation as well as investment risk:

Short-Term

Short-term investments include cash equivalents and fixed income investments with maturities of less than one year. Short-term investments are valued using observable market data and are categorized as Level 1 based on quoted market prices in active markets. The majority of these short-term investments are held in a US Treasury money market account.

Equity

Equity investments consist of direct holdings of public securities in managed accounts as well as mutual funds and private funds. The securities held in managed accounts, along with mutual funds, are generally valued based on quoted market prices in active markets obtained from exchange or dealer markets for identical assets, and are accordingly categorized as Level 1. Private funds are valued at NAV.

Debt

Debt investments consist of direct holdings of securities in managed accounts and private funds. Securities such as US Treasuries, held in managed accounts, are valued based on quoted market prices in active markets and are categorized as Level 1. Securities such as corporate and sovereign bonds, also held in managed accounts, are valued based on quoted market prices or dealer or broker quotations and are categorized as Level 2 or in the cases where inputs are unobservable as Level 3. Private funds are valued at NAV.

Absolute Return

Absolute return investments are made up of allocations to private funds. The fund managers of these private funds invest in a variety of securities, based on the strategy of the fund, which may or may not be quoted in an active market. Private funds are valued at NAV.

Real Estate

Investments in real estate are primarily in the form of private funds. The fund managers of these private funds primarily invest in investments for which there is no readily determinable market value. The fund managers may value the underlying investments based on an appraised value, discounted cash flow, industry comparables or some other method. Private funds are valued at NAV.

Consolidated Notes to Financial Statements

Private Equity

Investments in private equity are in the form of close-ended private funds. The fund managers primarily invest in investments for which there is no readily determinable market value. The fund managers may value the underlying private investments based on an appraised value, discounted cash flow, industry comparables or some other method. These private fund investments are valued at NAV.

Natural Resources

Investments in natural resources are made up of private funds and securities in managed accounts. The fund managers of these private funds primarily invest in investments for which there is no readily determinable market value. The fund managers may value the underlying investments based on an appraised value, discounted cash flow, industry comparables or some other method. Private funds are valued at NAV. The securities held in managed accounts are generally valued based on quoted market prices in active markets obtained from exchange or dealer markets for identical assets, and are accordingly categorized as Level 1.

Derivatives

The University, in the normal course of business, utilizes derivative financial instruments in connection with its investment activity. Derivatives utilized by the University include futures, options, swaps and forward currency contracts and are reflected at fair value following the definition of Level 1 and 2 assets and liabilities as previously described. Investments in derivative contracts are subject to foreign exchange and equity price risks that can result in a loss of all or part of an investment. In addition, the University is also subject to additional counterparty risk should its counterparties fail to meet the terms of their contracts.

Investment Risks

The University's investing activities expose it to a variety of risks including market, credit and liquidity risks. The University attempts to identify, measure and monitor risk through various mechanisms including risk management strategies and credit policies.

Market risk is the potential for changes in the fair value of the University's investment portfolio. Commonly used categories of market risk include currency risk (exposure to exchange rate differences between functional currency relative to other foreign currencies), interest rate risk (changes to prevailing interest rates or changes in expectations of futures rates) and price risk (changes in market value other than those related to currency or interest rate risk, including the use of NAV provided).

Credit risk is the risk that one party to a financial investment will cause a financial loss for the other party by failing to discharge an obligation (counterparty risk).

Liquidity risk is the risk that the University will not be able to meet its obligations associated with financial liabilities.

Endowment

The University's endowment consists of 6,909 donor-restricted endowment funds and 928 quasi-endowment funds established by management for a variety of purposes. The University reports all endowment investments at fair value. The majority of the endowment funds of the University have been pooled in the University's AIF. The endowment funds not pooled in the AIF are primarily invested in equities and bonds.

The Commonwealth of Pennsylvania has not adopted the Uniform Management of Institutional Funds Act (UMIFA) or the Uniform Prudent Management of Institutional Funds Act (UPMIFA). Rather, the Pennsylvania Act governs the investment, use and management of the University's endowment funds.

Consolidated Notes to Financial Statements

The Pennsylvania Act does not require the preservation of the fair value of a donor's original gift as of the gift date of a donor-restricted endowment fund, absent explicit donor stipulations to the contrary. However, based on its interpretation of the Pennsylvania Act and relevant accounting literature, the University classifies the following as net assets with donor restrictions for reporting purposes: (i) the original value of donated assets required to be invested in perpetuity; (ii) the original value of subsequent donated assets required to be invested in perpetuity; (iii) accumulations to the donated assets invested in perpetuity made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund; and (iv) donated assets and accumulations that are subject to legal or donor-imposed restrictions that will be met by actions of the University and/or the passage of time. The Pennsylvania Act allows a nonprofit to elect to appropriate for expenditure between 2% and 7% of the endowment fair value, determined at least annually and averaged over a period of three or more preceding years, including funds whose fair value is less than the original donated value.

In accordance with the Pennsylvania Act, the University has elected to adopt and follow an investment policy seeking a total return for the investments held by the AIF, whether the return is derived from appreciation of capital or earnings and distributions with respect to capital or both. The endowment spending policy which the Board of Trustees has elected to govern the expenditure of funds invested in the AIF, including funds whose fair value is less than the original donated value, is designed to manage annual spending levels and is independent of the cash yield and appreciation of investments for the year. For fiscal year 2020, the spending rule target payout was based on the sum of: (i) 70% of the prior fiscal year distribution adjusted by an inflation factor; and (ii) 30% of the prior fiscal year-end fair value of the AIF, lagged one year, multiplied by 5.0% for all funds. The payout or allocation to operations exceeded actual income, net of expenses, by \$654,691,000 in 2020 and by \$577,039,000 in 2019.

Property, Plant and Equipment

Property, plant and equipment (PPE) is reported net of related depreciation. Donated PPE is reported based on estimated fair value at the date of acquisition. All other PPE is reported at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the assets or the shorter of the lease term or estimated useful life of the asset for capital lease assets. Contributions of library materials, as well as rare books and other collectibles, are not recorded for financial statement presentation, while purchases are recorded as Other operating expenses on the Consolidated Statement of Activities in the period acquired.

Split-Interest Agreements

The University's split-interest agreements with donors consist of irrevocable charitable remainder trusts, charitable gift annuities, pooled income funds, perpetual trusts and charitable lead trusts. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements.

The University recognizes assets contributed to charitable remainder trusts, charitable gift annuities and pooled income funds, where it serves as trustee, at fair value, recognizes a liability to the beneficiaries based on the present value of the estimated future payments to beneficiaries to be made over the estimated remaining life of those beneficiaries using current market rates at the date of the contribution, and recognizes the difference as contribution revenue. Subsequently, the trust assets, invested in equity and debt securities, are measured at fair value at quoted market prices, and are categorized as Level 1, with the changes reported as an adjustment to Investments, at fair value on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities. Liabilities to beneficiaries are revalued based on current market rates, and are categorized as Level 2, with the changes reported as an adjustment to Accrued expense and other liabilities on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities.

Charitable remainder trust assets, where the University does not serve as trustee, are initially valued using the current fair value of the underlying assets, using observable market inputs based on its beneficial interest in the trust, discounted to a single present value using current market rates at the date of the contribution. The initially contributed assets are

Consolidated Notes to Financial Statements

categorized as Level 3, and reported as Investments, at fair value on the Consolidated Statements of Financial Position and Contribution revenue on the Consolidated Statements of Activities. Subsequent valuation follows this same approach with changes in fair value reported as an adjustment to Investments, at fair value on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities. The primary unobservable input used in the fair value measurement of the charitable remainder trust assets is the discount rate. Significant fluctuation in the discount rates utilized in this calculation could result in a material change in fair value.

Perpetual trust assets are initially valued at the current fair value of the underlying assets using observable market inputs based on its beneficial interest in the trust. The initially contributed assets are categorized as Level 3 and are reported as Investments, at fair value on the Consolidated Statements of Financial Position and as Contribution revenue on the Consolidated Statements of Activities. Subsequent valuation follows this same approach with changes in fair value reported as an adjustment to Investments, at fair value on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities. The primary unobservable inputs used in the fair value measurement of the perpetual trust assets are the underlying securities held by the trust. Significant fluctuation in the market value of these underlying securities could result in a material change in fair value.

The University reports charitable lead trust assets by discounting future cash flows using current market rates at the measurement date, matched to the payment period of the agreement. The initially contributed assets are categorized as Level 3, and reported as Investments, at fair value on the Consolidated Statements of Financial Position and as Contribution revenue on the Consolidated Statements of Activities. Subsequent valuation follows this same approach with changes in fair value reported as an adjustment to Investments, at fair value on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities. The primary unobservable input used in the fair value measurement of the charitable lead trust assets is the discount rate. Significant fluctuation in the discount rates utilized in this calculation could result in a material change in fair value.

Income Taxes

The University is a tax exempt organization under Section 501(c)(3) of the Internal Revenue Code. Most of its activities and income are related to its exempt purposes and are exempt from federal and state income taxes. None of its activities and income is subject to Pennsylvania income tax. Unrelated activities and income are subject to federal "Unrelated Business Income Tax."

The University regularly evaluates its tax position and does not believe it has any uncertain tax positions that require disclosure or adjustment to the consolidated financial statements.

Tuition and Fees

Tuition and fees includes tuition, room and board, and other student fees which are recognized as revenue over time during the fiscal year in which the related academic services are rendered. Tuition and fees received in advance of services to be rendered are reported as Deferred income on the Consolidated Statements of Financial Position. The University maintains a policy of offering qualified applicants admission to the University without regard to financial circumstance, as well as meeting in full the demonstrated financial need of those admitted. Tuition and fees have been reduced by certain grants and scholarships in the amount of \$360,863,000 in 2020 and \$349,981,000 in 2019.

Sponsored Programs

Sponsored programs includes revenue from exchange and conditional non-exchange agreements with governments, foundations and private sources generally for research activities. Revenue from exchange agreements is generally recognized at a point in time when performance obligations are met, and revenue from conditional non-exchange agreements is generally recognized as the related costs are incurred. Non-exchange agreements are considered conditional if the terms of the agreement include both a right of return/release of assets received/promised and a barrier. These agreements become unconditional as barriers are met. At June 30, 2020, the University has unrecorded conditional agreements of \$2,164,163,000. In 2020 and 2019, sponsored programs revenue earned from governmental sources totaled

Consolidated Notes to Financial Statements

\$753,901,000 and \$753,118,000, respectively. Indirect costs recovered on federally-sponsored programs are generally based on predetermined reimbursement rates which are stated as a percentage and distributed based on the modified total direct costs incurred. The University negotiates its federal indirect rate with its cognizant federal agency. Indirect costs recovered on all other grants and contracts are based on rates negotiated with the respective sponsors. Funds received for sponsored research activity are subject to audit. Based upon information currently available, management believes that any liability resulting from such audits will not materially affect the financial position or operations of the University.

Contributions

Contributions are revenues from unconditional non-exchange agreements with private sources and foundations. Contributions are recognized in the period received and reported as increases in the appropriate net asset category based on the presence or absence of donor-imposed restrictions. Non-exchange agreements are considered conditional if the terms of the agreement include both a right of return/release of assets received/promised and a barrier. These agreements become unconditional as barriers are met. Contributions and donor support without donor restrictions also includes net assets released as a result of corresponding expenditures which met donor-imposed restrictions. Contributions designated for the acquisition of long-lived assets and long-term investment are reported in Nonoperating activities.

The University reports unconditional pledges at fair value by discounting future cash flows using current market rates at the measurement date, ranging from 0.53% to 1.93%, matched to the payment period of the agreement, and accordingly categorizes these assets as Level 3. The primary unobservable input used in the fair value measurement of the University's Contributions receivable is the discount rate. Significant fluctuation in the discount rates utilized in this calculation could result in a material change.

Net Patient Service Revenue

Net patient service revenue is derived from contracts with patients of UPHS in which its performance obligation is to provide health care services. Net patient service revenue is recorded over time during the period these performance obligations are satisfied and at the determined transaction price, which represents the estimated net realizable amounts due from patients, third-party payers and others for health care services rendered. Estimated net realizable amounts represent amounts due, net of implicit and explicit price concessions. Implicit price concessions are based on management's assessment of expected net collections considering economic conditions, historical experience, trends in health care coverage and other collection indicators. After satisfaction of amounts due from insurance and reasonable efforts to collect from patients have been exhausted, UPHS follows established guidelines for placing certain past-due patient balances with collection agencies, subject to terms of certain restrictions on collection efforts as determined by UPHS. Patient receivables are written off after collection efforts have been followed in accordance with UPHS' policy. Certain revenue received from third-party payers is subject to audit and retroactive adjustment. Any changes in estimates under these contracts are recorded in operations currently.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

COVID-19

In January 2020, the World Health Organization declared the novel strain of coronavirus ("COVID-19") a Public Health Emergency of International Concern. The COVID-19 pandemic has caused disruptions to our nation's healthcare and higher education systems, including the University's. Such disruptions included reductions in availability of staffing and in the availability of personal protective equipment to prevent spread of the disease during patient treatment. Generally, elective procedures were postponed by physicians and acute care facilities to prepare for the expected volume of COVID-

Consolidated Notes to Financial Statements

19 patients and reduce the risk of exposure to COVID-19. Other negatively impacted areas include, but are not limited to, student enrollment, housing and dining revenues, research, faculty, staff & student travel, investment performance, philanthropy and increased financial need of students. The University is monitoring legislative developments, including future relief funding opportunities, and directives from federal, state, and local officials to determine additional precautions and procedures that may need to be implemented.

In response, on March 27, 2020 the Federal Government passed the Coronavirus Aid, Relief, and Economic Stimulus Act (CARES Act) which made funds available to UPHS and the Academic Component through various provisions of the legislation. As of June 30, 2020, UPHS received CARES Act provider relief funding of \$213,160,000 reported as Other income on the Consolidated Statements of Activities. In addition, UPHS received \$599,498,000 in advanced payments from the Centers for Medicare and Medicaid Services (CMS) Accelerated and Advanced Payments Program reported as Accrued expense and other liabilities on the Consolidated Statements of Financial Position. Furthermore, the CARES Act allowed employers to defer the deposits and payments of the employer's share of the Social Security taxes. As of June 30, 2020, \$34,731,000 and \$27,314,000 were deferred and reported as Accrued expense and other liabilities on the Consolidated Statements of Financial Position, for UPHS and the Academic Component, respectively. UPHS recognized revenue related to the CARES Act funding based on information available at June 30, 2020 based upon laws and regulations governing the funding as well as interpretations issued by the Department of Health and Human Services (HHS). In September 2020, HHS issued new reporting requirements for the CARES Act funding. Due to these new reporting requirements there is at least a reasonable possibility that amounts recorded under CARES Act funding may change in future periods.

Recent Authoritative Pronouncements

Periodically, the Financial Accounting Standards Board (FASB) issues updates to the Accounting Standards Codification (ASC) which impacts the University's financial reporting and related disclosures. The paragraphs which follow summarize a number of relevant updates.

In February 2016, the FASB issued a standard on Leases. This standard requires lessees to recognize assets and liabilities for the rights and obligations created by leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily depends on its classification as a finance or operating lease. The University adopted this standard for fiscal year 2020 on a modified retrospective basis, the impact of which is noted in the accompanying Leases footnote.

In November 2016, the FASB issued a standard on Restricted Cash. This standard requires the Consolidated Statements of Cash Flows explain the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents during a fiscal year. It is also required that this total be reconciled to the amounts reported on the Consolidated Statements of Financial Position and that the nature of the restrictions be disclosed. The University adopted this standard for fiscal year 2020 on a retrospective basis.

2. University of Pennsylvania Health System - Summarized Financial and Related Information

The Trustees formed Penn Medicine, the governance structure which oversees the activities of UPHS and the University of Pennsylvania Perelman School of Medicine (PSOM) in order to operate, oversee and coordinate its academic, research and clinical missions.

UPHS is comprised of the following operating entities: Clinical Practices of the University of Pennsylvania; Clinical Care Associates; Hospital of the University of Pennsylvania; Penn Presbyterian Medical Center; Pennsylvania Hospital of the University of Pennsylvania Health System; Chester County Hospital and Health System; Lancaster General Health (LGH); Wissahickon Hospice of the University of Pennsylvania Health System; Princeton HealthCare System (PHCS);

Consolidated Notes to Financial Statements

Franklin Casualty Insurance Company, a wholly owned Risk Retention Group; and, Quaker Insurance Company Ltd., a wholly owned offshore captive insurance company, (collectively referred to as RRG/Captive).

Throughout the year, certain transactions (primarily billings for allocations of common costs, physicians' salaries and benefits, certain purchased services and support for PSOM) are conducted between UPHS and the University. Nonoperating, net, as shown below, includes transfers from UPHS to the University of \$207,085,000 and \$234,722,000 in 2020 and 2019, respectively, to further the research and educational activities of PSOM and \$6,581,000 and \$5,671,000 in 2020 and 2019, respectively, for other activities. In addition, UPHS recognized operating expenses of \$19,618,000 and \$19,770,000 in 2020 and 2019, respectively, to support academic operating activities in the clinical departments of PSOM.

The effect of all these transactions is included in the following summarized financial information of UPHS as of and for the years ended June 30, 2020 and 2019 (in thousands):

	2020	2019
Net patient service revenue	\$ 6,813,226	\$ 6,940,977
Other revenue	994,662	653,071
Total expenses	(7,565,166)	(7,156,362)
Excess of revenue over expenses from operations	242,722	437,686
Nonoperating, net	(393,237)	(310,922)
(Decrease) increase in net assets	\$ (150,515)	\$ 126,764
Total current assets	\$ 2,554,537	\$ 1,876,193
Assets whose use is limited:		
Held by trustees	139,028	163,598
RRG/Captive	243,622	219,879
Donor restricted and other	657,776	678,137
Designated	2,833,871	2,731,038
Property and equipment, net	5,369,409	4,760,563
Investments and other assets	1,361,266	1,152,231
Total assets	\$ 13,159,509	\$ 11,581,639
Total current liabilities	\$ 1,973,427	\$ 1,243,888
Long-term debt, net of current portion	2,692,254	2,283,002
Other liabilities	2,722,567	2,132,973
Total liabilities	\$ 7,388,248	\$ 5,659,863
Net assets		
Without donor restrictions	\$ 5,098,229	\$ 5,234,000
With donor restrictions	673,032	687,776
Total net assets	\$ 5,771,261	\$ 5,921,776
Total liabilities and net assets	\$ 13,159,509	\$ 11,581,639

Net Patient Service Revenue

Net Patient Service Revenue (NPSR) for the years ended June 30, 2020 and 2019 is derived from the following payers:

	2020	2019
Medicare (including Managed Medicare)	32%	34%
Medicaid (including Managed Medicaid)	12%	10%
Managed Care	36%	35%
Independence Blue Cross (IBC)	15%	16%
Commercial	4%	4%
Self Pay	1%	1%
	100%	100%

Consolidated Notes to Financial Statements

UPHS has agreements with the following third-party payers that provide for payments at amounts that differ from its established rates:

Inpatient acute care services and outpatient services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. Inpatient psychiatric services and medical education costs related to Medicare beneficiaries are paid based on a cost reimbursement methodology. UPHS is reimbursed for cost reimbursable items at a tentative rate with final settlement determined after submission of annual cost reports by each hospital and audits thereof by the Medicare fiscal intermediary.

Inpatient and outpatient services rendered to Medicaid program beneficiaries are paid at prospectively determined rates. Additional amounts are allocated to each hospital for training residents and serving a disproportionate indigent population.

Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term.

During 2017, UPHS and IBC reached agreement on terms of a five-year agreement. Payments made for inpatient services provided to IBC traditional and managed care subscribers are effected on a per case rate basis for most services. Payment for outpatient services is principally based upon negotiated fee schedules. Hospital and physician rates also provide for annual inflationary increases. In addition, incentives are paid for high performance with regard to clinical outcomes and patient quality. The agreement continues unless terminated by the parties.

During 2015, UPHS and Aetna reached agreement on terms of a five-year agreement. A one-year bridge agreement is effective July 1, 2020. The terms of the agreement provide payments for inpatient hospital services on a per case rate basis. Payments for outpatient services continue to be predominantly based upon negotiated fee schedules.

UPHS also has reimbursement agreements with other commercial insurance carriers, health maintenance organizations and preferred provider organizations. The basis for reimbursement under these agreements includes prospectively determined rates per discharge, discounts from established charges and prospectively determined per diem rates.

Charity Care

UPHS provides services to patients who meet certain criteria under its charity care policy without charge or at amounts less than UPHS' established rates. Because UPHS does not pursue collections, such amounts have been excluded from NPSR. UPHS estimates the costs of providing charity care services based on data derived from a combination of UPHS' cost accounting system and the ratio of costs to charges. Of the Total expenses reported above by UPHS, an estimated \$29,793,000 and \$24,968,000 were incurred as a result of providing services to charity patients for the years ended June 30, 2020 and 2019, respectively.

Medical Professional Liability Claims

The University is insured for medical professional liability claims through the combination of the Medical Care Availability and Reduction of Error Fund (Mcare), various commercial insurance companies and risk retention programs.

Mcare levies health care provider surcharges, as a percentage of the Pennsylvania Joint Underwriters Association rates for basic coverage, to pay claims and pay administrative expenses of Mcare participants. These surcharges are recognized as expenses in the period incurred. Mcare operates on a pay-as-you-go basis and no provision has been made for any future Mcare assessments in the accompanying financial statements, as the University's portion of the unfunded Mcare liability cannot be estimated.

Consolidated Notes to Financial Statements

Anticipated insurance recoveries and estimated liabilities for medical malpractice claims or similar contingent liabilities are presented separately on the Consolidated Statement of Financial Position in Accounts receivable, net of allowances and Accrued expenses and other liabilities, respectively. The University accrues for estimated risks arising from both asserted and unasserted medical professional liability claims. The estimate of the gross liability and corresponding receivable for unasserted claims arising from unreported incidents is based on analysis of historical claims data by an independent actuary, which is recorded utilizing a 2.25% to 3.50% discount rate as of June 30, 2020 and 2019. The gross liability recorded under this program is \$750,633,000 and \$732,389,000 at June 30, 2020 and 2019, respectively, with a corresponding receivable of \$119,255,000 and \$103,777,000 at June 30, 2020 and 2019, respectively.

3. Accounts Receivable

Accounts receivable are reported at their net realizable value. The major components of receivables, net of allowances for doubtful accounts of \$22,771,000 and \$22,086,000 at June 30, 2020 and 2019, respectively, are as follows (in thousands):

	2020	2019
Sponsored research	\$ 159,528	\$ 130,161
Malpractice	119,255	103,777
Student	26,450	18,614
Trade	63,233	60,949
Investment income	4,343	8,096
Other	134,230	76,461
Total Accounts receivable	\$ 507,039	\$ 398,058

4. Loans Receivable

Loans receivable, and related allowances for doubtful accounts, consist of the following at June 30, 2020 and 2019 (in thousands):

	2020		
	Receivable	Allowance	Net
Student Loans:			
Federally-sponsored	\$ 42,410		\$ 42,410
Other	13,748	\$ 2,994	10,754
Total Student loans	\$ 56,158	\$ 2,994	\$ 53,164
Other	10,658	424	10,234
Total Loans receivable, net	\$ 66,816	\$ 3,418	\$ 63,398

	2019		
	Receivable	Allowance	Net
Student Loans:			
Federally-sponsored	\$ 50,509		\$ 50,509
Other	14,406	\$ 3,275	11,131
Total Student loans	\$ 64,915	\$ 3,275	\$ 61,640
Other	10,964	242	10,722
Total Loans receivable, net	\$ 75,879	\$ 3,517	\$ 72,362

Consolidated Notes to Financial Statements

Loans receivable primarily consists of student loans. Student loans include federally-sponsored student loans and donor-restricted student loans with mandated interest rates and repayment terms. The federally-sponsored student loans represent amounts due from current and former students under various Federal Government funded loan programs offered to graduate and undergraduate students. Loans disbursed under these programs are able to be assigned to the Federal Government upon default by the borrower; therefore, no related allowance is considered necessary. Funding received under these programs is ultimately refundable to the Federal Government in the event the University no longer participates and accordingly is reported as a liability in Federal student loan advances in the Consolidated Statements of Financial Position. Determination of the fair value of student loans receivable is not practicable.

Loans receivable are reported at their net realizable value. The University regularly assesses the adequacy of the allowances for credit losses of its loans by performing ongoing evaluations, including such factors as aging, differing economic risks associated with each loan category, financial condition of specific borrowers, economic environment in which the borrowers operate, level of delinquent loans, value of collateral and existence of guarantees or indemnifications.

5. Contributions Receivable

A summary of contributions receivable at June 30, 2020 and 2019, is as follows (in thousands):

	2020	2019
Unconditional promises expected to be collected in:		
Less than one year	\$ 169,979	\$ 171,791
One year to five years	249,791	280,978
Over five years	120,726	117,343
	540,496	570,112
Less: Discount	(27,699)	(45,638)
Less: Allowances for doubtful amounts	(34,647)	(36,024)
Total Contributions receivable, net	\$ 478,150	\$ 488,450

At June 30, 2020 and 2019, the University has outstanding unrecorded conditional promises to give, including non-legally binding bequests, of \$467,797,000 and \$474,184,000, respectively. When conditional promises to give become unconditional or non-legally binding bequests cash payments are received, they are recorded and are generally restricted for operations, endowment and capital projects as stipulated by the donors.

Consolidated Notes to Financial Statements

6. Investments, at Fair Value

A summary of investments, including the AIF, as of June 30, 2020 and 2019, categorized in accordance with the fair value hierarchy, is as follows (in thousands):

Assets	Level 1	Level 2	Level 3	Investments at NAV	2020
Short-term	\$ 594,126				\$ 594,126
Equity:					
US equities	719,227			\$ 1,299,712	2,018,939
International equities	141,939			1,111,548	1,253,487
Emerging market equities	175,705			1,087,617	1,263,322
Total Equity	1,036,871			3,498,877	4,535,748
Debt:					
US treasuries	1,642,721	\$ 19,999			1,662,720
Corporate bonds	1,449	114,512			115,961
High yield				119	119
Total Debt	1,644,170	134,511		119	1,778,800
Split-interest agreements	87,085		\$ 325,701		412,786
Absolute return				3,893,852	3,893,852
Real estate		59		978,372	978,431
Private equity			14,473	4,110,984	4,125,457
Natural resources	86,075			445,171	531,246
Derivative instruments		17,132			17,132
Other			2,538		2,538
Total assets	\$ 3,448,327	\$ 151,702	\$ 342,712	\$ 12,927,375	\$ 16,870,116

Assets	Level 1	Level 2	Level 3	Investments at NAV	2019
Short-term	\$ 1,188,571				\$ 1,188,571
Equity:					
US equities	721,261			\$ 1,077,918	1,799,179
International equities	190,694			1,055,871	1,246,565
Emerging market equities	153,435			1,091,866	1,245,301
Total Equity	1,065,390			3,225,655	4,291,045
Debt:					
US treasuries	1,716,743	\$ 41,860			1,758,603
Corporate bonds	1,548	100,706		26,849	129,103
High yield				98	98
Total Debt	1,718,291	142,566		26,947	1,887,804
Split-interest agreements	86,492		\$ 322,631		409,123
Absolute return				3,259,286	3,259,286
Real estate		59		804,620	804,679
Private equity			14,426	3,832,884	3,847,310
Natural resources	157,440			650,414	807,854
Derivative instruments		1,167			1,167
Other			2,547		2,547
Total assets	\$ 4,216,184	\$ 143,792	\$ 339,604	\$ 11,799,806	\$ 16,499,386

Included in Short-term investments is \$20,947,000 and \$43,287,000 of amounts held by trustees under indenture and escrow agreements at June 30, 2020 and 2019, respectively.

Consolidated Notes to Financial Statements

At June 30, 2020 and 2019, Short-term investments include \$40,915,000 and \$85,301,000, respectively, of outstanding receivables from trading activities. At June 30, 2020 and 2019, Short-term investments also include \$64,542,000 and \$49,929,000, respectively, of outstanding payables from trading activities.

As of June 30, 2020 and 2019 there were no transfers between Level 1 and 2.

Liabilities related to equity short positions of \$329,955,000 and \$362,826,000 at June 30, 2020 and 2019, respectively, are reported in Accrued expenses and other liabilities on the Consolidated Statements of Financial Position. These liabilities are valued using observable market data and are categorized as Level 1 based on quoted market prices in active markets.

The University has made investments in various long-lived partnerships and, in other cases, has entered into contractual agreements that may limit its ability to initiate redemptions due to notice periods, lock-ups and gates. The University has also made commitments to various limited partnerships. The University expects these funds to be called over the next 5 years. The total amount of unfunded commitments is \$3,316,965,000 which represents 23.3% of the AIF value as of June 30, 2020.

Consolidated Notes to Financial Statements

Details on the fair value, remaining estimated life, outstanding commitments, current redemption terms and restrictions by strategy and type of investment are provided below (in thousands):

Strategy	Fair Value		Outstanding Commitments	Redemption Terms	Redemption Restrictions
	June 30, 2020	June 30, 2019			
Short-term	\$ 594,126	\$ 1,188,571		Daily	None
Equity					
Managed accounts	761,773	764,350		Daily and semi-annually with varying notice periods	None
Mutual funds	275,098	257,144		Daily	None
Private funds (1)	3,498,877	3,269,551	\$ 47,550	Weekly to annually with varying notice periods	Lock-up provisions ranging from 0 to 5 years and side pocket investments (2)
Total Equity	4,535,748	4,291,045	47,550		
Debt					
Managed accounts	1,778,681	1,860,857		Daily	None
Private funds (1)	119	26,947		Daily	None; side pocket investments (2)
Total Debt	1,778,800	1,887,804			
Absolute return	3,893,852	3,259,286	230,186	Range from monthly to annually and close-ended funds not available for redemption	Lock-up provisions ranging from 0 to 5 years with earlier redemptions subject to redemption fee, close-ended funds not available for redemption, and side pocket investments (2)
Real estate	978,431	804,679	923,667	Close-ended funds not available for redemption	Close-ended funds not available for redemption
Private equity	4,125,457	3,847,310	1,899,101	Close-ended funds not available for redemption	Close-ended funds not available for redemption
Natural resources					
Managed accounts	86,075	149,433		Daily	None
Private funds (1)	445,171	658,421	216,461	Close-ended funds not available for redemption	Close-ended funds not available for redemption
Total Natural Resources	531,246	807,854	216,461		
Totals	\$ 16,437,660	\$ 16,086,549	\$ 3,316,965		

(1) Private funds consist of close-ended and open-ended funds generally in the form of limited partnerships. Close-ended funds have varying remaining fund terms between 1 to 15 years.

(2) Side pocket investments represent investments designated by a manager that are not available for liquidity in an otherwise liquid fund vehicle.

Included in Level 1 split-interest agreement investments above are readily marketable assets invested by the University separately from the AIF where the University serves as trustee with an aggregate fair value of \$87,085,000 and \$86,492,000 at June 30, 2020 and 2019, respectively. These amounts include assets related to the University Academic Component charitable gift annuities totaling \$43,979,000 and \$42,158,000 at June 30, 2020 and 2019, respectively. Included in these split-interest agreement investments are amounts held to meet legally mandated annuity reserves of \$29,006,000 and \$27,323,000 as of June 30, 2020 and 2019, respectively, as required by the laws of the following states where certain individual donors reside: California, Maryland, New Jersey and New York. Level 3 split-interest agreement investments are managed and invested outside of the University by external trustees.

Invested in the AIF with an aggregate fair value of \$168,792,000 and \$171,392,000 at June 30, 2020 and 2019, respectively, is a perpetual trust managed by an external trustee who has delegated investment decisions to the University. The University invests the assets of this trust in accordance with its endowment policy.

Consolidated Notes to Financial Statements

A summary of Level 3 assets included in split-interest agreement investments, where the University is not trustee, measured at fair value, as of June 30, 2020 and 2019 is as follows (in thousands):

	2020	2019
Charitable remainder trusts	\$ 19,487	\$ 18,511
Charitable lead trusts	5,763	4,568
Perpetual trusts	300,451	299,552
Total	\$ 325,701	\$ 322,631

Changes to the reported amounts of split-interest agreement investments measured at fair value using unobservable (Level 3) inputs as of June 30, 2020 and 2019 are as follows (in thousands):

	Charitable Remainder Trusts	Charitable Lead Trusts	Perpetual Trusts	Total
June 30, 2019	\$ 18,511	\$ 4,568	\$ 299,552	\$ 322,631
Net realized gains			2,974	2,974
Net unrealized gains/(losses)	976	1,225	(2,610)	(409)
Acquisitions			535	535
Liquidations		(30)		(30)
June 30, 2020	\$ 19,487	\$ 5,763	\$ 300,451	\$ 325,701

	Charitable Remainder Trusts	Charitable Lead Trusts	Perpetual Trusts	Total
June 30, 2018	\$ 17,239	\$ 5,621	\$ 298,116	\$ 320,976
Net realized gains			6,994	6,994
Net unrealized gains/(losses)	724	(1,023)	(4,055)	(4,354)
Acquisitions	1,191			1,191
Liquidations	(643)	(30)	(1,503)	(2,176)
June 30, 2019	\$ 18,511	\$ 4,568	\$ 299,552	\$ 322,631

The following tables set forth the fair value, related gains (losses) and notional amounts of the University's derivative instruments by contract type as of June 30, 2020 and 2019 (in thousands):

	2020			
	Notional Amount	Gross Derivative Assets	Gross Derivative Liabilities	Derivative Gains
Foreign currency contracts	\$ 112,672	\$ 301	\$ 916	\$ (2,442)
Futures contracts	(542,830)	16,403		(17,423)
Options contracts	(125,284)	428	1,306	(7,606)
Total	\$ (555,442)	\$ 17,132	\$ 2,222	\$ (27,471)

Consolidated Notes to Financial Statements

2019

	Notional Amount	Gross Derivative Assets	Gross Derivative Liabilities	Derivative Losses
Foreign currency contracts	\$ 121,124	\$ 1,167	\$ 33	\$ 369
Futures contracts	(398,548)			3,210
Options contracts	(122,014)		627	
Total	\$ (399,438)	\$ 1,167	\$ 660	\$ 3,579

The notional amount is representative of the volume and activity of the respective derivative type during the years ended June 30, 2020 and 2019.

Gross derivatives assets and liabilities are shown on the Consolidated Statements of Financial Position in Investments, at fair value and Accrued expenses and other liabilities, respectively. Derivative gains (losses) are shown in Return on investments, net on the Consolidated Statements of Activities, in the appropriate net asset classification.

A summary of the University's total investment return, net of external and direct internal investment expenses, for the years ended June 30, 2020 and 2019 is presented below (in thousands):

	2020	2019
AIF investment income	\$ 59,105	\$ 90,494
AIF realized and unrealized gains	457,907	793,459
Return on AIF	517,012	883,953
Other investment gains	37,940	69,588
Total Return on investments, net	\$ 554,952	\$ 953,541

7. Endowment

The composition and changes to the amount of the University's endowment at June 30, 2020 are as follows (in thousands):

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds		\$ 7,513,627	\$ 7,513,627
Quasi-endowment funds	\$ 7,363,736		7,363,736
June 30, 2020	\$ 7,363,736	\$ 7,513,627	\$ 14,877,363

	Without Donor Restrictions	With Donor Restrictions	Total
Net assets, June 30, 2019	\$ 7,252,228	\$ 7,397,533	\$ 14,649,761
Investment return	123,658	216,502	340,160
New gifts	11,219	236,657	247,876
Allocation of endowment assets for expenditure	(654,691)		(654,691)
Other investment allocation	(6,918)		(6,918)
Transfers to create board designated funds	302,623		302,623
Donor imposed Income Reinvestments		955	955
Other transfers	21,940	(24,343)	(2,403)
Released from restriction	313,677	(313,677)	
Net assets, June 30, 2020	\$ 7,363,736	\$ 7,513,627	\$ 14,877,363

Consolidated Notes to Financial Statements

The composition and changes to the amount of the University's endowment as of June 30, 2019 are as follows (in thousands):

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds		\$ 7,397,533	\$ 7,397,533
Quasi-endowment funds	\$ 7,252,228		7,252,228
June 30, 2019	\$ 7,252,228	\$ 7,397,533	\$ 14,649,761

	Without Donor Restrictions	With Donor Restrictions	Total
Net assets, June 30, 2018	\$ 6,828,370	\$ 6,949,071	\$ 13,777,441
Investment return	414,032	400,565	814,597
New gifts	6,999	357,012	364,011
Allocation of endowment assets for expenditure	(577,039)		(577,039)
Other investment allocation	(3,793)		(3,793)
Transfers to create board designated funds	288,291		288,291
Other transfers	3,634	(17,381)	(13,747)
Released from restriction	291,734	(291,734)	
Net assets, June 30, 2019	\$ 7,252,228	\$ 7,397,533	\$ 14,649,761

At June 30, 2020 and 2019, the aggregate amount of funds reported in Net assets with donor restrictions for which the fair value was below historic value was \$1,265,000 and \$0, respectively.

8. Property, Plant and Equipment, net

The components of PPE at June 30, 2020 and 2019 are as follows (in thousands):

	Estimated Useful Life in years	2020	2019
			\$
Land and land improvements	N/A to 20	423,467	438,885
Buildings and fixed equipment	5 to 50	10,475,473	10,032,085
Moveable equipment and other	4 to 20	2,136,837	2,013,160
Construction-in-progress		2,046,652	1,354,708
		15,082,429	13,838,838
Less: Accumulated depreciation		(6,304,344)	(5,809,846)
Property, plant and equipment, net		\$ 8,778,085	\$ 8,028,992

The University recorded \$533,289,000 and \$539,372,000 of depreciation expense for the years ended June 30, 2020 and 2019, respectively.

The University capitalized \$55,940,000 and \$35,748,000 of interest costs for the years ended June 30, 2020 and 2019, respectively.

The University has conditional asset retirement obligations of \$15,278,000 and \$16,320,000 as of June 30, 2020 and 2019, respectively, which primarily relate to asbestos contained in buildings and underground steam distribution piping and are included within Accrued expenses and other liabilities in the Consolidated Statements of Financial Position.

9. Split-Interest Agreements

Changes in the value of assets, liabilities and net assets pursuant to split-interest agreements as of June 30, 2020 and 2019 are as follows (in thousands):

2020	Assets	Liabilities	Net Assets
June 30, 2019	\$ 409,123	\$ (50,311)	\$ 358,812
New contributions	7,418	(3,951)	3,467
Investment income	2,038	(1,673)	365
Realized and unrealized gain, net	2,515		2,515
Payments and settlements	(8,308)	7,517	(791)
Actuarial adjustment		(2,418)	(2,418)
Net change	3,663	(525)	3,138
June 30, 2020	\$ 412,786	\$ (50,836)	\$ 361,950
2019	Assets	Liabilities	Net Assets
June 30, 2018	\$ 398,793	\$ (46,965)	\$ 351,828
New contributions	8,552	(8,898)	(346)
Investment income	1,882	(1,545)	337
Realized and unrealized gain, net	7,787		7,787
Payments and settlements	(7,891)	8,593	702
Actuarial adjustment		(1,496)	(1,496)
Net change	10,330	(3,346)	6,984
June 30, 2019	\$ 409,123	\$ (50,311)	\$ 358,812

10. Contingencies, Guarantees and Commitments

The University offers various loan programs for students and families to pay tuition, fees and other costs. Certain loans issued by private lending institutions are guaranteed by the University totaling \$20,644,000 and \$27,979,000 at June 30, 2020 and 2019, respectively. Upon default by the borrower, the University is required to pay all or a portion of the outstanding loan balance. The University recognizes a liability for the greater of the fair value of the guarantee or defaults in the portfolio of guaranteed loans. The recognized liability is \$3,005,000 and \$3,182,000 at June 30, 2020 and 2019, respectively and reflects the fair value of the guarantee on these outstanding loan balances.

Various lawsuits, claims and other contingent liabilities arise in the ordinary course of the University's education and health care activities. Based upon information currently available, management believes that any liability resulting therefrom will not materially affect the financial position or operations of the University.

The University is currently involved in various projects that have resulted in capital and property acquisition commitments from the University. As of June 30, 2020, approximately \$486,351,000 has been committed by the University.

11. Pension and Other Postretirement Benefit Costs

Retirement benefits are principally provided to employees through contributory defined contribution plans. The Academic Component's policy with respect to its contribution is to provide up to 9% of eligible employees' salaries, while the UPHS contribution can be up to 6.5%. The University's contributions to these plans amounted to \$231,054,000 and \$212,316,000 as of June 30, 2020 and 2019, respectively.

The University also has non-contributory defined benefit pension plans. Benefits under the plans generally are based on the employee's years of service and compensation during the years preceding retirement. Contributions to the plans are made in amounts necessary to at least satisfy the minimum required contributions as specified in the Internal Revenue Service Code and related regulations. The Academic Component's plan was frozen to new full-time entrants effective July 1, 2000 and part-time entrants effective July 1, 2018. UPHS' primary plan was frozen to new entrants effective July 1, 2010; the benefit accruals for all participants of the LGH and PHCS plans were frozen effective June 30, 2013 and December 31, 2011, respectively. In June 2020, UPHS paid \$78,879,000 from plan assets to an insurance company to buy out the total pension benefit for a portion of its retired participants.

Additionally, the University provides certain healthcare and life insurance benefits (OPEB) for retired employees. Only a limited number of employees may become eligible for such benefits if they reach retirement age while working for the University. These and similar benefits for active and certain retired employees are provided through insurance contracts.

The University uses a measurement date of June 30 for its defined benefit pension and OPEB plans.

Change in Plan Assets/ Obligation and Funded Status

The funded status of the plans is measured as the difference between the plan assets at fair value and the projected benefit obligation (PBO) for Pension Benefits or accumulated postretirement benefit obligation (APBO) for Other Postretirement Benefits. The resulting net liability is recorded in Accrued retirement benefits on the Statements of Financial Position. The following shows changes in the benefit obligation, plan assets and funded status (in thousands):

2020	Pension Benefits	Other Postretirement Benefits	Total
Change in Plan Assets			
Fair value of plan assets, beginning of year	\$ 2,696,740	\$ 522,365	\$ 3,219,105
University contributions	130,008	42,698	172,706
Plan participants' contributions	151	8,729	8,880
Actual return on plan assets	150,317	17,778	168,095
Benefits paid	(184,881)	(36,619)	(221,500)
Fair value of plan assets, end of year	\$ 2,792,335	\$ 554,951	\$ 3,347,286
Change in Benefit Obligation			
Benefit obligation, beginning of year (PBO/APBO)	\$ 3,750,476	\$ 1,014,328	\$ 4,764,804
Service cost	77,085	35,476	112,561
Interest cost	136,674	38,148	174,822
Plan participants' contributions	151	8,729	8,880
Net actuarial (gain)/loss	342,211	30,238	372,449
Benefits paid	(184,881)	(36,619)	(221,500)
Benefit obligation, end of year (PBO/APBO)	\$ 4,121,716	\$ 1,090,300	\$ 5,212,016
Funded status, end of year	\$ 1,329,381	\$ 535,349	\$ 1,864,730
Other retirement programs			103,521
Accrued retirement benefits			\$ 1,968,251

Consolidated Notes to Financial Statements

2019	Pension Benefits	Other Postretirement Benefits	Total
Change in Plan Assets			
Fair value of plan assets, beginning of year	\$ 2,590,798	\$ 505,340	\$ 3,096,138
University contributions	87,634	32,244	119,878
Plan participants' contributions	159	6,419	6,578
Actual return on plan assets	120,702	13,198	133,900
Benefits paid	(102,553)	(34,836)	(137,389)
Fair value of plan assets, end of year	\$ 2,696,740	\$ 522,365	\$ 3,219,105
Change in Benefit Obligation			
Benefit obligation, beginning of year (PBO/APBO)	\$ 3,319,649	\$ 916,367	\$ 4,236,016
Service cost	68,923	30,269	99,192
Interest cost	139,344	38,741	178,085
Plan participants' contributions	159	6,419	6,578
Net actuarial (gain)/loss	324,954	57,368	382,322
Benefits paid	(102,553)	(34,836)	(137,389)
Benefit obligation, end of year (PBO/APBO)	\$ 3,750,476	\$ 1,014,328	\$ 4,764,804
Funded status, end of year	\$ 1,053,736	\$ 491,963	\$ 1,545,699
Other retirement programs			105,986
Accrued retirement benefits			\$ 1,651,685

The Accumulated Benefit Obligation for the Pension Benefits was \$3,766,340,000 and \$3,354,141,000 at June 30, 2020 and 2019, respectively.

Net Periodic Benefit Cost

The components of net periodic benefit cost for pension benefits and other postretirement benefits are detailed below (in thousands). In the Consolidated Statements of Activities, service cost is reported as Compensation and benefits while the remaining components of net periodic benefit cost are reported as Pension, OPEB and other, net.

2020	Pension Benefits	Other Postretirement Benefits	Total
Net Periodic Cost			
Service cost	\$ 77,085	\$ 35,476	\$ 112,561
Interest cost	136,674	38,148	174,822
Expected return on plan assets	(184,845)	(39,251)	(224,096)
Amortization of:			
Net prior service cost		(387)	(387)
Net losses	53,500	6,992	60,492
Net periodic benefit cost	\$ 82,414	\$ 40,978	\$ 123,392

Consolidated Notes to Financial Statements

2019	Pension Benefits	Other Postretirement Benefits	Total
Net Periodic Cost			
Service cost	\$ 68,923	\$ 30,269	\$ 99,192
Interest cost	139,344	38,741	178,085
Expected return on plan assets	(169,595)	(37,969)	(207,564)
Amortization of:			
Net prior service cost		(386)	(386)
Net losses	30,968	2,447	33,415
Net periodic benefit cost	\$ 69,640	\$ 33,102	\$ 102,742

Net Assets Without Donor Restrictions

The University recorded the following year-end valuation adjustments to its Pension and Other Postretirement Benefit Plans in Pension, OPEB and Other, net in the Consolidated Statements of Activities (in thousands):

2020	Pension Benefits	Other Postretirement Benefits	Total
Net Assets Without Donor Restrictions			
Net actuarial loss	\$ 1,251,922	\$ 239,885	\$ 1,491,807
Net prior service cost/(credit)		(2,372)	(2,372)
Total	\$ 1,251,922	\$ 237,513	\$ 1,489,435
Adjustment to net assets without donor restrictions (gain)/loss	\$ 323,237	\$ 45,107	\$ 368,344

2019	Pension Benefits	Other Postretirement Benefits	Total
Net Assets Without Donor Restrictions			
Net actuarial loss	\$ 928,685	\$ 195,165	\$ 1,123,850
Net prior service cost/(credit)		(2,759)	(2,759)
Total	\$ 928,685	\$ 192,406	\$ 1,121,091
Adjustment to net assets without donor restrictions (gain)/loss	\$ 342,879	\$ 80,077	\$ 422,956

The estimated amount that will be amortized from Net assets without donor restrictions into net periodic benefit cost in 2021 is as follows (in thousands):

	Pension Benefits	Other Postretirement Benefits
Amortization of prior service credit		\$ (387)
Amortization of net losses	\$ 77,225	9,765

Actuarial Assumptions

The expected long-term rate of return on plan assets is management's best estimate of the average investment return expected to be received on the assets invested in the plan over the benefit period. The expected long-term rate of return on plan assets has been established by considering historical and future expected returns of the asset classes invested in by the pension trust, and the allocation strategy currently in place among those classes.

Consolidated Notes to Financial Statements

	Pension Benefits		Other Postretirement Benefits	
Weighted-Average Assumptions Used to Determine Benefit Obligations at Year End				
	2020	2019	2020	2019
Discount rate	3.05%	3.72%	3.28%	3.81%
Salary increase	3.22%	3.92%	N/A	N/A
Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost				
Discount rate	3.72%	4.26%	3.81%	4.29%
Expected long-term return on plan assets	7.26%	7.30%	7.50%	7.50%
Salary increase	4.03%	3.80%	N/A	N/A
Assumed Health Care Cost Trend Rates				
Initial trend rate	N/A	N/A	6.24%	6.28%
Ultimate trend rate	N/A	N/A	4.72%	4.71%
Fiscal year end that ultimate trend rate is reached	N/A	N/A	2037	2037

Assumed health care cost trend rates have a significant effect on the amounts reported for the Other postretirement benefits. A one-percentage-point change in assumed health care trend rates would have the following effects on Other postretirement benefits (in thousands):

	1-Percentage Point Increase	1-Percentage Point Decrease
2020		
Effect on total of service and interest cost	\$ 20,125	\$ (14,723)
Effect on APBO	224,798	(172,029)

Expected Contributions

The University expects to contribute \$133,894,000 and \$31,171,000 for pension benefits and other postretirement benefits, respectively, during the fiscal year ending June 30, 2021.

Expected Benefits Payments (in thousands):

Expected benefit payments for the year ending:	Pension Benefits	Other Postretirement Benefits before Medicare Part D Subsidy	Impact of Medicare Part D Subsidy
June 30, 2021	\$ 127,688	\$ 28,197	\$ 152
June 30, 2022	133,421	30,055	156
June 30, 2023	141,527	32,073	159
June 30, 2024	150,171	34,162	162
June 30, 2025	158,907	36,129	165
June 30, 2026 to June 30, 2030	915,914	209,711	852

Plan Assets and Allocations

The principal investment objectives for the pension and other postretirement benefits plans are to ensure the availability of funds to pay pension benefits as they become due under a broad range of future economic scenarios, to maximize long-term investment returns with an acceptable level of risk based on the pension obligations, and to invest the pension trust in a diversified manner.

Consolidated Notes to Financial Statements

The University's Office of Investments is responsible for the day-to-day management of the majority of the investments of the pension and other postretirement benefits. The investments are made in accordance with policies set out by the Investment Board which has been appointed by the Trustees. The pension and other postretirement benefit investments are similar in nature to those investments discussed in Notes 1 and 6 – Investments, at Fair Value. However, the actual allocations to specific investments within each asset class may vary due to certain restrictions imposed by investment managers and ERISA regulations.

A summary of plan assets, measured at fair value, as of June 30, 2020 and 2019, is as follows (in thousands):

Pension Benefits:

Assets	Level 1	Level 2	Level 3	Investments at NAV	2020
Short-term	\$ 49,251				\$ 49,251
Equity:					
US equities	197,651	\$ 949		\$ 195,134	393,734
International equities	143,448			225,478	368,926
Emerging market equities	135			158,366	158,501
Debt:					
US treasuries	250,287	10,160		1,944	262,391
Corporate bonds	121,245	114,848		211,629	447,722
Absolute return				660,490	660,490
Real estate				76,464	76,464
Private equity	2,016			261,780	263,796
Natural resources	51,196			60,232	111,428
Total assets	\$ 815,229	\$ 125,957	\$ -	\$ 1,851,517	\$ 2,792,703

Liabilities	Level 1	Level 2	Level 3	Investments at NAV	2020
Derivative instruments		\$ 368			\$ 368
Total liabilities	\$ -	\$ 368	\$ -	\$ -	\$ 368

Assets	Level 1	Level 2	Level 3	Investments at NAV	2019
Short-term	\$ 68,135				\$ 68,135
Equity:					
US equities	224,330	\$ 459		\$ 165,882	390,671
International equities	126,403			234,903	361,306
Emerging market equities	191			163,689	163,880
Debt:					
US treasuries	358,601	7,699		1,301	367,601
Corporate bonds	85,863	79,915		188,261	354,039
Absolute return				547,478	547,478
Real estate				60,890	60,890
Private equity	2,611			221,968	224,579
Natural resources	68,499			89,928	158,427
Total assets	\$ 934,633	\$ 88,073	\$ -	\$ 1,674,300	\$ 2,697,006

Liabilities	Level 1	Level 2	Level 3	Investments at NAV	2019
Derivative instruments		\$ 266			\$ 266
Total liabilities	\$ -	\$ 266	\$ -	\$ -	\$ 266

Consolidated Notes to Financial Statements

Other Postretirement Benefits:

Assets	Level 1	Level 2	Level 3	Investments at NAV	2020
Short-term	\$ 28,467				\$ 28,467
Equity:					
US equities	4,685			\$ 67,369	72,054
International equities				82,376	82,376
Emerging market equities	70			43,251	43,321
Debt:					
US treasuries	20,692				20,692
Corporate bonds				11,077	11,077
Absolute return				185,917	185,917
Real estate				33,203	33,203
Private equity				59,059	59,059
Natural resources	12,122			6,781	18,903
Total	\$ 66,036	\$ -	\$ -	\$ 489,033	\$ 555,069

Liabilities	Level 1	Level 2	Level 3	Investments at NAV	2020
Derivative instruments		\$ 118			\$ 118
Total	\$ -	\$ 118	\$ -	\$ -	\$ 118

Assets	Level 1	Level 2	Level 3	Investments at NAV	2019
Short-term	\$ 25,184				\$ 25,184
Equity:					
US equities				\$ 62,356	62,356
International equities				79,723	79,723
Emerging market equities	4,409			48,233	52,642
Debt:					
US treasuries	22,771				22,771
Corporate bonds				10,702	10,702
Absolute return				165,196	165,196
Real estate				24,102	24,102
Private equity				47,373	47,373
Natural resources	22,752			9,629	32,381
Total	\$ 75,116	\$ -	\$ -	\$ 447,314	\$ 522,430

Liabilities	Level 1	Level 2	Level 3	Investments at NAV	2019
Derivative instruments		\$ 65			\$ 65
Total	\$ -	\$ 65	\$ -	\$ -	\$ 65

As of June 30, 2020, the University has unfunded commitments to limited partnerships totaling \$270,012,000, which are expected to be called over the next 5 years.

Transfers between leveled assets are based on the actual date of the event which caused the transfer. As of June 30, 2020 and 2019 there were no transfers between Level 1 and 2.

Consolidated Notes to Financial Statements

Plan asset allocations by category are as follows:

2020 Allocation of Plan Assets	Pension Benefits		Other Postretirement Benefits	
	Target	Actual	Target	Actual
Short-term	0.0%	1.8%	0.0%	5.1%
Equity:				
US equities	12.2%	14.1%	10.0%	13.0%
International equities	13.1%	13.2%	16.0%	14.8%
Emerging markets equities	6.0%	5.7%	10.0%	7.8%
Debt:				
US treasuries	23.9%	9.4%	7.0%	3.7%
Corporate bonds	3.5%	16.0%	0.0%	2.0%
Absolute return	22.1%	23.7%	34.0%	33.5%
Real estate	2.7%	2.7%	4.0%	6.0%
Private equity	9.2%	9.4%	9.0%	10.7%
Natural resources	7.3%	4.0%	10.0%	3.4%
Total	100.0%	100.0%	100.0%	100.0%

Consolidated Notes to Financial Statements

12. Debt Obligations

Debt obligations at June 30, 2020 and 2019 are as follows (in thousands):

	Final Maturity	Effective Interest Rate at June 30, 2020	2020	2019
Academic Component:				
<u>Fixed rate debt obligations:</u>				
The Trustees of the University of Pennsylvania				
Series A of 2019 revenue bonds	02/2119	3.61%	\$ 300,000	
Series 2012 Taxable Bonds	09/2112	4.67%	300,000	\$ 300,000
Pennsylvania Higher Educational Facilities Authority (PHEFA)				
Series B of 2019 revenue bonds	02/2045	2.40% - 2.97%	213,585	
Series A of 2018 revenue bonds	08/2048	2.08% - 4.70%	183,145	183,145
Series A of 2017 revenue bonds	08/2046	2.26% - 3.72%	178,395	178,395
Series A of 2016 revenue bonds	08/2041	1.08% - 2.93%	120,680	167,435
Series A of 2015 revenue bonds	10/2045	1.40% - 2.63%	49,125	191,090
Series B of 2015 revenue bonds	10/2038	1.40% - 3.38%	159,460	160,950
Series C of 2015 revenue bonds	10/2035	3.68%	8,020	8,020
Series A of 2011 revenue bonds	09/2021	3.49% - 3.68%	7,590	7,590
Series of 2010 revenue bonds	09/2033			16,935
Series B of 2009 revenue bonds	09/2020	3.99%	2,245	4,435
Series C of 2009 revenue bonds	09/2019			4,095
Other loans	05/2031	3.00% - 4.50%	21,468	12,774
<u>Variable rate debt obligations:</u>				
PHEFA Series of 1990 revenue bonds	12/2020	0.36%	6,500	6,500
Washington County Authority Series of 2004	07/2034	0.01%	48,900	51,200
Total Academic Component outstanding bonds payable			1,599,113	1,292,564
Unamortized issuance costs, premiums and discounts, net			66,130	83,910
Total Academic Component debt obligations			\$ 1,665,243	\$ 1,376,474
UPHS:				
<u>Fixed rate debt obligations:</u>				
Lancaster County Hospital Authority (LCHA)				
Series A of 2016 revenue bonds	08/2042	1.25% - 3.52%	\$ 156,455	\$ 160,590
Series B of 2016 revenue bonds	08/2046	1.43% - 3.58%	128,050	128,050
PHEFA				
Series A of 2019 revenue bonds	08/2049	1.67% - 3.22%	534,870	
Series A of 2017 revenue bonds	08/2047	2.60% - 3.68%	400,000	400,000
Series C of 2016 revenue bonds	08/2041	0.94% - 3.08%	128,435	128,730
Series A of 2015 revenue bonds	08/2045	1.60% - 4.00%	257,495	278,975
Series A of 2012 revenue bonds	08/2042	2.27% - 4.08%	134,650	136,360
Series A of 2009 revenue bonds	08/2021	4.52% - 4.67%	12,115	22,780
New Jersey Health Care Facilities Financing Authority (NJHCFFA)				
Princeton Healthcare System Series A of 2016	07/2039	1.70% - 3.88%	173,660	178,670
University of Pennsylvania Health System Taxable Note	08/2047	4.01%	200,000	200,000
Lancaster General Hospital 2015 Taxable Note	08/2022	2.66%	67,798	70,335
Build to suit lease, net of related interest	Various	Various		75,094
Line of credit, outstanding balance	Various	Various		87,000
Mortgages, notes and other	Various	Various	160,914	76,312
<u>Variable rate debt obligations:</u>				
PHEFA Series A of 2014 revenue bonds	08/2044	1.30%	100,000	100,000
PHEFA Series A of 2008 revenue bonds	08/2038	0.12%	69,995	69,995
NJHCFFA Princeton Healthcare System Series B of 2016	07/2045	0.66%	65,000	65,000
NJHCFFA Princeton Healthcare System Series C of 2016	07/2045	0.67%	20,000	20,000
Total UPHS outstanding bonds payable			2,609,437	2,197,891
Unamortized issuance costs, premiums and discounts, net			181,480	132,128
Total UPHS debt obligations			2,790,917	2,330,019
Total University debt obligations			\$ 4,456,160	\$ 3,706,493

Consolidated Notes to Financial Statements

Contractual maturities of debt obligations are as follows (in thousands):

Fiscal Year	Academic Component	UPHS	Total
2021	\$ 28,837	\$ 98,663	\$ 127,500
2022	25,455	54,266	79,721
2023	26,520	116,629	143,149
2024	35,151	58,712	93,863
2025	29,128	62,006	91,134
Thereafter	1,454,022	2,219,161	3,673,183
Total Principal	1,599,113	2,609,437	4,208,550
Unamortized issuance costs, premiums & discounts	66,130	181,480	247,610
Total debt obligation	\$ 1,665,243	\$ 2,790,917	\$ 4,456,160

The University has letters of credit with various financial institutions to secure certain self-insured liabilities totaling \$19,096,000 and \$15,540,000 at June 30, 2020 and 2019, respectively, of which \$8,843,000 and \$7,829,000 were issued under a line of credit. The letters of credit have evergreen provisions for automatic renewal. There have been no draws under the letters of credit.

Academic Component

On August 6, 2019, the Trustees of the University of Pennsylvania (the "University") issued Taxable Bonds, Series A of 2019 in the aggregate principal amount of \$300,000,000. The proceeds of the sale of the Series A of 2019 Bonds will be used by the University for its general corporate purposes, including the financing or refinancing of capital projects and the payment of the cost of issuing the Series A of 2019 Bonds. Interest on the Series A of 2019 is fixed with coupons of 3.61%.

On August 14, 2019, Pennsylvania Higher Educational Facilities Authority (PHEFA) issued Series B of 2019 Taxable Refunding Revenue Bonds (PHEFA 2019B bonds) with an aggregate principal amount of \$213,585,000. The proceeds were used to fund an escrow which will be used to refund \$16,935,000 from the PHEFA Series 2010 revenue bonds, \$136,745,000 PHEFA Series A of 2015, and \$45,570,000 from the PHEFA Series A of 2016. The refunded bonds were legally defeased, and as such are no longer included among the University's reported liabilities. Interest on the PHEFA 2019B bonds is fixed with coupons ranging between 2.40% to 2.97%.

As a result of the legal defeasance of debt associated with the issuance of PHEFA 2019B bonds, the University reported a loss on early extinguishment of debt in Pension, OPEB and other net on the Consolidated Statements of Activities in the amount of \$3,618,000 for the year ended June 30, 2020.

On October 18, 2018, PHEFA issued Series A of 2018 revenue bonds (PHEFA 2018A bonds) with an aggregate principal amount of \$183,145,000. The proceeds were used to fund or reimburse the University for the cost of various capital projects. Interest on the PHEFA 2018A bonds is fixed with coupons ranging between 3.25% to 5.00%.

The University has variable rate debt in the amount of \$55,400,000 which is subject to optional tender by the holders upon seven days' notice. These bonds are reflected in the table above based on original scheduled maturities. In the event that the University receives notice of any optional tender on its variable rate demand bonds, the purchase price will be repaid from the remarketing of the bonds. However, in the event that the entire remarketing effort were to fail, the University would have the general obligation to purchase the bonds.

On June 14, 2016, the University entered into a five-year agreement with a financial institution, whereby the institution has agreed to provide a line of credit in the amount of \$100,000,000 for general purposes of the University. The University pays a fee annually on the unused amount of the line of credit. As of June 30, 2020, \$1,000,000 has been drawn under the agreement.

Consolidated Notes to Financial Statements

UPHS

The PHEFA Revenue Bonds, Lancaster County Hospital Authority (LCHA) Revenue Bonds and New Jersey Health Care Facilities Financing Authority (NJHCFFA) Revenue Bonds are secured by master notes issued under the UPHS Master Trust Indenture (MTI). The MTI and related agreements contain certain restrictive covenants which limit the issuance of additional indebtedness, and among other things, require UPHS to meet an annual debt service coverage requirement of “income available for debt service” (excess of revenue over expenses plus depreciation, amortization, interest expense and extraordinary items) at an amount equal to 110% of the annual debt service requirements. If the coverage requirement for a particular year is not met, within six months of the close of that fiscal year, UPHS must retain the services of a consultant to make recommendations to improve the coverage requirement. UPHS must also implement the recommendations of the consultant to the extent that they can be feasibly implemented. UPHS will not be considered to be in default of the provisions of the MTI so long as UPHS has sufficient cash flow to pay total operating expenses and debt service for the fiscal year. In both 2020 and 2019, UPHS met its debt service coverage requirement under the MTI. Additionally, UPHS has pledged its gross revenues to secure its obligation under the MTI.

On December 5, 2019, Pennsylvania Higher Educational Facilities Authority (PHEFA) issued UPHS Series A of 2019 revenue bonds in an aggregate principal amount of \$534,870,000. The proceeds were used to reimburse UPHS for \$484,738,000 million incurred in relation to various capital projects, and \$112,276,000 million of the remaining proceeds, including the issued premium, were deposited in a capital project fund held by trustee to be drawn upon for future capital expenditures. This portion of the financing is reflected as a noncash transaction in the Statement of Cash Flows. Future reimbursements from the capital project fund will be accounted for as a cash inflow from investing activities in the Statement of Cash Flows. The bonds have stated interest rates that range between 3.00% and 5.00%.

UPHS has variable rate debt in the amount of \$69,995,000 which is subject to optional tender by the holders upon seven days’ notice. These bonds are reflected in the debt obligations maturity table above based on original scheduled maturities. In the event that UPHS receives notice of any optional tender on its variable rate demand bonds, the purchase price will be repaid from the remarketing of the bonds. However, in the event that the entire remarketing effort were to fail, UPHS has in place a renewable direct pay letter of credit issued by Bank of America with an expiration date of April 15, 2023. In the event that the letter of credit cannot be drawn upon, UPHS would have the general obligation to purchase the bonds.

UPHS secured an \$82,132,000 loan on December 21, 2018 for the sole purpose of funding the development of a new ambulatory building. As of June 30, 2020, the entire balance has been drawn down to reimburse construction costs incurred by UPHS and is accounted for as a cash inflow from investing activities in the Statement of Cash Flows.

Upon adoption of the new accounting standard for leases, UPHS derecognized a build-to-suit lease liability of \$75,094,000 from Debt obligations with a corresponding asset of \$67,307,000 from PPE, resulting in a gain of \$8,022,000 recorded in Pension, OPEB and other, net. The remainder of the lease was accounted for as an operating lease under the new leasing guidance.

UPHS maintains lines of credit in the amount of \$250,000,000 to supplement liquidity and issue letters of credit to cover balances due on construction projects and reinsurance agreements. On April 7, 2020, UPHS entered into a one-year agreement with a commercial bank for \$150,000,000 line of credit which was immediately drawn down to provide additional liquidity during the COVID-19 pandemic. The remaining \$100,000,000 has a maturity of April 13, 2022. The outstanding balance as of June 30, 2020 and 2019 was \$0 and \$87,000,000, respectively.

Consolidated Notes to Financial Statements

Interest Rate Swap Agreements

The University enters into interest rate swap agreements to synthetically modify the interest rate terms of its long term debt portfolio. These agreements are not entered into for trading or speculative purposes. Fair value of these agreements is determined by obtaining quotes from Goldman Sachs Mitsui Marine Derivative Products, L.P. (GSMMDP) and Merrill Lynch, respectively, which are based on the income approach, using observable market data to discount future net payment streams and accordingly considers this to be a Level 2 measurement. The quotes provided also represent the amount the University would accept or be required to pay to transfer the agreement to GSMMDP and Merrill Lynch, respectively, or exit price as defined by the Fair Value Measurements standard. The University also takes into account the risk of nonperformance.

The following table summarizes the terms of the University's remaining interest rate swap agreements (in thousands):

	Academic Component		UPHS		
Notional Amounts	\$ 101,950	\$ 21,550	\$ 14,355	\$ 14,355	
Trade Date	11/6/2007	7/28/2006	7/15/2009	1/7/2010	
Maturity Date	7/1/2034	7/1/2041	8/15/2023	8/15/2023	
Rates:					
Receive	67% of 1-Month LIBOR	70% of 1-month LIBOR	3.184%	2.902%	
Pay	3.573%	3.980%	SIFMA index	SIFMA index	

The following tables summarize the fair value of the interest rate swap agreements, not designated as hedging instruments, as of June 30, 2020 and 2019, and the related gains/(losses) on the interest rate swap agreements, both realized and unrealized, for the years ended June 30, 2020 and 2019 (in thousands):

Consolidated Statements of Financial Position	Line Item	2020	2019
<u>Asset interest rate swaps</u>			
UPHS	Other assets	\$ 1,425	\$ 1,469
Total Asset interest rate swaps		\$ 1,425	\$ 1,469
<u>Liability interest rate swaps</u>			
Academic Component	Accrued expenses and other liabilities	\$ 28,801	\$ 21,379
UPHS	Accrued expenses and other liabilities	8,854	6,371
Total Liability interest rate swaps		\$ 37,655	\$ 27,750
Consolidated Statements of Activities	Line Item	2020	2019
Academic Component	Return on investments, net	\$ (9,772)	\$ (7,497)
UPHS	Return on investments, net	511	737
Total		\$ (9,261)	\$ (6,760)

Consolidated Notes to Financial Statements

13. Net Assets

The major components of net assets at June 30, 2020 and 2019 are as follows (in thousands):

2020	Without donor restrictions	With donor restrictions	Total
General operating	\$ 3,931,320	\$ 503,062	\$ 4,434,382
Sponsored programs	63,592		63,592
Capital		130,462	130,462
Student loans	7,713		7,713
Planned giving agreements		52,757	52,757
Quasi-endowment	7,363,736		7,363,736
Endowment, subject to spending rule		3,109,738	3,109,738
Endowment, held in perpetuity		4,403,889	4,403,889
Total	\$ 11,366,361	\$ 8,199,908	\$ 19,566,269

2019	Without donor restrictions	With donor restrictions	Total
General operating	\$ 4,085,420	\$ 449,779	\$ 4,535,199
Sponsored programs	44,217		44,217
Capital		133,693	133,693
Student loans	10,387		10,387
Planned giving agreements		51,576	51,576
Quasi-endowment	7,252,228		7,252,228
Endowment, subject to spending rule		3,203,289	3,203,289
Endowment, held in perpetuity		4,194,244	4,194,244
Total	\$ 11,392,252	\$ 8,032,581	\$ 19,424,833

14. Leases

The University leases research labs and office space under operating leases expiring through December 2043. Under the newly adopted accounting standard for leases, a lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. On the Consolidated Statements of Financial Position, lessees are required to record Right-of-Use assets, representing the right to use the underlying assets for the lease term, and Lease liabilities, representing the obligation to make lease payments arising from the lease based on the present value of lease payments over the lease term. The University has made the following elections: (1) to adopt a package of practical expedients relating to reassessment, (2) to exclude leases with a term of less than one year, and (3) to use an incremental borrowing rate for discounting leases, as applicable. At June 30, 2020, Right-of-Use assets recorded in Other assets were \$438,368,000 and Lease liabilities recorded in Accrued expenses and other liabilities were \$447,778,000. At June 30, 2020, the weighted average remaining lease term was 10.6 years and the weighted average discount rate was 3.55%. Rental expense, totaling \$136,529,000 (including amortizations related to Right-of-Use assets and Lease liabilities of \$68,189,000) and \$120,960,000, for the years ended June 30, 2020 and 2019, respectively, is included in Other operating expenses on the Consolidated Statements of Activities.

Consolidated Notes to Financial Statements

Future maturities of lease liabilities at June 30, 2020 are as follows (in thousands):

Year ending June 30,	
2021	\$ 70,862
2022	64,262
2023	54,887
2024	50,878
2025	45,651
Thereafter	<u>267,196</u>
Total lease payments	<u>\$ 553,736</u>
Less imputed interest	<u>(105,958)</u>
Total Future lease payments	<u>\$ 447,778</u>

Future minimum lease payments at June 30, 2019 (prior to newly adopted standard) were as follows (in thousands):

Year ending June 30,	
2020	\$ 101,735
2021	88,750
2022	78,748
2023	67,668
2024	63,082
Thereafter	<u>310,212</u>
Total minimum lease payments	<u>\$ 710,195</u>

15. Functional Classification of Expenditures

Expenses for the years ended June 30, 2020 and 2019 are categorized on a functional basis as follows (in thousands):

	2020					
	Instruction, student services & academic support	Hospital & physician practices	Research	Institutional support	Enterprises & independent operations	Total
Compensation and benefits	\$ 1,095,779	\$ 4,256,950	\$ 490,783	\$ 266,324	\$ 203,832	\$ 6,313,668
Depreciation and amortization	88,149	324,642	44,648	20,510	57,054	535,003
Interest on indebtedness	16,027	36,741	23,637	207	11,148	87,760
Other operating expense	532,648	2,929,459	332,312	42,231	171,605	4,008,255
Total operating expense	1,732,603	7,547,792	891,380	329,272	443,639	10,944,686
Non-service net periodic benefit cost	1,880	7,302	842	457	350	10,831
Total	\$ 1,734,483	\$ 7,555,094	\$ 892,222	\$ 329,729	\$ 443,989	\$ 10,955,517

	2019					
	Instruction, student services & academic support	Hospital & physician practices	Research	Institutional support	Enterprises & independent operations	Total
Compensation and benefits	\$ 1,044,075	\$ 4,026,781	\$ 466,938	\$ 257,576	\$ 195,821	\$ 5,991,191
Depreciation and amortization	86,651	332,813	43,898	20,147	56,726	540,235
Interest on indebtedness	7,789	54,492	23,665	296	8,568	94,810
Other operating expense	564,089	2,727,834	347,405	44,087	189,287	3,872,702
Total operating expense	1,702,604	7,141,920	881,906	322,106	450,402	10,498,938
Non-service net periodic benefit cost	619	2,386	277	153	115	3,550
Total	\$ 1,703,223	\$ 7,144,306	\$ 882,183	\$ 322,259	\$ 450,517	\$ 10,502,488

Consolidated Notes to Financial Statements

Operation and maintenance of PPE and depreciation are allocated to functional classifications based on square footage. Interest expense is generally allocated to functional classifications of the activity that directly benefited from the proceeds of the debt. Non-service net periodic benefit cost is allocated to functional classifications based on compensation and benefits.

16. Liquidity and Availability

As of June 30, 2020 and 2019, respectively, financial assets and liquidity resources available within one year for general expenditure, such as operating expenses, scheduled principal payments on debt and capital construction costs not financed with debt, were as follows (in thousands):

	2020	2019
Financial assets:		
Cash & cash equivalents	\$ 2,117,979	\$ 1,375,469
Receivables, net	1,213,513	1,217,065
Pledge payments available for operations	65,559	75,598
Investments	7,103,005	7,958,710
Total financial assets available within one year	10,500,056	10,626,842
Liquidity resources:		
Bank lines of credit	340,157	113,000
Total financial assets and liquidity resources available within one year	\$ 10,840,213	\$ 10,739,842

The University's cash flows have seasonal variations during the year attributable to tuition billing, patient service reimbursement and a concentration of contributions received at calendar and fiscal year-end. To manage liquidity, the University maintains lines of credit with several banks that are drawn upon as needed during the year to manage cash flows. Management has the discretion to utilize the full amount of quasi-endowment funds for general expenditures.

17. Subsequent Events

The University has evaluated subsequent events for the period from June 30, 2020 through October 7, 2020, the date the consolidated financial statements were issued.

On July 14, 2020, the University issued Taxable Bonds, Series A of 2020 in the aggregate principal amount of \$300,000,000. The proceeds of the sale of the Series A of 2020 Bonds will be used by the University for its general corporate purposes, including the financing or refinancing of capital projects and the payment of the cost of issuing the Series A of 2020 Bonds. Interest on the Series A of 2020 is fixed with coupons of 2.396%.

Schedule of Expenditures of Federal Awards

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification (Optional)	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DEPARTMENT OF AGRICULTURE									
AGRICULTURAL RESEARCH BASIC AND APPLIED RESEARCH	10.001		CRDF GLOBAL	59-0210-8-184		\$3,901	\$37,764	RESEARCH AND DEVELOPMENT	\$710,017,793
AGRICULTURAL RESEARCH BASIC AND APPLIED RESEARCH	10.001		CRDF GLOBAL	59-0210-6-004		\$6,160	\$37,764	RESEARCH AND DEVELOPMENT	\$710,017,793
AGRICULTURAL RESEARCH BASIC AND APPLIED RESEARCH	10.001	58-8072-6-027				\$27,703	\$37,764	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - PLANT AND ANIMAL DISEASE, PEST CONTROL, AND ANIMAL CARE	10.025	AP19VSNVSL00C030				\$826	\$191,430	RESEARCH AND DEVELOPMENT	\$710,017,793
PLANT AND ANIMAL DISEASE, PEST CONTROL, AND ANIMAL CARE	10.025	AP18VSNVSL00C025				\$2,229	\$191,430	RESEARCH AND DEVELOPMENT	\$710,017,793
PLANT AND ANIMAL DISEASE, PEST CONTROL, AND ANIMAL CARE	10.025	AP19PPQS&T00C206				\$52,212	\$191,430	RESEARCH AND DEVELOPMENT	\$710,017,793
PLANT AND ANIMAL DISEASE, PEST CONTROL, AND ANIMAL CARE	10.025	AP19VSNVSL00C030				\$136,163	\$191,430	RESEARCH AND DEVELOPMENT	\$710,017,793
ANIMAL HEALTH AND DISEASE RESEARCH	10.207	NL18AHDRXXXG067				\$21,346	\$56,855	RESEARCH AND DEVELOPMENT	\$710,017,793
ANIMAL HEALTH AND DISEASE RESEARCH	10.207	NI19AHDRXXXG046				\$35,509	\$56,855	RESEARCH AND DEVELOPMENT	\$710,017,793
SUSTAINABLE AGRICULTURE RESEARCH AND EDUCATION	10.215		UNIVERSITY OF VERMONT	GNE18-164-32231		\$699		RESEARCH AND DEVELOPMENT	\$710,017,793
AGRICULTURAL AND RURAL ECONOMIC RESEARCH, COOPERATIVE AGREEMENTS AND COLLABORATIONS	10.250	58-4000-5-0092				\$1,815	\$1,815	RESEARCH AND DEVELOPMENT	\$710,017,793
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2018-67015-27494			\$83,440	\$231,667	\$335,255	RESEARCH AND DEVELOPMENT	\$710,017,793
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2017-67021-26601				\$9,736	\$335,255	RESEARCH AND DEVELOPMENT	\$710,017,793
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2014-67013-21725				\$17,210	\$335,255	RESEARCH AND DEVELOPMENT	\$710,017,793
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2017-67015-26910				\$76,642	\$335,255	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - STATE ADMINISTRATIVE MATCHING GRANTS FOR THE SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM	10.561		PENNSYLVANIA STATE UNIVERSITY	5000426-COP-UN		\$410	\$1,059,621	SNAP CLUSTER	\$1,059,621
STATE ADMINISTRATIVE MATCHING GRANTS FOR THE SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM	10.561		PENNSYLVANIA STATE UNIVERSITY	5984-UNI-COP-9151		\$288,806	\$1,059,621	SNAP CLUSTER	\$1,059,621
STATE ADMINISTRATIVE MATCHING GRANTS FOR THE SUPPLEMENTAL NUTRITION ASSISTANCE PROGRAM	10.561		PENNSYLVANIA STATE UNIVERSITY	5000426-COP-UN		\$770,405	\$1,059,621	SNAP CLUSTER	\$1,059,621
COLLABORATIVE FOREST RESTORATION	10.679	14-JV-11242308-138				\$11,376	\$11,376	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL DEPARTMENT OF AGRICULTURE						\$83,440	\$1,694,815		
DEPARTMENT OF COMMERCE									
CLIMATE AND ATMOSPHERIC RESEARCH	11.431		PRINCETON UNIVERSITY	NA100AR4310092		\$22	\$22	RESEARCH AND DEVELOPMENT	\$710,017,793
ARRANGEMENTS FOR INTERDISCIPLINARY RESEARCH INFRASTRUCTURE	11.619		UNIVERSITY OF DELAWARE	SUB TO 70NANB17H002		-\$6,472	\$128,449	RESEARCH AND DEVELOPMENT	\$710,017,793
ARRANGEMENTS FOR INTERDISCIPLINARY RESEARCH INFRASTRUCTURE	11.619		CARNEGIE MELLON UNIVERSITY	1042521-400291		\$27,969	\$128,449	RESEARCH AND DEVELOPMENT	\$710,017,793
ARRANGEMENTS FOR INTERDISCIPLINARY RESEARCH INFRASTRUCTURE	11.619		UNIVERSITY OF DELAWARE	SUB TO 70NANB17H002		\$37,703	\$128,449	RESEARCH AND DEVELOPMENT	\$710,017,793
ARRANGEMENTS FOR INTERDISCIPLINARY RESEARCH INFRASTRUCTURE	11.619		UNIVERSITY OF DELAWARE	SUB TO 70NANB17H002		\$69,249	\$128,449	RESEARCH AND DEVELOPMENT	\$710,017,793
NATASHA SARIN RESEARCH WITH CFPB ECONOMISTS	11.RD	IPA NATASHA SARIN				\$24,756	\$24,756	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL DEPARTMENT OF COMMERCE							\$153,227		
DEPARTMENT OF DEFENSE									
DOD PHASE II STTR 12.A, TOPIC NO. A12A-T009	12.000		CHARLES RIVER ANALYTICS, INC.	SC1906402		\$99,316	\$99,316	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2690				\$104,465	\$162,196	\$10,539,042	RESEARCH AND DEVELOPMENT
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2930				\$150,299	\$266,424	\$10,539,042	RESEARCH AND DEVELOPMENT
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2012				\$351,829	\$563,923	\$10,539,042	RESEARCH AND DEVELOPMENT
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-1-2497				\$1,098,927	\$1,797,699	\$10,539,042	RESEARCH AND DEVELOPMENT
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2661				\$1,179,350	\$1,417,039	\$10,539,042	RESEARCH AND DEVELOPMENT
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	FA8750-20-20-0501				\$57	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-11-1-0596				\$71	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-08-1-0747				\$2,807	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300		GEORGIA INSTITUTE OF TECHNOLOGY	RF228-G2		\$4,586	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300		DUKE UNIVERSITY	SUB TO ONR ADV ACCT		\$10,141	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-15-1-2047				\$27,673	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300		STANFORD UNIVERSITY	61805594-125845		\$29,348	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-1-2620				\$34,179	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300		UNIVERSITY OF ILLINOIS	099963-17889		\$51,527	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-1-2580				\$56,820	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-1-2253				\$63,032	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300		UNIVERSITY OF MASSACHUSETTS-AMHERST	17-009730 A 00		\$75,173	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-20-1-2744				\$87,455	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-01-2076				\$92,879	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-16-1-2350				\$95,365	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-1-2248			\$102,801	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-1-2574			\$121,039	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	FA8750-19-2-3334			\$196,083	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
<i>BASIC AND APPLIED SCIENTIFIC RESEARCH</i>	12.300		STANFORD UNIVERSITY	62145214-107484	\$197,050	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-15-1-2006			\$210,684	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-16-1-2539			\$230,213	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
<i>BASIC AND APPLIED SCIENTIFIC RESEARCH</i>	12.300		RENSELAER POLYTECHNIC INSTITUTE	A20-0047-5002	\$259,072	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-1-2353			\$270,666	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-1-2618			\$329,620	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-17-1-2093			\$450,189	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-1-2557			\$490,968	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-15-1-2029			\$497,174	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00015-16-1-2010			\$518,389	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-16-1-2817			\$696,153	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-1-2021			\$1,130,547	\$10,539,042	RESEARCH AND DEVELOPMENT	\$710,017,793	
<i>SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION</i>	12.351		UNIVERSITY OF MICHIGAN	SUBK0009972	\$171,610	\$171,610	RESEARCH AND DEVELOPMENT	\$710,017,793	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-14-1-0060			\$17,194	\$442,595	RESEARCH AND DEVELOPMENT	\$710,017,793	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-14-1-0008			\$18,050	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-14-1-0008				-\$15,075	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1910461			\$45,489	\$290,024	RESEARCH AND DEVELOPMENT	\$710,017,793	
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		CITIZENS UNITED FOR RESEARCH IN EPILEPSY	CURE	\$46,709	\$288,038	RESEARCH AND DEVELOPMENT	\$710,017,793	
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		DENVER RESEARCH INSTITUTE	MSRC-FY19-02	\$136,780	\$336,196	RESEARCH AND DEVELOPMENT	\$710,017,793	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH18C0163			\$222,410	\$333,132	RESEARCH AND DEVELOPMENT	\$710,017,793	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0796			\$228,750	\$255,013	RESEARCH AND DEVELOPMENT	\$710,017,793	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0555			\$416,919	\$555,059	RESEARCH AND DEVELOPMENT	\$710,017,793	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0630				-\$15,636	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		UNIVERSITY OF SOUTHERN CALIFORNIA	74900858		-\$5,820	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0717				-\$777	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO CHILDREN'S HOSPITAL OF PHILADELPHIA	161083-155536		-\$680	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION WISTAR INSTITUTE	1820		\$2,071	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420			35521-02-314; XU		\$2,998	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810503				\$4,009	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		UNIVERSITY OF MARYLAND-BALTIMORE COUNTY	DOD00006-01		\$5,073	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		WISTAR INSTITUTE	35551-02-382		\$6,166	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0780				\$6,310	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0363				\$7,108	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		OREGON HEALTH & SCIENCE UNIVERSITY	1008339_UPA		\$15,899	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		NATIONAL TRAUMA INSTITUTE	NTI-CLOTT17-04		\$15,982	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		FOX CHASE CANCER CENTER	22782-01		\$19,029	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		UNIVERSITY OF WASHINGTON	UWSC9138		\$20,032	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		FOX CHASE CANCER CENTER	27799-01		\$20,562	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0013				\$22,477	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0237				\$23,741	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		UNIVERSITY OF MASSACHUSETTS	19-010887-A 00		\$34,403	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010009				\$35,029	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		UNIVERSITY OF ILLINOIS AT CHICAGO	17094		\$48,526	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1910829				\$56,030	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0675				\$56,797	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0399				\$59,479	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		GEORGETOWN UNIVERSITY	413814_GR413762-UPENN		\$60,808	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420					\$61,377	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		THOMAS JEFFERSON UNIVERSITY	08004000X16001		\$62,543	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		UNIVERSITY OF CINCINNATI	010376-003		\$66,960	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		MOFFITT CANCER CTR	12-18717-99-1-G2		\$71,583	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0404				\$73,243	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		CHILDREN'S HOSPITAL OF PHILADELPHIA	8901940917		\$90,719	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	102255C		\$91,071	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0595				\$125,251	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</i>	12.420		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	113305C		\$130,936	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810274				\$134,076	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1910137			\$138,619	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0404			\$154,283	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810734			\$163,477	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1820067			\$172,509	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0092			\$199,008	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0082			\$199,981	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0447			\$208,282	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0264			\$224,735	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810289			\$272,662	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810635			\$309,914	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010008			\$341,777	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810503			\$347,450	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0594			\$366,631	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1920002			\$731,655	\$7,743,134	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910263			\$69,377	\$232,768	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-17-1-0438			\$70,490	\$202,776	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-17-1-0229			\$101,312	\$137,263	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-12-1-0509			\$119,364	\$119,364	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1810327			\$449,843	\$1,022,027	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1810244			\$734,040	\$1,424,549	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1810119				-\$828	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF2010113				\$60	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910503				\$7,106	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910458				\$14,869	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431		CARNEGIE MELLON UNIVERSITY	1130203-373301	\$16,574	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431		NORTHEASTERN UNIV	504139-78050	\$43,085	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910350			\$51,407	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-16-1-0447			\$55,206	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-16-1-0288			\$69,914	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-16-1-0290			\$71,523	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431		CALIFORNIA INSTITUTE OF TECHNOLOGY	52-1097908	\$100,971	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-17-1-0017			\$114,816	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431		GEORGE WASHINGTON UNIVERSITY	38850-1-CCNS21590F	\$115,218	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910342			\$131,977	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910109			\$136,754	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-17-1-0436			\$138,993	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431		UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN	0078446-16767	\$159,133	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-17-1-0083			\$165,146	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910155			\$170,164	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431		UNIVERSITY OF ROCHESTER	417358 / URFAD: GR510801	\$187,914	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910249			\$214,623	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431		UNIVERSITY OF CALIFORNIA, SANTA BARBARA	KK1711	\$234,850	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC SCIENTIFIC RESEARCH	12.431	W911NF1910087			\$396,191	\$5,734,413	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC, APPLIED, AND ADVANCED RESEARCH IN SCIENCE AND ENGINEERING	12.630	FA9550-18-1-0194			\$93,554	\$357,750	RESEARCH AND DEVELOPMENT	\$710,017,793
BASIC, APPLIED, AND ADVANCED RESEARCH IN SCIENCE AND ENGINEERING	12.630	W911NF-17-2-0181			\$5,065,065	\$7,873,813	RESEARCH AND DEVELOPMENT	\$710,017,793
UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS	12.750		HENRY M. JACKSON FOUNDATION	307226-1.00-64373		\$464	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA2386-18-1-4083			\$18,961	\$122,912	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-18-1-0133				\$140	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-20-1-0111				\$2,423	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-20-1-0060				\$25,121	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-19-1-0265				\$50,425	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-19-1-0326				\$113,981	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800		UNIVERSITY OF TEXAS AT AUSTIN	UTA16-001254	\$116,382	\$2,094,071	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800		EMORY UNIVERSITY	A007760	\$118,466	\$2,094,071	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-18-1-0497			\$121,028	\$2,094,071	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800		HARVARD UNIVERSITY	123885-5079398	\$125,482	\$2,094,071	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-19-1-0285			\$134,182	\$2,094,071	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800		TULANE UNIVERSITY	TUL-SCC-553957-15/16	\$152,487	\$2,094,071	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-18-1-0133			\$179,971	\$2,094,071	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800		WRIGHT STATE UNIVERSITY	669737-1	\$181,456	\$2,094,071	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA9550-20-1-0092			\$319,260	\$2,094,071	RESEARCH AND DEVELOPMENT	\$710,017,793
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA2386-17-1-4656			\$330,355	\$2,094,071	RESEARCH AND DEVELOPMENT	\$710,017,793
LANGUAGE GRANT PROGRAM	12.900	H98230-19-0164			\$63,246	\$63,246	OTHER PROGRAMS	\$15,539,552
MATHEMATICAL SCIENCES GRANTS	12.901	H98230-19-1-0004			\$1,390	\$1,390	OTHER PROGRAMS	\$15,539,552
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011820056			\$32,048	\$113,132	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	N66001-14-2-4032			\$156,463	\$660,362	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	FA8650-18-2-7840			\$159,937	\$239,077	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	FA8750-19-2-0201			\$197,202	\$599,828	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011623730 & HR0011623730-1			\$239,871	\$414,366	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-16-C-0056			\$261,155	\$786,378	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-19-2-0016			\$291,912	\$747,493	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-18-2-0053			\$354,600	\$528,423	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	FA8750-18-2-0117			\$954,323	\$1,331,347	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		COLUMBIA UNIVERSITY	1(GG010681-01)		-\$567	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	FA8750-18-2-0117				\$16	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-19-2-0016				\$279	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011624364-00				\$9,852	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		GLADSTONE INSTITUTES	R2451-E		\$40,250	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	FA8650-18-1-7828				\$62,980	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		DUKE UNIVERSITY	3130755		\$107,498	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		RUTGERS UNIVERSITY	5911		\$119,844	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		CENTER FOR OPEN SCIENCE	SUB TO N660011924015		\$152,804	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-19-2-0013				\$154,427	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		UNIVERSITY OF NOTRE DAME	203488UPENN		\$202,278	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-15-2-0023				\$203,970	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR00111820052				\$314,568	\$6,788,605	RESEARCH AND DEVELOPMENT	\$710,017,793
SPECIFICATION AND CORRECT-BY-CONSTRUCTION SYNTHESIS OF CONTROLPROTODC	12.RD	FA8650-15-C-2546			-\$46,419	-\$46,419	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
NEURAL SIGNALS OF MESSAGE EFFECTIVENESS	12.RD	FA8650-17-C-7712	NEXT CENTURY CORPORATION	POINT-1001	\$75,955	\$317,205	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
INTEGRATED STATIC AND DYNAMIC APPROACHES TO HIGH-ASSURANCE FOR LEARNIN	12.RD	FA8750-18-C-0090			\$94,269	\$1,155,341	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
CORPORA OF ANNOTATED EVENTS REPRESENTED UNDER SCHEMAS (CAERUS)	12.RD	FA8750-19-C-0203			\$117,125	\$833,378	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
SONICVIPER	12.RD	H98230-15-C-0825			\$163,691	\$2,704,445	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
CAIRO-MS: CONFLICTING ACCOUNT INFORMATION RESOURCES IN OMNIVOROUS MEDI	12.RD	FA8750-18-C-0013			\$288,989	\$1,505,888	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
SIREN-IL: SPECIALIZED INTRA/INTERLINGUAL RESOURCES FOR EMERGENT NEWS -	12.RD	HR0011-15-C-0123			\$291,232	\$1,258,915	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
ELECTROCHEMICAL DEPOSITION OF THICK AND CONTINUOUS ELECTRODES FOR HIGH	12.RD	HR001119C0056			\$326,368	\$464,645	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
TRANSFORMING RESEARCH AND CLINICAL KNOWLEDGE IN TBI (TRACK-TBI) HIGH	12.RD	W911QY-14-C-0070	UNIVERSITY OF PITTSBURGH	0043845-11		-\$287,144	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
PROGRESSIVE MODEL GENERATION FOR ADAPTIVE RESILIENT SYSTEM SOFTWARE	12.RD	N00014-15-C-0126	GRAMMATECH	GT S14-04		-\$1,878	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
LIMB COOLING DEVICE TO PRESERVE ISCHEMIC EXTREMITY FOR PROLONGED FIELD	12.RD	W81XWH19C0036	ADVANCED COOLING TECHNOLOGIES, INC	35115		-\$12	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - UNDO: UNDERACTUATED NATURALLY-STABILIZED ONE-MOTOR ROBOT	12.RD	HR001119C0052				\$141	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
A MULTI CENTER PROSPECTIVE OBSERVATIONAL STUDY OF NERVE REPAIR AND REC	12.RD	W81XWH-15-2-0074	JOHNS HOPKINS UNIVERSITY	SUB TO W81XWH-15-2-0074		\$201	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - DISTINGUISHING BRAIN STATES AND RESOLVING STATE TRANSITIONS	12.RD	W911NF-10-2-0022	DCS CORPORATION	APX02-0006 - TASK ORDER 001		\$558	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
THE EFFECT OF TRANEXAMIC ACID ON HYPERFIBRINOLYSIS IN THE DOG FOLLOWIN	12.RD	W81XWH-17-C-0054	NORTH CAROLINA STATE UNIVERSITY	2016-2475-02		\$1,321	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
INFRASCAN 3000: NEAR-INFRARED SPECTROSCOPY (MODEL 3000) IN SEVERE BRAI	12.RD	W911QY-14-C-0082	INFRASCAN, INC.	KALANURIA - 827947		\$6,293	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
SELF-RECONFIGURABLE MODULAR GROUND ROBOTS	12.RD	140D0420C0049	TRITON SYSTEMS, INC	TSI-2650-20-20201255		\$9,180	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
DEVELOPMENT OF THERAPEUTIC STRATEGIES FOR NF1-ASSOCIATED OPTIC PATHWAY	12.RD	W81XWH-18-1-0685	CHILDREN'S RESEARCH INSTITUTE	30004908-01		\$9,954	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
REGULATION OF MYELOMA PROGRESSION BY PROTEIN CITRULLINATION	12.RD	W81XWH1910630	WISTAR INSTITUTE	35611-02-370		\$16,895	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
EXPLOITING LANGUAGE INFORMATION FOR SITUATIONAL AWARENESS (ELISA)	12.RD	HR0011-15-C-0115	UNIVERSITY OF SOUTHERN CALIFORNIA	67104157		\$18,587	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
WARETOWN WIND TUNNEL IMPROVEMENTS FOR DUNE ECOGEOMORPHOLOGY RESEARCH &	12.RD	W912HZ 18P0090				\$24,834	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
APPLYING NOVEL MATERIALS AND FABRICATION TECHNIQUES TO HIGH EFFICIENCY	12.RD	W911NF18C0057	SPARK THERMIONICS	SUB TO W911NF18C0057		\$28,001	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
INCIDENTAL SUPERVISION FOR INFORMATION EXTRACTION IN LOW RESOURCE LANG	12.RD	HR0011-15-C-0113	BBN SYSTEMS AND TECHNOLOGIES	SUB TO HR0011-15-C-0113		\$34,808	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
RAPID QUANTITATIVE IN-SITU PROTEIN AND GENE EXPRESSION PLATFORM TECHNO	12.RD	HDTRA114-AMD3-CBA-01-2-0061	OPTICAL BIOSYSTEMS INC	UPENN		\$36,339	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
HYPOTHESIS-GUIDED MODEL REVISION OVER MULTIPLE ALIGNED REPRESENTATIONS	12.RD	HR001120C0040	PALO ALTO RESEARCH CENTER	P315541		\$37,056	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
SECURE HANDLING OF ISOLATED EXECUTABLES WITHOUT LEAKING (CLOSURE).	12.RD	HR001119S0017	PERSPECTA LABS INC	PO-0018618		\$41,352	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
IBIS: IMPLANTABLE BIOLUMINESCENCE INTERFACE SYSTEM FOR AN ALL-OPTICAL	12.RD	N66001-17-C-4012	PIERCE (JOHN B.) LABORATORY	275-F		\$45,660	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
CONTOUR BASED IMAGE SEGMENTATION 0 STTR PHASE I	12.RD	FA8750-19-C-0066	VY CORPORATION	SUB TO FA8750-19-C-0066		\$47,380	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
BEHAVIORAL CHARACTERIZATION OF ODOR DETECTION DOGS FOR SELECTION OF PO	12.RD	70RSAT19CB0000014	BATTELLE MEMORIAL INSTITUTE	769331		\$52,225	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
BRASS	12.RD	FA8750-16-C-007	BAC SYSTEMS	921073		\$52,919	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
FUEL-EFFICIENT NANO FLUID GEAR OIL	12.RD	W56HZV-18-C-0025	PIXELLENT TECHNOLOGIES	10053480		\$60,345	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

ELECTROMECHANICAL COMPONENTS FOR EFFICIENT, SMALL SCALE POWER CONVERTERS	12.RD	2019-19090900002			\$64,960	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
2500: EVALUATION OF INFRASCANNER MODEL 2500	12.RD	(BLANK)	INFRASCAN, INC.	SUB TO W81XWH-17-C-0244	\$66,138	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
TAMBA: TESTING AND MODELING OF BRANDEIS ARTIFACTS	12.RD	BAA-15-29	GALOIS, INC.	2015-016	\$73,130	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
POST-CMOS COMPATIBLE ALUMINUM SCANDIUM NITRIDE FERROELECTRIC FIELD EFF	12.RD	HR00112090046			\$77,708	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
LINKING INVESTIGATIONS IN TRAUMA AND EMERGENCY SERVICES (LITES)	12.RD	W81XWH16D00240002	UNIVERSITY OF PITTSBURGH	0058514-2	\$97,957	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
TRANSFORMING RESEARCH AND CLINICAL KNOWLEDGE IN TRAUMATIC BRAIN INJURY	12.RD	(BLANK)	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	UFRA-137	\$100,927	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
MULTI-SOURCE ACTIVITY GRAPH LATENT UNCOVERING & MERGING (MAGNUM)	12.RD	FAB750-17-C-0157	LOCKHEED MARTIN CORPORATION	SUB TO FAB750-17-C-0157	\$101,228	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
ACES PHASE III	12.RD	HR0011-16-C-0118	DRAPER LABORATORY	SC001-1338	\$117,188	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
INSIGHT: A SILICON NEURAL PROBE VISUAL PROSTHESIS	12.RD	2017-606-001	SCIENTIFIC AND BIOMEDICAL MICROSYSTEMS, LLC	2017-PENN-001	\$129,633	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
REAL-TIME COMPUTER VISION	12.RD	(BLANK)	NOVATEUR RESEARCH SOLUTIONS	SUB TO FA9550-18-C-0050	\$136,560	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
BIO-FABRICATED NERVE-MUSCLE COMPLEXES TO AUGMENT REGENERATION AND FACI	12.RD	(BLANK)	PHILADELPHIA RESEARCH AND EDUCATION FOUNDATION	JPA	\$141,639	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
TASK-AND-USER AWARE REPRESENTATION LEARNING FOR FINE GRAINED CROSSLING	12.RD	2019-19051600004	BROWN UNIVERSITY	00001475	\$165,075	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
ROBOTIC PERCEPTION, INTELLIGENCE, AND DEXTEROUS MANIPULATION & UNIQUE	12.RD	W911NF-10-2-0016	GENERAL DYNAMICS ROBOTIC SYSTEMS	PO #40228149	\$196,130	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTCAT: AUTONOMIC RESPONSE TO DISRUPTIVE CYBER-ATTACKS SYSTEM SECURITY INTEGRATED THROUGH HARDWARE AND FIRMWARE (SSITH)	12.RD	N68335-19-C-0200	GRAMMATECH	GT S19-01	\$206,595	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
BETTER EXTRACTION FROM TEXT TOWARDS ENHANCED RETRIEVAL (BETTER)	12.RD	HR001118C0011	DRAPER LABORATORY	SUB TO HR001118C0011	\$213,353	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
DISTINGUISHING BRAIN STATES AND RESOLVING STATE TRANSITIONS	12.RD	2019-19051600006	BBN SYSTEMS AND TECHNOLOGIES	SUB TO 2019-19051600006	\$282,079	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
DCOMP	12.RD	W911NF-10-2-0022	DCS CORPORATION	APX02-0006 - TASK ORDER 001	\$328,418	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
INTEGRATED HIGH VOLTAGE BATTERY AND MAGNETIC CONVERSION MICROPOWER SYS	12.RD	HR001119C0039	PERSPECTA LABS INC	PO-0011396	\$374,755	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
UNO: UNDERACTUATED NATURALLY-STABILIZED ONE-MOTOR ROBOT	12.RD	HR001119C0052			\$987,123	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
FOCUS - FORECASTING COUNTERFACTUALS IN UNCONTROLLED SETTINGS	12.RD	140D0419C0049			\$2,617,183	\$15,306,584	RESEARCH AND DEVELOPMENT	\$710,017,793
DARPA IPA #0246 J.M. SMITH	12.U02	IPA 0246			\$239,683	\$239,683	OTHER PROGRAMS	\$15,539,552
TOTAL DEPARTMENT OF DEFENSE					\$14,697,898	\$57,013,121		
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT								
HOMELESS MANAGEMENT INFORMATION SYSTEMS TECHNICAL ASSISTANCE	14.261		ABT ASSOCIATES INC.	50001	\$12,342	\$12,342	RESEARCH AND DEVELOPMENT	\$710,017,793
CONTINUUM OF CARE PROGRAM	14.267	N/A			\$868,927	\$868,927	OTHER PROGRAMS	\$15,539,552
TOTAL DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT						\$881,269		
DEPARTMENT OF THE INTERIOR								
YOUTH ENGAGEMENT, EDUCATION, AND EMPLOYMENT	15.676	F19AC00830			\$30,076	\$30,076	OTHER PROGRAMS	\$15,539,552
U.S. GEOLOGICAL SURVEY RESEARCH AND DATA COLLECTION	15.808	G16AC00332			\$18,579	\$18,579	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P17AC01226			\$704	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P17AC01710			\$5,629	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P16AC01266			\$5,867	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC00782			\$8,617	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC00058			\$9,410	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P16AC00931			\$18,285	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC00737			\$18,917	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC01299			\$20,817	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P17AC00788			\$30,033	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC00666			\$35,822	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC00253			\$41,836	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC00723			\$43,482	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P19AC01183			\$44,042	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P18AC01009			\$51,147	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
COOPERATIVE RESEARCH AND TRAINING PROGRAMS RESOURCES OF THE NATIONAL PARK SYSTEM	15.945	P19AC01226			\$79,305	\$413,913	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL PARK SERVICE CONSERVATION, PROTECTION, OUTREACH, AND EDUCATION	15.954		NATIONAL WRITING PROJECT	92-PA06-NPS2019	\$3,514	\$3,514	OTHER PROGRAMS	\$15,539,552
PROJECT WRITE - JULY 15-AUGUST 31,2019	15.U08	PHILA WRITING PROJECT			\$900	\$900	OTHER PROGRAMS	\$15,539,552
TOTAL DEPARTMENT OF THE INTERIOR								\$466,982
DEPARTMENT OF JUSTICE								
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	16.560	2016-R2-CX-0049			\$24,760	\$39,864	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	16.560	2014-CK-BX-0008			\$61,946	\$552,496	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	16.560	2017-CK-BX-0016			\$326,779	\$577,179	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	16.560	2015-R2-CX-K040				\$30,481	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	16.560	2017-MU-MU-K021			\$118,200	\$1,318,220	RESEARCH AND DEVELOPMENT	\$710,017,793
CRIME VICTIM ASSISTANCE	16.575	2017-VF-05-29010			\$38,343	\$157,430	OTHER PROGRAMS	\$15,539,552
CRIME VICTIM ASSISTANCE	16.575	2017-VF-05-28107			\$119,087	\$157,430	OTHER PROGRAMS	\$15,539,552
CRIME VICTIM ASSISTANCE/DISCRETIONARY GRANTS	16.582	2019-V3-GX-0036			\$74,631	\$74,631	OTHER PROGRAMS	\$15,539,552
EDWARD BYRNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	16.738		INTERNATIONAL ASSOCIATION OF CHIEFS OF POLICE	SUB TO 2017-VI-BX-K001	\$444,119	\$444,119	OTHER PROGRAMS	\$15,539,552
CAPITAL CASE LITIGATION INITIATIVE	16.746	2018-FA-BX-K003			\$232,214	\$232,214	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPREHENSIVE OPIOID, STIMULANT, AND SUBSTANCE ABUSE PROGRAM	16.838	2018-CO-01-30255			\$236,922	\$236,922	OTHER PROGRAMS	\$15,539,552
TOTAL DEPARTMENT OF JUSTICE								\$413,485 \$2,463,536
DEPARTMENT OF STATE								
INVESTING IN PEOPLE IN THE MIDDLE EAST AND NORTH AFRICA	19.021	SIZ10019GR0033			\$118,214	\$272,199	RESEARCH AND DEVELOPMENT	\$710,017,793
INVESTING IN PEOPLE IN THE MIDDLE EAST AND NORTH AFRICA	19.021	SIZ-100-19-GR0021			\$268,903	\$329,948	RESEARCH AND DEVELOPMENT	\$710,017,793
U.S. AMBASSADORS FUND FOR CULTURAL PRESERVATION	19.025	SNEAAC18CA0043			\$33,870	\$496,717	OTHER PROGRAMS	\$15,539,552
INTERNATIONAL PROGRAMS TO SUPPORT DEMOCRACY, HUMAN RIGHTS AND LABOR	19.345		INTERNATIONAL ORGANIZATION FOR MIGRATION	IOM/CM-CPC2019	\$58,509	\$58,509	RESEARCH AND DEVELOPMENT	\$710,017,793
ACADEMIC EXCHANGE PROGRAMS - ENGLISH LANGUAGE PROGRAMS	19.421		FHI 360	PO18000081	\$14,450	\$14,450	OTHER PROGRAMS	\$15,539,552
FULBRIGHT FOREIGN LANGUAGE TEACHING ASSISTANTS SUMMER ORIENTATION 2019	19.U09	S-ECAGD-19-CA-0045	INSTITUTE OF INTERNATIONAL EDUCATION	FST1901_UPENN_FLTA_5.1.19	\$58,592	\$58,592	OTHER PROGRAMS	\$15,539,552
TOTAL DEPARTMENT OF STATE								\$420,987 \$1,230,415
DEPARTMENT OF TRANSPORTATION								
AIR TRANSPORTATION CENTERS OF EXCELLENCE	20.109	13-C-AJFE-UPENN				\$17,462	RESEARCH AND DEVELOPMENT	\$710,017,793
HIGHWAY RESEARCH AND DEVELOPMENT PROGRAM	20.200	693JJ31750012			\$29,545	\$427,605	RESEARCH AND DEVELOPMENT	\$710,017,793
HIGHWAY TRAINING AND EDUCATION	20.215	693JJ32045052				\$855	RESEARCH AND DEVELOPMENT	\$710,017,793
HIGHWAY TRAINING AND EDUCATION	20.215	693JJ31945273				\$13,360	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL HIGHWAY TRAFFIC SAFETY ADMINISTRATION (NHTSA) DISCRETIONARY SAFETY GRANTS AND COOPERATIVE AGREEMENTS	20.614		AMERICAN COLLEGE OF EMERGENCY PHYSICIANS	SUB TO 693JJ91850017	\$61,115	\$61,115	RESEARCH AND DEVELOPMENT	\$710,017,793
UNIVERSITY TRANSPORTATION CENTERS PROGRAM	20.701		UNIVERSITY OF TEXAS AT AUSTIN	UTA17-000185	\$287,439	\$734,629	RESEARCH AND DEVELOPMENT	\$710,017,793
UNIVERSITY TRANSPORTATION CENTERS PROGRAM	20.701		CARNEGIE MELLON UNIVERSITY	1080376-379208	\$447,190	\$734,629	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL SLEEP STUDY TECHNICAL SUPPORT	20.RD	DTFACT-15-D-00007/DO 0045	CSRA, INC.	SRAS002489-1	\$221,368	\$616,883	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL SLEEP STUDY TECHNICAL SUPPORT	20.RD	692M15-19-T-00020			\$395,515	\$616,883	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL DEPARTMENT OF TRANSPORTATION								\$29,545 \$1,871,909
DEPARTMENT OF TREASURY								
FEDERAL RESERVE FINANCIAL LITERACY PROJECT (FLP- YEAR 3)	21.RD	FEDERAL RESERVE SYS			\$2,979	\$2,979	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL DEPARTMENT OF TREASURY								\$2,979
LIBRARY OF CONGRESS								

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

THE LIFE OF FREE AFRICAN AMERICANS IN 19TH CENTURY PHILADELPHIA: USING	42.007		WAYNESBURG UNIVERSITY	GA GA08C0016	\$7,174	\$7,174	OTHER PROGRAMS	\$15,539,552
TOTAL LIBRARY OF CONGRESS						\$7,174		
NATIONAL AERONAUTICS & SPACE ADMINISTRATION								
SCIENCE	43.001	80NSSC18K0481			\$145,953	\$453,600	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - SCIENCE	43.001	80NSSC18K0481				\$432	RESEARCH AND DEVELOPMENT	\$710,017,793
SCIENCE	43.001	NNX15AM69G				\$4,549	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - SCIENCE	43.001	1650126				\$9,289	RESEARCH AND DEVELOPMENT	\$710,017,793
SCIENCE	43.001	80NSSC20K0497				\$29,204	RESEARCH AND DEVELOPMENT	\$710,017,793
SCIENCE	43.001	NNX17AH24G				\$29,987	RESEARCH AND DEVELOPMENT	\$710,017,793
SCIENCE	43.001		GEORGIA INSTITUTE OF TECHNOLOGY	RH809-G1		\$57,787	RESEARCH AND DEVELOPMENT	\$710,017,793
SCIENCE	43.001	NNX13AI79G				\$78,826	RESEARCH AND DEVELOPMENT	\$710,017,793
SCIENCE	43.001		PLANETARY SCIENCE INSTITUTE	1565 UNIV OF PA		\$96,363	RESEARCH AND DEVELOPMENT	\$710,017,793
SCIENCE	43.001		UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN	097657-17658		\$106,154	RESEARCH AND DEVELOPMENT	\$710,017,793
SCIENCE	43.001	80NSSC18K0694				\$140,399	RESEARCH AND DEVELOPMENT	\$710,017,793
SCIENCE	43.001	80NSSC18K0765				\$154,918	RESEARCH AND DEVELOPMENT	\$710,017,793
AERONAUTICS	43.002	80NSSC18M0155				\$158,749	RESEARCH AND DEVELOPMENT	\$710,017,793
EXPLORATION	43.003	NNX15AK76A			\$59,377	\$122,248	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - EXPLORATION	43.003	80NSSC17K0644				\$4,357	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - EXPLORATION	43.003		BAYLOR COLLEGE OF MEDICINE	T0408		\$6,438	RESEARCH AND DEVELOPMENT	\$710,017,793
EXPLORATION	43.003		BAYLOR COLLEGE OF MEDICINE	7000000801		\$26,104	RESEARCH AND DEVELOPMENT	\$710,017,793
EXPLORATION	43.003	80NSSC19K1046				\$52,708	RESEARCH AND DEVELOPMENT	\$710,017,793
EXPLORATION	43.003	NNX16AI53G				\$232,865	RESEARCH AND DEVELOPMENT	\$710,017,793
EXPLORATION	43.003		BAYLOR COLLEGE OF MEDICINE	7000000839		\$317,502	RESEARCH AND DEVELOPMENT	\$710,017,793
EXPLORATION	43.003		BAYLOR COLLEGE OF MEDICINE	T0408		\$361,481	RESEARCH AND DEVELOPMENT	\$710,017,793
EXPLORATION	43.003	80NSSC17K0644				\$704,424	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - SPACE OPERATIONS	43.007	80NSSC19K0599				\$418	RESEARCH AND DEVELOPMENT	\$710,017,793
SPACE OPERATIONS	43.007	NNX14AN49G				\$648	RESEARCH AND DEVELOPMENT	\$710,017,793
SPACE OPERATIONS	43.007	80NSSC19K0348				\$37,741	RESEARCH AND DEVELOPMENT	\$710,017,793
SPACE OPERATIONS	43.007	80NSSC19K0599				\$63,496	RESEARCH AND DEVELOPMENT	\$710,017,793
SPACE OPERATIONS	43.007	80NSSC19K1602				\$114,698	RESEARCH AND DEVELOPMENT	\$710,017,793
SPACE TECHNOLOGY	43.012	80NSSC19K1179				\$56,000	RESEARCH AND DEVELOPMENT	\$710,017,793
SPACE TECHNOLOGY	43.012	80NSSC19K0214				\$78,018	RESEARCH AND DEVELOPMENT	\$710,017,793
REVEALING THE ENVIRONMENTAL DEPENDENCE IN SUPERLUMINOUS SUPERNOVAE DIV	43.RD	NASS-26555	SPACE TELESCOPE SCIENCE INSTITUTE	HST-GO-15303.001-A		\$6,655	RESEARCH AND DEVELOPMENT	\$710,017,793
AN EXTREME PRECISION DOPPLER SPECTROMETER FOR THE US O/IR SYSTEM	43.RD	1547612	PENNSYLVANIA STATE UNIVERSITY	5405-UP-JPL-7612		\$55,219	RESEARCH AND DEVELOPMENT	\$710,017,793
LGM2605 AS A MITIGATOR OF SPACE RADIATION-INDUCED VASCULAR DAMAGE	43.RD	80NSSC18C0089	LIGNAMED	SUB TO LGM2605		\$155,709	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL NATIONAL AERONAUTICS & SPACE ADMINISTRATION					\$205,330	\$3,716,986		
INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES								
PROMOTION OF THE ARTS GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1807815-34-18				\$1,400	OTHER PROGRAMS	\$15,539,552
PROMOTION OF THE ARTS GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1809320-44-18				\$3,239	OTHER PROGRAMS	\$15,539,552
PROMOTION OF THE ARTS GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1849823-31-19				\$14,173	OTHER PROGRAMS	\$15,539,552
PROMOTION OF THE ARTS GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1854917-44-19				\$24,569	OTHER PROGRAMS	\$15,539,552
PROMOTION OF THE ARTS PARTNERSHIP AGREEMENTS	45.025		MID ATLANTIC ARTS FOUNDATION	31414		\$8,000	OTHER PROGRAMS	\$15,539,552
PROMOTION OF THE HUMANITIES FEDERAL/STATE PARTNERSHIP	45.129		PA HUMANITIES COUNCIL	SPS-19-01		\$1,315	OTHER PROGRAMS	\$15,539,552
PROMOTION OF THE HUMANITIES DIVISION OF PRESERVATION AND ACCESS	45.149	PW-253771-17				\$20,191	RESEARCH AND DEVELOPMENT	\$710,017,793
PROMOTION OF THE HUMANITIES RESEARCH	45.161	RZ-266063-19				\$1,606	RESEARCH AND DEVELOPMENT	\$710,017,793
PROMOTION OF THE HUMANITIES RESEARCH	45.161	RZ-266119-19				\$3,020	RESEARCH AND DEVELOPMENT	\$710,017,793
PROMOTION OF THE HUMANITIES RESEARCH	45.161	RZ-266202-19				\$7,061	RESEARCH AND DEVELOPMENT	\$710,017,793
PROMOTION OF THE HUMANITIES PUBLIC PROGRAMS	45.164	GA-274783-20				\$70,949	OTHER PROGRAMS	\$15,539,552
PROMOTION OF THE HUMANITIES OFFICE OF DIGITAL HUMANITIES	45.169	HAA-255999-17				\$378	OTHER PROGRAMS	\$15,539,552
PROMOTION OF THE HUMANITIES OFFICE OF DIGITAL HUMANITIES	45.169	HAA-258754-18				\$4,750	OTHER PROGRAMS	\$15,539,552
MUSEUMS FOR AMERICA	45.301	MA-30-19-0708-19				\$140,805	OTHER PROGRAMS	\$15,539,552
MUSEUMS FOR AMERICA	45.301	MA-10-18-0211-18				\$235,767	OTHER PROGRAMS	\$15,539,552
NATIONAL LEADERSHIP GRANTS	45.312	LG-00-17-0102-17				\$29,877	OTHER PROGRAMS	\$15,539,552

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 Fiscal Period 7/1/2019 - 6/30/2020

TOTAL INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL
 ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE
 HUMANITIES

\$567,100

NATIONAL SCIENCE FOUNDATION

CIF: SMALL: COLLABORATIVE RESEARCH: COMMUNICATIONS IN ULTRA-

LOW-RATE R	47.040	1910056			\$17,941	\$17,941	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CBET-1449337			\$4,592	\$18,539	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	EFMA-1542879			\$12,137	\$74,481	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	IIP-1450467			\$16,544	\$37,049	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1935294			\$32,837	\$41,544	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	ECCS-1842655			\$38,645	\$238,981	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	ECCS-1542153			\$46,192	\$1,149,525	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	ECCS-1842612			\$72,025	\$202,597	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	EFMA-1542707			\$243,730	\$265,300	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ENGINEERING	47.041	CMMI-1548571			\$1,421,081	\$3,811,368	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	EEC-1659190				-\$5,440	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CBET-1437482				-\$5,031	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1536914				-\$742	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1839535				\$393	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CMMI-1401164				\$2,039	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041		UNIVERSITY OF MINNESOTA	A006382201		\$2,951	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041		DREXEL UNIVERSITY	820095_2		\$3,027	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	ECCS-1654985				\$3,593	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041		UNIVERSITY OF HOUSTON	R-19-0095		\$4,193	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1944691				\$4,756	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041		PENNSYLVANIA STATE UNIVERSITY	S000078-NSF		\$5,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CMMI-1463344				\$5,947	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041		VIFANT LLC	SUB TO GRANT # 1746353 ADV ACCT		\$6,614	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	EFRI-1331583				\$8,068	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CMMI-1760369				\$10,219	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1511437				\$10,520	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	ECCS-1811393				\$16,143	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1830475				\$19,355	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1903673				\$21,088	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041		LEHIGH UNIVERSITY	1		\$22,595	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1804523				\$23,384	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1937031				\$25,016	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CMMI-1929268				\$25,200	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CBET-1604536				\$26,991	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CBET-1508048				\$34,633	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	ECCS-1846766				\$35,177	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1944248				\$36,056	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041		CARNEGIE MELLON UNIVERSITY	1122380-424804		\$38,104	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1932803				\$38,135	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1933704				\$40,794	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1840457				\$42,276	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CBET-1704833				\$44,717	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CBET-1554200				\$56,126	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CMMI-1745912				\$60,357	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CMMI-1840672				\$64,074	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	ECCS-1553511				\$65,530	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CBET-1920156				\$71,421	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1830218				\$72,080	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CBET-1705891				\$73,703	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041		RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (BUFFALO)	R1107943		\$77,046	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1804145				\$86,584	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041		UNIVERSITY OF MICHIGAN NORTH CAROLINA STATE UNIVERSITY	3004604526 2017-1-718-02		\$91,215	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1728360				\$92,521	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CMMI-1662695				\$95,069	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CMMI-1548571				\$97,697	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CMMI-1653216				\$98,016	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	ECCS-1651433				\$99,060	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1662101				\$99,533	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1943243				\$100,077	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1663037				\$100,948	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041		UNIVERSITY OF BUFFALO	R1106709		\$108,615	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1761726				\$112,927	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

ENGINEERING	47.041	1827673			\$115,461	\$10,371,788	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CBET-1845933			\$117,934	\$10,371,788	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1727717			\$118,739	\$10,371,788	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CBET-1803215			\$131,356	\$10,371,788	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CMMI-1761874			\$133,715	\$10,371,788	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CBET-1652646			\$151,534	\$10,371,788	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1661858			\$162,469	\$10,371,788	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	CBET-1706014			\$179,989	\$10,371,788	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>GEORGIA INSTITUTE OF TECHNOLOGY</i>								
ENGINEERING	47.041			<i>RJ375-G1</i>	\$192,629	\$10,371,788	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1837253			\$221,155	\$10,371,788	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1734355			\$316,179	\$10,371,788	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERING	47.041	1933400			\$327,262	\$10,371,788	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1818513			\$16,803	\$26,398	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1720530			\$17,750	\$3,561,622	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1545935			\$54,535	\$54,535	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1545935				-\$2,296	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1838412			\$66,568	\$85,296	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	OMA-1936276			\$100,097	\$176,846	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1916859			\$135,109	\$216,690	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1925708			\$272,677	\$442,492	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1915752				-\$2,411	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1505662				-\$380	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1200271				-\$240	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1463733				-\$69	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1603526				\$55	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MATHEMATICAL AND PHYSICAL SCIENCES	47.049	AST-1816330				\$64	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1851640				\$229	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1922278				\$246	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MATHEMATICAL AND PHYSICAL SCIENCES	47.049	2017119				\$527	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1943925				\$530	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	2017119				\$566	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1562665				\$661	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1720530				\$1,632	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1505127				\$2,878	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1900040				\$4,801	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1601438				\$7,756	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1600670				\$8,089	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1506148				\$9,068	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>UNIVERSITY OF PUERTO RICO</i>								
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1902360		<i>DMR-1523463</i>	\$15,431	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1506726			\$16,039	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1522603			\$16,475	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1764143			\$17,464	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1352060			\$17,849	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1609267			\$28,298	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1941318			\$28,523	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1609784			\$31,822	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1600263			\$33,682	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1827457			\$34,771	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1262047			\$40,518	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1709827			\$41,175	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1916245			\$43,423	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1850644			\$43,575	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1613926			\$43,673	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1664928			\$43,777	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	AST-1615555			\$45,793	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1659512			\$48,742	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1838456			\$52,200	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1757479			\$54,088	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1905045			\$54,288	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1910496			\$56,030	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1808202			\$59,756	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1664818			\$65,199	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1628407			\$67,460	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	PHY-1756996			\$67,642	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1847415			\$68,022	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1808065			\$68,295	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1844514			\$69,867	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1764177			\$77,070	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>PRINCETON UNIVERSITY</i>								
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	AST-1615604		<i>SUB0000223</i>	\$77,413	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1554130			\$84,409	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1609525			\$84,694	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1902509			\$84,863	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1805439			\$85,811	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049				\$86,031	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1904776			\$86,971	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1665291			\$90,338	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1712735			\$92,184	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1515804			\$95,650	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1709763			\$96,401	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1507713			\$100,129	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1901876			\$101,443	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1922278			\$105,419	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	AST-1455151			\$106,691	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1764298			\$108,856	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049		STONY BROOK	76749/1136652/2/2R7D	\$109,494	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1904767			\$111,030	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1708759			\$114,977	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1952877			\$115,050	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	PHY-1554887			\$116,287	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	AST-1816330			\$120,562	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	PHY-1554488			\$122,198	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1610525			\$122,265	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1607878			\$126,186	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1506625			\$129,420	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1665339			\$133,401	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1607378			\$139,029	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1856547			\$143,473	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049		PRINCETON UNIVERSITY	SUB0000032	\$153,373	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMS-1603526			\$153,739	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1709518			\$155,346	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1905853			\$157,257	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1719353			\$179,093	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1764329			\$187,872	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	CHE-1764365			\$191,604	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1809398			\$213,361	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1664572			\$214,629	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1807127			\$226,946	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1905203			\$227,069	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	1562665			\$466,777	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DMR-1828545			\$555,476	\$12,135,553	RESEARCH AND DEVELOPMENT	\$710,017,793
GEOSCIENCES	47.050	1951462			\$2,351	\$513,060	RESEARCH AND DEVELOPMENT	\$710,017,793
GEOSCIENCES	47.050	1624504			\$7,641	\$513,060	RESEARCH AND DEVELOPMENT	\$710,017,793
GEOSCIENCES	47.050		UNIVERSITY OF NEW HAMPSHIRE	14-064	\$16,942	\$513,060	RESEARCH AND DEVELOPMENT	\$710,017,793
GEOSCIENCES	47.050	EAR-1550112			\$54,440	\$513,060	RESEARCH AND DEVELOPMENT	\$710,017,793
GEOSCIENCES	47.050	1923743			\$67,820	\$513,060	RESEARCH AND DEVELOPMENT	\$710,017,793
GEOSCIENCES	47.050	1939913			\$78,302	\$513,060	RESEARCH AND DEVELOPMENT	\$710,017,793
GEOSCIENCES	47.050	OCE-1756808			\$128,191	\$513,060	RESEARCH AND DEVELOPMENT	\$710,017,793
GEOSCIENCES	47.050	1846777			\$157,373	\$513,060	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1446592			\$24,662	\$74,083	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1739012			\$38,384	\$93,146	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1827472			\$218,183	\$997,129	RESEARCH AND DEVELOPMENT	\$710,017,793
SHF: SMALL: RANDOM TESTING FOR LANGUAGE DESIGN	47.070	CCF-1421243			\$29,714	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1505799			-\$35,419	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1910864			-\$3,900	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1626008			-\$1,917	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1733794			\$834	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1910308			\$1,332	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1328805			\$2,635	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1546151			\$4,200	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1934960			\$4,575	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1943064			\$4,846	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1844816			\$7,547	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1547360			\$8,523	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1812319			\$9,600	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1513679			\$11,002	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1829197			\$12,228	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1910594			\$14,088	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1926757			\$17,861	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1750158			\$20,652	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1931419			\$23,922	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1253842			\$25,071	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1837964			\$28,215	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1703541			\$28,396	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1910108			\$30,034	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1917545			\$30,059	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	2008456			\$30,244	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1813624			\$31,955	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1513108			\$38,148	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1703936			\$39,086	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1845749			\$40,260	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1703319			\$40,829	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1421193			\$45,872	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1748771			\$53,531	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1837210			\$58,256	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1926872			\$59,395	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1934876			\$61,310	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1526270			\$62,891	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1513671			\$63,906	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1845339			\$65,250	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	17557077			\$65,282	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1253345			\$73,745	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1925587			\$75,272	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1763314			\$81,257	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1910769			\$81,403	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1513687			\$86,455	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	IIS-1717290			\$87,301	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1513854			\$89,904	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1912232			\$93,221	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1617851			\$97,432	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1763307			\$103,646	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070		VANDERBILT UNIVERSITY	3834-019899	\$103,887	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1850356			\$109,725	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070		PURDUE UNIVERSITY	10001171-018	\$118,627	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1915398			\$122,868	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070		UNIVERSITY OF MEMPHIS	1640813	\$129,811	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1703835			\$146,287	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1703791			\$150,254	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1755544			\$152,002	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1836936			\$157,410	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1525296			\$160,541	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1763514			\$197,517	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1717120			\$234,641	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1730377			\$278,458	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1563873			\$287,247	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1446664			\$294,103	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1513694			\$380,278	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CCF-1521539			\$566,076	\$6,054,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	1557529			\$14,465	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	IOS-1849708			\$8,063	\$306,680	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	IOS-1343159			\$36,606	\$299,039	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	IOS-1444490			\$198,657	\$314,894	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	MCB-1409137				-\$579	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOLOGICAL SCIENCES	47.074	IOS-1457282				-\$511	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - BIOLOGICAL SCIENCES	47.074	1856587				\$201	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793
			DONALD DANFORTH PLANT SCIENCE CENTER	23020-P					
BIOLOGICAL SCIENCES	47.074				\$1,773	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	DBI-1601697			\$2,612	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	DBI-1743744			\$13,336	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	MCB-1614355			\$17,277	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074		UNIVERSITY CORPORATION, THE	A16-0018-S001	\$20,250	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	DEB-1926114			\$26,143	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	DBI-2016487			\$33,042	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	DBI-1458390			\$38,624	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	MCB-1614191			\$40,375	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	MCB-1350601			\$59,355	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	1557499			\$107,129	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	IOS-1452520			\$114,041	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	1929671			\$134,161	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	MCB-1856292			\$142,203	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	MCB-1652003			\$197,787	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	MCB-1916431			\$205,776	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	1817518			\$207,380	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	1905062			\$250,147	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	IOS-1853719			\$257,944	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOLOGICAL SCIENCES	47.074	1856587			\$303,006	\$3,077,620	RESEARCH AND DEVELOPMENT	\$710,017,793	
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1917573			\$2,314	\$11,458	RESEARCH AND DEVELOPMENT	\$710,017,793	
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1747642			\$6,733	\$8,484	RESEARCH AND DEVELOPMENT	\$710,017,793	
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1627972				-\$2,400	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1755237				-\$2,082	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SMA-1606869				-\$96	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1459353				\$523	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1851033				\$1,287	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1533623				\$2,430	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1751863				\$4,763	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1557138				\$4,930	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1849495				\$7,039	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS**

Fiscal Period 7/1/2019 - 6/30/2020

SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075		UNIVERSITY OF MICHIGAN	3004216837		\$7,459	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1430404				\$8,462	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1756738				\$13,480	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1626825				\$14,478	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1729412				\$14,683	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1459353				\$14,998	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1917900				\$15,393	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1825583				\$18,489	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1852987				\$20,909	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1918240				\$21,175	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SMA-1917608				\$25,584	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1761934				\$31,944	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1559369				\$32,073	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075		EMORY UNIVERSITY	A140427		\$32,332	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1726976				\$34,185	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1729469				\$35,864	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075		CARNEGIE MELLON UNIVERSITY	1122598-38829		\$39,627	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1919029				\$43,033	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1942917				\$47,786	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1824520				\$47,797	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1851629				\$51,045	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075		SYRACUSE UNIV	30158-05060-S01		\$62,729	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1918173				\$63,339	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1758653				\$69,181	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1851634				\$76,271	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1847794				\$77,251	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1851879				\$80,824	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1729185				\$107,988	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075		COLUMBIA UNIVERSITY	1(GG008689)		\$111,145	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1851707				\$113,309	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1749397				\$114,346	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1851449				\$115,227	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1823521				\$138,430	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1824826				\$150,471	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	SES-1559370				\$161,002	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1847598				\$211,974	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1827876				\$220,103	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1631550				\$273,385	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	BCS-1265480				\$274,048	\$3,028,155	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	DUE-1665216			\$58,853	\$280,287	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	DRL-1621333			\$113,349	\$444,498	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	1721003			\$154,672	\$301,019	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076		DREXEL UNIVERSITY	235920		-\$6,083	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076		MISSOURI BOTANICAL GARDEN	NSF1513043-UP		\$5,900	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	1946150				\$12,704	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	1623018				\$17,068	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	1623258				\$19,182	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	DRL-1509245				\$20,249	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	DRL-1907437				\$20,554	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	1840933				\$32,246	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	1839686				\$34,639	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	DGE-1544130				\$42,507	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	DGE-1937490				\$45,622	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	DRL-1620888				\$65,436	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	1661153				\$100,176	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	DRL-1742140				\$279,106	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	DRL-1812738				\$296,088	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	DUE-1760867				\$347,728	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	DRL-1813048				\$603,171	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION AND HUMAN RESOURCES	47.076	DGE-1845298				\$3,862,897	\$6,824,994	RESEARCH AND DEVELOPMENT	\$710,017,793
POLAR PROGRAMS	47.078		UNIVERSITY OF CALIFORNIA, BERKELEY	00009389		\$27,793	\$27,793	RESEARCH AND DEVELOPMENT	\$710,017,793
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	OISE-1545884			\$12,500	\$606,472	\$606,472	RESEARCH AND DEVELOPMENT	\$710,017,793
OFFICE OF CYBERINFRASTRUCTURE	47.080		BRANDEIS UNIVERSITY	4-02069		-\$924	-\$924	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERGOVERNMENTAL PERSONNEL ACT ASSIGNMENT - KIMBERLY GALLAGHER	47.RD	IPA AGREEMENT				\$25,582	\$25,582	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL NATIONAL SCIENCE FOUNDATION						\$3,424,298	\$42,682,073		
SMALL BUSINESS ADMINISTRATION									
STATE TRADE EXPANSION	59.061		KUTZTOWN UNIVERSITY OF PENNSYLVANIA	SBA20190215		\$100,352	\$100,352	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL SMALL BUSINESS ADMINISTRATION							\$100,352		

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

DEPARTMENT OF VETERANS AFFAIRS

TRANSPLANTABLE MICRO-TISSUE ENGINEERED NEURAL NETWORKS TO RESTORE THE	64.000	IPA CASSIDY FETTERMAN	\$23,570	\$99,389	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA SHIMRIT KEDDEM	64.000	IPA AGREEMENT	\$75,819	\$99,389	RESEARCH AND DEVELOPMENT	\$710,017,793
CHRONIC NEURODEGENERATIVE AND NEUROPHYSIOLOGICAL SEQUELA OF CLOSED-HEA	64.RD	PO #642D36047	-\$413	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
TRANSPLANTABLE MICRO-TISSUE ENGINEERED NEURAL NETWORKS TO RESTORE THE	64.RD	IPA AGREEMENT	-\$357	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
OSLIN TOP IPA-PETRO	64.RD	IPA CHRISTOPHER PETRO	\$966	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
DESIGNING NEURONAL TISSUE CONSTRUCTS THAT MIMIC BRAIN-SPECIFIC ARCHITE	64.RD	IPA JAMES LIM	\$1,145	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA RACHEL DJARAHER	64.RD	IPA RACHEL DJARAHER	\$1,265	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
VA MERIT AWARD: IMMUNE AND GENETIC CONTROLS OF TISSUE REGENERATION IN	64.RD	IPA AGREEMENT	\$1,384	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA HOWARD	64.RD	IPA AGREEMENT	\$1,411	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA-SUMEDHA CHHATRE PARIKH PROJECT	64.RD	IPA SUMEDHA CHHATRE	\$1,775	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOACTIVE INJECTABLE IMPLANTS FOR FUNCTIONAL INTERVERTEBRAL DISC REGE	64.RD	IPA AGREEMENT	\$2,174	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA KAYLA RENEE CLARK	64.RD	IPA KAYLA R CLARK	\$2,221	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA MOLLY KNOWLES	64.RD	IPA	\$3,051	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA OLENGA ANABUI	64.RD	IPA OLENGA ANABUI	\$3,206	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
FY17 VA IPA-DANIEL DEL ALCAZAR	64.RD	IPA DANIEL DEL ALCAZAR	\$3,894	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA ANDREA SEGAL	64.RD	IPA AGREEMENT	\$4,880	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
INTEGRATED COGNITIVE BEHAVIORAL THERAPY TO IMPROVE OUTCOMES IN SCHIZOP	64.RD	IPA PAUL M. GRANT	\$5,098	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
LYNCH IPA - TOP	64.RD	IPA AGREEMENT	\$5,407	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
ROLE OF NKG2D SIGNALING IN PERIPHERAL ARTERIAL DISEASE	64.RD	IPA AGREEMENT	\$5,880	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
CARTILAGE RESPONSE TO COMPRESSION INJURY: A PLATFORM FOR THERAPEUTICS	64.RD	IPA AGREEMENT	\$5,881	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
INHIBITION OF TNF- SIGNALING TO REDUCE INTERVERTEBRAL DISC INFLAMMATI	64.RD	IPA HONGTAO ZHANG	\$6,300	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA MORRIS	64.RD	IPA PAIGE MORRIS	\$7,888	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA - RICHARD CRIST (GAMMA)	64.RD	IPA - RICHARD CRIST	\$8,198	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
THE INTRA-INDIVIDUAL CHANGES IN AMBULATION AND FUNCTIONAL OUTCOMES AMO	64.RD	IPA PAMELA CACCHIONE	\$9,668	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
KAEMPF TOP IPA	64.RD	IPA GAIL KAEMPF	\$9,990	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA TORY HARRINGTON	64.RD	IPA TORY HARRINGTON	\$10,028	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
PATHOGENESIS OF CHRONIC RHINOSINUSITIS	64.RD	IPA MICHAEL DODSON	\$10,522	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
THE ROLE OF FUNCTIONAL IRON DEFICIENCY IN SYSTEMIC COMPLICATIONS OF CK	64.RD	36C24E19P0068	\$10,638	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
PHENOTYPIC AND GENOMIC ARCHITECTURE OF CARDIOVASCULAR DISEASE SUBTYPES	64.RD	IPA AGREEMENT	\$11,303	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA PETRO (HARTWELL-MIRECC)	64.RD	IPA PAIGE MORRIS	\$12,146	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
VA IPA LIZBETH NOVELO	64.RD	IPA LIZBETH NOVELO	\$12,171	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
VU NGUYEN FY20 VA IPA	64.RD	IPA AGREEMENT	\$13,035	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA CHALANDA EVANS	64.RD	IPA CHALANDA EVANS	\$13,069	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA CAROLYN SABINI	64.RD	IPA CAROLYN SABINI	\$13,114	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA FOR VICTORIA A. (TORI) HILBERT	64.RD	IPA AGREEMENT	\$14,647	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA SUMEDHA CHHATRE	64.RD	IPA SUMEDHA CHHATRE	\$15,077	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
PETRO MIRECC IPA	64.RD	IPA CHRISTOPHER PETRO	\$15,218	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA RORY HARTE	64.RD	IPA RORY HARTE	\$15,540	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
MIRECC IPA AGREEMENT KEMBER YEAR 2	64.RD	IPA RACHEL KEMBER	\$16,006	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
CRISWELL LAVERY FY20 IPA	64.RD	IPA CRISWELL LAVERY	\$16,080	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA # 3 DAMRAUER DOE (M. VUJKOVIC)	64.RD	IPA MARIJANA VUJKOVIC	\$17,160	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA LINDSEY NORTON	64.RD	IPA LINDSEY NORTON	\$17,906	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA FOR DAWEI XIE	64.RD	IPA DAWEI XIE	\$18,167	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
LIZBETH NOVELO STRIDE GO IPA	64.RD	IPA LIZBETH NOVELO	\$18,257	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
LIZBETH NOVELO SPIRE IPA	64.RD	IPA LIZBETH NOVELO	\$18,257	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
NEUROMODULATION AS A THERAPY FOR PTSD FOLLOWING CHRONIC TBI	64.RD	IPA AGREEMENT	\$19,848	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA # 2 CHANG R&D (M. VUJKOVIC)	64.RD	IPA AGREEMENT	\$19,999	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
LYNCH PRIME IPA	64.RD	IPA KEVIN LYNCH	\$20,938	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
IPA VANIA FREIRE	64.RD	IPA VANIA FREIRE	\$21,706	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
PERIOPERATIVE POST-PROSTATECTOMY INCONTINENCE HOME TELEHEALTH PROGRAM	64.RD	521D87110	\$23,628	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
OPTIMIZATION OF ENGINEERED ENDPLATES TO IMPROVE IN VIVO INTEGRATION OF	64.RD	IPA - SARAH GULLBRAND ADV ACT	\$24,009	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
CRISWELL LAVERY FY20 IPA	64.RD	IPA CRISWELL LAVERY	\$24,119	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
ENGINEERED MULTI-FUNCTIONAL NANOFIBROUS MENISCUS IMPLANTS	64.RD	IPA- BURDICK/SCHAER	\$24,247	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
INHIBITION OF TNF-A SIGNALING TO REDUCE INTERVERTEBRAL DISC INFLAMMATI	64.RD	IPA AGREEMENT	\$26,401	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
DOWNING IPA-TOP	64.RD	IPA - LAURIE DOWNING	\$26,943	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793
TRANSPLANTABLE MICRO-TISSUE ENGINEERED NEURAL NETWORKS TO RESTORE THE	64.RD	IPA JUSIN BURRELL	\$27,241	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

INCORPORATING VETERANS' PREFERENCES INTO LUNG CANCER SCREENING DECISIO	64.RD	IPA AGREEMENT		\$27,860	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA - MILLION VETERAN PROGRAM (MVP)	64.RD	IPA DANISH SALEHEEN		\$28,158	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
TISSUE ENGINEERED CONSTRUCTS FOR TREATMENT OF INTERVERTEBRAL DISC DEGE	64.RD	IPA AGREEMENT		\$28,782	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
INVESTIGATING MULTI-LEVEL DETERMINANTS OF RACIAL/ETHNIC DISPARITIES IN	64.RD	IPA AGREEMENT		\$29,345	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
JIALI (HELEN) YAN IPA	64.RD	IPA AGREEMENT		\$29,459	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
REMOTE AMBULATORY MANAGEMENT OF VETERANS WITH SLEEP APNEA (REVAMP)	64.RD	(BLANK)		\$29,620	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
LIVING ELECTRODES FOR AUDITORY REHABILITATION	64.RD	IPA AGREEMENT		\$29,770	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA ANEEZA AGHA	64.RD	IPA ANEEZA AGHA		\$31,426	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA AGREEMENT FOR MELISSA NASCHEK	64.RD	IPA AGREEMENT		\$31,435	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA SHIMRIT KEDDEM	64.RD	IPA SHIMRIT KEDDEM		\$32,494	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA AILEEN OON	64.RD	IPA AGREEMENT		\$33,015	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA ANEEZA AGHA	64.RD	IPA ANEEZA AGHA		\$33,852	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA #1, CHANG-MVP (M. VUJKOVIC)NO RESTRICTS NON-U.S. ENTITY PARTICIPAT	64.RD	IPA AGREEMENT		\$34,618	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA AGREEMENT FOR DANIEL TRAUM	64.RD	IPA DANIEL TRAUM		\$35,613	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
EVIDENCE BASED PSYCHOTHERAPY PROGRAM	64.RD	IPA GREGORY K BROWN		\$37,982	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA-TIMOTHY POND	64.RD	IPA AGREEMENT		\$43,566	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
THE ROLE OF TNF-ALPHA IN CUTANEOUS INTEGRITY	64.RD	JPA - MEENA SHARMA		\$44,569	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
DESIGNING NEURONAL TISSUE CONSTRUCTS THAT MIMIC BRAIN-SPECIFIC ARCHITE	64.RD	IPA AGREEMENT		\$45,045	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA KEMBER	64.RD	IPA - RACHEL KEMBER		\$48,001	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
NEUROMODULATION AS A THERAPY FOR PTSD FOLLOWING CHRONIC TBI	64.RD	IPA AGREEMENT		\$48,082	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA: LAKSHMI PRAYOSHA VILLA	64.RD	IPA LAKSHMI P VILLA		\$52,181	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA RANDY HASTINGS	64.RD	IPA RANDY HASTINGS		\$57,011	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA ANTHONY DAVIS	64.RD	IPA ANTHONY DAVIS		\$59,863	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
THE ROLE OF LOCAL NSAID ADMINISTRATION AND INFLAMMATION ON TENDON HEAL	64.RD	00979-R		\$60,832	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
VA COMPREHENSIVE END-OF-LIFE CARE'S PROMISE CENTER	64.RD	IPA AGREEMENT		\$61,729	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
PRECISION CARDIO-METABOLIC PHENOTYPING FOR GENETIC DISCOVERY AND RISK	64.RD	IPA AGREEMENT		\$65,817	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
NEUROMODULATION AS A THERAPY FOR PTSD FOLLOWING CHRONIC TBI IMPLEMENTING GOALS OF CARE CONVERSATIONS WITH VETERANS IN VA LTC SETTI	64.RD	IPA OCEANE FRUCHET		\$68,215	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA	64.RD	IPA		\$96,830	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
SDR: GENOMIC ANALYSIS OF BLAST TUBE INDUCED TBI IN MICE	64.RD	IPA - MARY VALIGA		\$104,767	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
BEERS - VA MERIT AWARD	64.RD	IPA AGREEMENT		\$108,702	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
TISSUE ENGINEERED TOTAL DISC REPLACEMENT IN A LARGE ANIMAL MODEL	64.RD	IPA SURAFEL MULUGETA		\$111,656	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
GROUP (PROJECT LIFE FORCE) VS. INDIVIDUAL SUICIDE SAFETY PLANNING RC	64.RD	IPA J LACHLAN SMITH		\$129,685	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOACTIVE INJECTABLE IMPLANTS FOR FUNCTIONAL INTERVERTEBRAL DISC REGE	64.RD	IPA AGREEMENT		\$153,247	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
VA MERIT AWARD: IMMUNE AND GENETIC CONTROLS OF TISSUE REGENERATION IN	64.RD	IPA AGREEMENT		\$153,928	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
INVOLVEMENT OF PECAM-1 IN VEGF-DEPENDENT PERMEABILITY	64.U03	IPA VALSAMMA ABRAHAM		\$210,588	\$2,836,075	RESEARCH AND DEVELOPMENT	\$710,017,793	
INTENSIVE TRAINING IN COGNITIVE BEHAVIORAL THERAPY FOR VETERANS EXPERI	64.U04	IPA AGREEMENT		\$37,211	\$37,211	OTHER PROGRAMS	\$15,539,552	
IPA - LAURIE DOWNING	64.U05	IPA LAURIE DOWNING		\$38,724	\$38,724	OTHER PROGRAMS	\$15,539,552	
CBT-SP TELE-HUB PROJECT	64.U07	IPA GREGORY K BROWN		\$3,154	\$3,154	OTHER PROGRAMS	\$15,539,552	
VA IPA FOR KEVIN LYNCH	64.U10	IPA KEVIN LYNCH		\$26,804	\$26,804	OTHER PROGRAMS	\$15,539,552	
VA IPA FOR KEVIN LYNCH	64.U11	IPA - KEVIN LYNCH		\$16,227	\$16,227	OTHER PROGRAMS	\$15,539,552	
IPA - LAURIE DOWNING	64.U12	IPA LAURIE DOWNING		\$14,020	\$14,020	OTHER PROGRAMS	\$15,539,552	
SUICIDE PREVENTION PROGRAMMATIC CONSULTATION	64.U13	IPA SHARI JAGER-HYMAN		\$5,951	\$5,951	OTHER PROGRAMS	\$15,539,552	
TOTAL DEPARTMENT OF VETERANS AFFAIRS				\$11,329	\$11,329	OTHER PROGRAMS	\$15,539,552	
				\$3,088,884				
ENVIRONMENTAL PROTECTION AGENCY								
<i>OFFICE OF RESEARCH AND DEVELOPMENT CONSOLIDATED RESEARCH/TRAINING/FELLOWSHIPS</i>	66.511		VIRGINIA POLYTECHNIC INSTITUTE & STATE UNIVERSITY	451533-19314	\$12,559	\$12,559	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL ENVIRONMENTAL PROTECTION AGENCY					\$12,559			
DEPARTMENT OF ENERGY								
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0020169		\$71,683	\$235,440	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-98ER45702			-\$50	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-88ER40479			\$215	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0007901			\$340	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-05ER46199			\$597	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0016421			\$850	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0016421			\$3,727	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0020360			\$17,116	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-07ER46431			\$25,680	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0019282			\$52,436	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0019116			\$64,900	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		STONY BROOK	63761/1108376/2	\$65,029	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		JOHNS HOPKINS UNIVERSITY	2004571414	\$70,626	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		UNIVERSITY OF TEXAS AT ARLINGTON	12608015661	\$72,816	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0019281			\$88,098	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0017646			\$88,174	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-07ER46431			\$90,612	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0017259			\$96,717	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-91ER20052			\$125,556	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0019781			\$138,333	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-84ER45118			\$141,718	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0016043			\$160,060	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0007063			\$164,674	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0018057			\$172,329	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0009440			\$183,229	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-87ER13792			\$184,047	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0019397			\$199,836	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0012486			\$201,848	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		CORNELL UNIVERSITY	85989-11289	\$207,711	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049		FLORIDA STATE UNIVERSITY	R01865	\$229,908	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-05ER46199			\$365,916	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-FG02-88ER40479			\$402,352	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0013528			\$608,684	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0007901			\$2,227,072	\$6,686,596	RESEARCH AND DEVELOPMENT	\$710,017,793	
CONSERVATION RESEARCH AND DEVELOPMENT	81.086	DE-EE0008314			\$259,359	\$569,687	RESEARCH AND DEVELOPMENT	\$710,017,793	
CONSERVATION RESEARCH AND DEVELOPMENT	81.086		UNITED STATES AUTOMOTIVE MATERIALS PARTNERSHIP, LLC	AMP803	\$32,228	\$601,915	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOSSIL ENERGY RESEARCH AND DEVELOPMENT	81.089	DE-FE0031673			\$86,972	\$94,653	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOSSIL ENERGY RESEARCH AND DEVELOPMENT	81.089	DE-FE0031252			\$46,336	\$140,989	RESEARCH AND DEVELOPMENT	\$710,017,793	
PREDICTIVE SCIENCE ACADEMIC ALLIANCE PROGRAM	81.124		SANDIA NATIONAL LABORATORY	PO #1350502	-\$3,816	-\$3,816	RESEARCH AND DEVELOPMENT	\$710,017,793	
ADVANCED RESEARCH PROJECTS AGENCY - ENERGY	81.135		UNIVERSITY OF TENNESSEE	8500051700	-\$603	-\$603	RESEARCH AND DEVELOPMENT	\$710,017,793	
WATCHMAN PDR EFFORT	81.RD	DE-ACS2-07NA27344	LAWRENCE LIVERMORE NATIONAL LABORATORY	B634739	\$77,386	\$151,861	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
DESIGN AND FABRICATION OF AN ELECTRONICS FOR THE 35 TONNE PROTOTYPE	81.RD	264851				-\$3,370	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
THE WATCHMAN PROGRAM- B626865	81.RD	DE-ACS2-07NA27344	LAWRENCE LIVERMORE NATIONAL LABORATORY	B626865		-\$913	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - RESEARCH FOR ATLAS EXPERIMENT	81.RD	80472				\$422	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
ANALYSIS OF THE MAGNETIC PROPERTIES OF NEW SPIN-CROSSOVER COMPLEXES	81.RD	472000				\$7,017	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
DESIGN OF A TARGET AND DICHOICON FOR PHOTON SORTING AT CHESS	81.RD	7528806				\$14,664	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
HIGH PERFORMANCE ELECTROMECHANICAL FILTERS REALIZED IN HIGHLY DOPED AL	81.RD	(BLANK)	SANDIA NATIONAL LABORATORY	2093801		\$35,002	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
WFIRST SCIENCE INVESTIGATION TEAMS AND ADJUTANT SCIENTISTS	81.RD	7372918				\$47,304	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
US-JAPAN ELECTRONICS EFFORT	81.RD	363624				\$48,157	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
ADVANCED ELECTRO-CATALYSTS THROUGH CRYSTALLOGRAPHIC ENHANCEMENT	81.RD	420085				\$80,698	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
HIGH-PERFORMANCE COMPUTING MODEL OF POWDER-SCALE MELTING AND SOLIDIFIC	81.RD	DE-AC05-00OR22725	UT-BATTELLE, LLC	4000171342		\$97,180	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
HYBRID QUANTUM/CLASSICAL ALGORITHMS FOR PHOTOCHEMISTRY AND NONADIABATI	81.RD	DE-AC02-76SF00515	STANFORD LINEAR ACCELERATOR CENTER	200073		\$122,895	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH FOR ATLAS EXPERIMENT	81.RD	80472				\$641,057	\$1,241,974	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL DEPARTMENT OF ENERGY						\$495,400	\$8,667,055		
DEPARTMENT OF EDUCATION									
FEDERAL SUPPLEMENTAL EDUCATIONAL OPPORTUNITY GRANTS	84.007	P007A183720				\$138,000	\$2,340,445	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701
FEDERAL SUPPLEMENTAL EDUCATIONAL OPPORTUNITY GRANTS	84.007	P007A193720				\$2,202,445	\$2,340,445	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701
NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015A140143			\$4,243	\$4,243	\$1,624,263	OTHER PROGRAMS	\$15,539,552
NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015A140143				-\$1,970	\$1,624,263	OTHER PROGRAMS	\$15,539,552

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015A180141		\$7,444	\$513,669	\$1,624,263	OTHER PROGRAMS	\$15,539,552
NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015A140137		\$12,562	\$69,933	\$1,624,263	OTHER PROGRAMS	\$15,539,552
NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015B180147			\$218,106	\$1,624,263	OTHER PROGRAMS	\$15,539,552
NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015A180144/P015B180144			\$359,247	\$1,624,263	OTHER PROGRAMS	\$15,539,552
NATIONAL RESOURCE CENTERS PROGRAM FOR FOREIGN LANGUAGE AND AREA STUDIES OR FOREIGN LANGUAGE AND INTERNATIONAL STUDIES PROGRAM AND FOREIGN LANGUAGE AND AREA STUDIES FELLOWSHIP PROGRAM	84.015	P015A180057/P015B180057			\$461,035	\$1,624,263	OTHER PROGRAMS	\$15,539,552
OVERSEAS PROGRAMS - GROUP PROJECTS ABROAD	84.021	P021A180010			-\$9,792	-\$9,792	OTHER PROGRAMS	\$15,539,552
OVERSEAS PROGRAMS - DOCTORAL DISSERTATION RESEARCH ABROAD	84.022	P022A190008			\$9,520	\$69,108	RESEARCH AND DEVELOPMENT	\$710,017,793
OVERSEAS PROGRAMS - DOCTORAL DISSERTATION RESEARCH ABROAD	84.022	P022A180006			\$59,588	\$69,108	RESEARCH AND DEVELOPMENT	\$710,017,793
FEDERAL WORK-STUDY PROGRAM	84.033	P033A183720			\$103,752	\$3,484,885	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701
FEDERAL WORK-STUDY PROGRAM	84.033	P033A193720			\$3,381,133	\$3,484,885	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701
PERKINS LOAN OUTSTANDING LOANS ISSUED AS JULY 1, 2019	84.038				\$35,821,896	\$35,821,896	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701
TRIO STUDENT SUPPORT SERVICES	84.042	P042A150394			\$278,179	\$278,179	TRIO CLUSTER	\$1,615,273
TRIO TALENT SEARCH	84.044	9044A160227			\$290,203	\$290,203	TRIO CLUSTER	\$1,615,273
TRIO UPWARD BOUND	84.047	P047M180267			\$263,367	\$1,046,891	TRIO CLUSTER	\$1,615,273
TRIO UPWARD BOUND	84.047	P047V170188			\$276,799	\$1,046,891	TRIO CLUSTER	\$1,615,273
TRIO UPWARD BOUND	84.047	P047A180557			\$506,725	\$1,046,891	TRIO CLUSTER	\$1,615,273
FEDERAL PELL GRANT PROGRAM	84.063	P063P20182158			\$339,900	\$7,789,243	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701
FEDERAL PELL GRANT PROGRAM	84.063	P063P20192158			\$7,449,343	\$7,789,243	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701
GRADUATE ASSISTANCE IN AREAS OF NATIONAL NEED	84.200	P200A160282			\$388,895	\$388,895	OTHER PROGRAMS	\$15,539,552
FEDERAL DIRECT LOANS	84.268				\$178,316,869	\$178,316,869	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701
TWENTY-FIRST CENTURY COMMUNITY LEARNING CENTERS	84.287		PENNSYLVANIA DEPARTMENT OF EDUCATION	FC4100053524	\$12,000	\$117,622	OTHER PROGRAMS	\$15,539,552
TWENTY-FIRST CENTURY COMMUNITY LEARNING CENTERS	84.287		PENNSYLVANIA DEPARTMENT OF EDUCATION	FC #4100071658	\$19,750	\$413,893	OTHER PROGRAMS	\$15,539,552
TWENTY-FIRST CENTURY COMMUNITY LEARNING CENTERS	84.287		PENNSYLVANIA DEPARTMENT OF EDUCATION	4100068078	\$20,250	\$510,526	OTHER PROGRAMS	\$15,539,552
TWENTY-FIRST CENTURY COMMUNITY LEARNING CENTERS	84.287		PENNSYLVANIA DEPARTMENT OF EDUCATION	SUB TO S287C170038	\$23,750	\$456,249	OTHER PROGRAMS	\$15,539,552
COVID-19 - TWENTY-FIRST CENTURY COMMUNITY LEARNING CENTERS	84.287		PENNSYLVANIA DEPARTMENT OF EDUCATION	SUB TO S287C170038		\$102	OTHER PROGRAMS	\$15,539,552
COVID-19 - TWENTY-FIRST CENTURY COMMUNITY LEARNING CENTERS	84.287		PENNSYLVANIA DEPARTMENT OF EDUCATION	4100068078		\$7,960	OTHER PROGRAMS	\$15,539,552
COVID-19 - TWENTY-FIRST CENTURY COMMUNITY LEARNING CENTERS	84.287		PENNSYLVANIA DEPARTMENT OF EDUCATION	FC4100053524		\$10,231	OTHER PROGRAMS	\$15,539,552
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305	R305A160109			\$43,504	\$461,169	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305	R305C150007			\$1,248,003	\$1,956,528	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305		CHILDREN'S HOSPITAL OF PHILADELPHIA	3272530622		\$25,769	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305		CHILDREN'S HOSPITAL OF PHILADELPHIA	20093819-RSUB		\$37,641	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305		UNIVERSITY OF DELAWARE	40809		\$60,840	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305		FLORIDA STATE UNIVERSITY	R011963		\$68,402	RESEARCH AND DEVELOPMENT	\$710,017,793
EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	84.305		AMERICAN INSTITUTE FOR RESEARCH	0440200001		\$99,532	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH IN SPECIAL EDUCATION	84.324	R324B180017			\$99,116	\$99,116	RESEARCH AND DEVELOPMENT	\$710,017,793
GAINING EARLY AWARENESS AND READINESS FOR UNDERGRADUATE PROGRAMS	84.334		SCHOOL DISTRICT OF PHILADELPHIA	005/F16	\$272,131	\$391,615	OTHER PROGRAMS	\$15,539,552
COVID-19 - GAINING EARLY AWARENESS AND READINESS FOR UNDERGRADUATE PROGRAMS	84.334		SCHOOL DISTRICT OF PHILADELPHIA	005/F16		\$116	OTHER PROGRAMS	\$15,539,552
SUPPORTING EFFECTIVE INSTRUCTION STATE GRANTS (FORMERLY IMPROVING TEACHER QUALITY STATE GRANTS)	84.367		SCHOOL DISTRICT OF PHILADELPHIA	582910		\$17,556	OTHER PROGRAMS	\$15,539,552
GEAR UP - AVID PARTNERSHIPS	84.U01	312-M03-97AO-2260-3291	SCHOOL DISTRICT OF PHILADELPHIA	593/F11		\$94	OTHER PROGRAMS	\$15,539,552

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

THE PENN LITERACY NETWORK EARLY CHILDHOOD LITERACY PROGRAM 2018-2019	84.U06	(BLANK)	PUBLIC HEALTH MANAGEMENT CORPORATION	8722-0619-15	\$1,899	\$1,899	OTHER PROGRAMS	\$15,539,552	
TEACH GRANT	84.U14	ADVANCE ACCOUNT			\$3,838	\$3,838	OTHER PROGRAMS	\$15,539,552	
TOTAL DEPARTMENT OF EDUCATION					\$1,663,637	\$236,181,783			
DEPARTMENT OF HEALTH AND HUMAN SERVICES									
TRAINING IN GENERAL, PEDIATRIC, AND PUBLIC HEALTH DENTISTRY	93.059	1 D85HP30830-01-00			\$269,761	\$269,761	RESEARCH AND DEVELOPMENT	\$710,017,793	
GLOBAL AIDS	93.067	1-UZG-GH-001498-01			\$1,415,628	\$1,415,628	RESEARCH AND DEVELOPMENT	\$710,017,793	
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1-U54-CA-229973-01			\$409,618	\$2,191,160	RESEARCH AND DEVELOPMENT	\$710,017,793	
COVID-19 - FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1-U54-CA-229973-01				\$2,176	\$3,010,970	RESEARCH AND DEVELOPMENT	\$710,017,793
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077		UNIVERSITY OF MIAMI	SPC-001035	\$22,663	\$3,010,970	RESEARCH AND DEVELOPMENT	\$710,017,793	
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1-R21-HL-144673-01A1			\$37,998	\$3,010,970	RESEARCH AND DEVELOPMENT	\$710,017,793	
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1-R01-DA-047743-01A1			\$81,676	\$3,010,970	RESEARCH AND DEVELOPMENT	\$710,017,793	
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1-R01-DA-036028-01			\$102,796	\$3,010,970	RESEARCH AND DEVELOPMENT	\$710,017,793	
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1-P50-CA-179546-01			\$274,418	\$3,010,970	RESEARCH AND DEVELOPMENT	\$710,017,793	
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077		WAKE FOREST UNIVERSITY CHILDREN'S HOSPITAL OF PHILADELPHIA	WFUHS 119379	\$298,083	\$3,010,970	RESEARCH AND DEVELOPMENT	\$710,017,793	
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080			8901210000	\$22,450	\$22,450	RESEARCH AND DEVELOPMENT	\$710,017,793	
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084	1-U54-CK-000485-01			\$120,542	\$1,678,603	RESEARCH AND DEVELOPMENT	\$710,017,793	
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084		RUSH UNIVERSITY	15122904-SUB02	\$3,517	\$2,017,911	RESEARCH AND DEVELOPMENT	\$710,017,793	
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084		WASHINGTON UNIVERSITY IN ST. LOUIS	WU-17-159	\$79,374	\$2,017,911	RESEARCH AND DEVELOPMENT	\$710,017,793	
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084		DUKE UNIVERSITY MEDICAL CENTER	2035586	\$111,204	\$2,017,911	RESEARCH AND DEVELOPMENT	\$710,017,793	
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084		RUSH UNIVERSITY	15122902-SUB02	\$145,213	\$2,017,911	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006449-01			-\$98	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006570-01			-\$5	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103		MASSACHUSETTS GENERAL HOSPITAL	231104	\$970	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
COVID-19 - FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006158-01			\$3,327	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006451-01			\$3,352	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-005164-01			\$13,953	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006713-01			\$15,275	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006855-01			\$17,841	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006450-01			\$18,732	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006660-01			\$25,350	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006856-01			\$27,109	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006661-01			\$49,550	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1-U18-FD-006158-01			\$49,658	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1U18FD006669-01			\$52,140	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103		CHILDREN'S HOSPITAL OF PHILADELPHIA	FP23610_SUB01_01	\$96,901	\$374,055	RESEARCH AND DEVELOPMENT	\$710,017,793	
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISTURBANCES (SED)	93.104		COMMUNITY BEHAVIORAL HEALTH CHILDREN'S HOSPITAL OF PHILADELPHIA	SUB TO 1U795M062463	\$39,154	\$39,154	OTHER PROGRAMS	\$15,539,552	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		FLORIDA ASSOCIATION OF HEALTHY START COALITIONS, INC	3258990618	\$9,269	\$424,423	RESEARCH AND DEVELOPMENT	\$710,017,793	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		CHILDREN'S HOSPITAL OF PHILADELPHIA	16-08-2019	\$16,008	\$424,423	RESEARCH AND DEVELOPMENT	\$710,017,793	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		CHILDREN'S HOSPITAL OF PHILADELPHIA	3258990618	\$25,852	\$424,423	RESEARCH AND DEVELOPMENT	\$710,017,793	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		CHILDREN'S HOSPITAL OF PHILADELPHIA	3210800519	\$34,174	\$424,423	RESEARCH AND DEVELOPMENT	\$710,017,793	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		CHILDREN'S HOSPITAL OF PHILADELPHIA	320961-06-01	\$37,318	\$424,423	RESEARCH AND DEVELOPMENT	\$710,017,793	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		UNIVERSITY OF CALIFORNIA, LOS ANGELES	2000 G TC248	\$301,802	\$424,423	RESEARCH AND DEVELOPMENT	\$710,017,793	
ENVIRONMENTAL HEALTH	93.113	1-R56-ES-030218-01			\$22,240	\$130,519	RESEARCH AND DEVELOPMENT	\$710,017,793	
ENVIRONMENTAL HEALTH	93.113	1-R01-ES-029294-01A1			\$101,018	\$417,545	RESEARCH AND DEVELOPMENT	\$710,017,793	
ENVIRONMENTAL HEALTH	93.113		UNIVERSITY OF CINCINNATI	011720-002	\$4,219	\$4,002,416	RESEARCH AND DEVELOPMENT	\$710,017,793	
ENVIRONMENTAL HEALTH	93.113		CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	SUB TO R01ES027224	\$4,965	\$4,002,416	RESEARCH AND DEVELOPMENT	\$710,017,793	
ENVIRONMENTAL HEALTH	93.113	2R25E021649-06			\$67,359	\$4,002,416	RESEARCH AND DEVELOPMENT	\$710,017,793	

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS**

Fiscal Period 7/1/2019 - 6/30/2020

ENVIRONMENTAL HEALTH	93.113		IT-MESH DIAGNOSTICS	SUB TO R41E5031778	\$104,583	\$4,002,416	RESEARCH AND DEVELOPMENT	\$710,017,793
ENVIRONMENTAL HEALTH	93.113		BAYLOR COLLEGE OF MEDICINE	PO #7000000399	\$120,829	\$4,002,416	RESEARCH AND DEVELOPMENT	\$710,017,793
ENVIRONMENTAL HEALTH	93.113	2-P30-ES-013508-15			\$203,504	\$4,002,416	RESEARCH AND DEVELOPMENT	\$710,017,793
ENVIRONMENTAL HEALTH	93.113	2-T32-ES-019851-06			\$392,151	\$4,002,416	RESEARCH AND DEVELOPMENT	\$710,017,793
ENVIRONMENTAL HEALTH	93.113	1-R01-ES-026023-01			\$408,066	\$4,002,416	RESEARCH AND DEVELOPMENT	\$710,017,793
ENVIRONMENTAL HEALTH	93.113	1-R01-ES-028206-01			\$408,415	\$4,002,416	RESEARCH AND DEVELOPMENT	\$710,017,793
ENVIRONMENTAL HEALTH	93.113	1-R01-ES-028114-01A1			\$417,106	\$4,002,416	RESEARCH AND DEVELOPMENT	\$710,017,793
ENVIRONMENTAL HEALTH	93.113	2-P30-ES-013508-10			\$1,323,155	\$4,002,416	RESEARCH AND DEVELOPMENT	\$710,017,793
PREVENTIVE MEDICINE RESIDENCY	93.117	1 D33HP31673-01-00			\$319,254	\$319,254	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7-R01-DE-024982-04			-\$34,272	\$202,734	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-025220-01			-\$5,387	\$257,549	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-028561-01A1			\$6,613	\$120,813	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1R21DE028414-01			\$9,994	\$21,332	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024748-01			\$32,111	\$431,724	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-025848-01A1			\$43,255	\$433,387	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-027901-01			\$98,701	\$390,203	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-018023-07A1			\$117,697	\$450,588	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R37-DE-026152-01			\$126,014	\$404,733	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7-U01-DE-027637-02			\$214,617	\$1,348,254	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-026603-01A1			\$293,877	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024570-01			-\$2,655	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-025848-01A1			\$19	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024716-01			\$30	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R37-DE-026152-01			\$30	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024153-01A1			\$30	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121		LANKENAU INSTITUTE FOR MEDICAL RESEARCH	06297-0793	\$30	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-028561-01A1			\$30	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1R01DE029436-01			\$30	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	4-R00-DE-025915-03			\$31	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R03-DE-028026-01A1			\$31	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	7-U01-DE-027637-02			\$41	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-017732-07A1			\$46	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-021921-06			\$46	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121		CAROLINAS HEALTH CARE SYSTEM	SUB TO 1U01DE022939-01	\$64	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	7R01DE027374-03			\$328	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-006014-34A1			\$333	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024160-01A1			\$359	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-025220-01			\$530	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-018023-07A1			\$530	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	4-R01-DE-023071-04			\$749	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121		NEW YORK UNIVERSITY	F0397-02	\$4,034	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121		NEW YORK UNIVERSITY	F0132-01	\$16,137	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121		NEW YORK UNIVERSITY	F0671-01	\$20,502	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-F31-DE-029361-01			\$28,839	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1R01DE029436-01			\$34,225	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-F32-DE-029407-01			\$48,435	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121		UNIVERSITY OF FLORIDA	UFDS00012134	\$57,023	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7R01DE024767-04			\$63,664	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-029648-01			\$67,276	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121		FOX CHASE CHEMICAL DIVERSITY CENTER	R41DE028489-UP	\$71,924	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-015254-12A1			\$77,286	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121		CAROLINAS HEALTH CARE SYSTEM	13-01455 (3000300177)	\$78,969	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-K08-DE-027129-01			\$82,008	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R21-DE-026700-01			\$82,526	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R21-DE-028417-01			\$89,320	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-009517-21A1			\$156,756	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121		LANKENAU INSTITUTE FOR MEDICAL RESEARCH	06297-0793	\$157,770	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R03-DE-028026-01A1			\$172,858	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7-R01-DE-023105-04			\$197,346	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024160-01A1			\$207,186	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-021921-06			\$215,241	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	4-R00-DE-025915-03			\$238,696	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121		CAROLINAS HEALTH CARE SYSTEM	3000301222 (A18-0261-5007)	\$251,487	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	4-R00-DE-026807-02			\$259,851	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7-R01-DE-025037-06			\$261,070	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7R01DE027374-03			\$270,220	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024716-01			\$277,991	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-027970-01			\$327,149	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-027185-01A1			\$346,642	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-017732-07A1			\$366,115	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

ORAL DISEASES AND DISORDERS RESEARCH	93.121	1-R01-DE-024153-01A1			\$385,805	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-006014-34A1			\$465,907	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
ORAL DISEASES AND DISORDERS RESEARCH	93.121	2-R01-DE-019108-06A1			\$474,270	\$10,210,354	RESEARCH AND DEVELOPMENT	\$710,017,793
GRANTS TO INCREASE ORGAN DONATIONS	93.134		ARBOR RESEARCH COLLABORATIVE FOR HEALTH	U3EHS32756	\$10,753	\$93,249	RESEARCH AND DEVELOPMENT	\$710,017,793
GRANTS TO INCREASE ORGAN DONATIONS	93.134		JOHNS HOPKINS UNIVERSITY	2003709181	\$82,496	\$93,249	RESEARCH AND DEVELOPMENT	\$710,017,793
CENTERS FOR RESEARCH AND DEMONSTRATION FOR HEALTH PROMOTION AND DISEASE PREVENTION	93.135	1-U48-DP-005053-01			\$28,859	\$328,137	RESEARCH AND DEVELOPMENT	\$710,017,793
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1-R49-CE-002474-01			\$9,771	\$284,235	RESEARCH AND DEVELOPMENT	\$710,017,793
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1-R01CE003049-01-00			\$586,750	\$1,062,968	RESEARCH AND DEVELOPMENT	\$710,017,793
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1-R01CE003143-01-00				\$223,744	RESEARCH AND DEVELOPMENT	\$710,017,793
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1-R49CE003083-01-00				\$400,005	RESEARCH AND DEVELOPMENT	\$710,017,793
NIEHS SUPERFUND HAZARDOUS SUBSTANCES_BASIC RESEARCH AND EDUCATION	93.143	1-P42-ES-023720-01				\$167,228	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	1-R01-HG-010646-01			\$15,597	\$431,699	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	1-R01-HG-010067-01			\$88,948	\$594,774	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	2-R01-HG-006137-07			\$140,719	\$293,787	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	1-RM1-HG-010023-01			\$551,832	\$2,334,047	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - HUMAN GENOME RESEARCH	93.172	1-T32-HG-009496-01				\$201	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - HUMAN GENOME RESEARCH	93.172	1-RM1-HG-010023-01				\$206	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	1-R21-HG-009545-01				\$1,255	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	1-F30-HG-010822-01A1				\$2,110	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	2-T32-HG-000046-21				\$27,260	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172		GEISINGER HEALTH SYSTEM	646017UP	\$38,948	\$6,146,941	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	1-F30-HG-010442-01			\$48,379	\$6,146,941	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172		BROAD INSTITUTE OF MIT AND HARVARD	5000950-5500001052	\$82,915	\$6,146,941	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172		BIOSPYDER	SUB TO R41.HG010638	\$92,805	\$6,146,941	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	4-R00-HG-007982-02			\$95,534	\$6,146,941	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172		UNIVERSITY OF CHICAGO	FP061089-01-C	\$121,575	\$6,146,941	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172		STANFORD UNIVERSITY	R01 HG010476 62166731-137013	\$136,249	\$6,146,941	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172		ALTIUS INSTITUTE FOR BIOMEDICAL SCIENCES	PF4172	\$141,354	\$6,146,941	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	R25-HG-010323				\$147,282	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	2-T32-HG-000046-16				\$240,141	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	1-R21-HG-010536-01				\$264,804	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	1-T32-HG-009496-01				\$271,681	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	1-T32-HG-009495-01				\$354,399	RESEARCH AND DEVELOPMENT	\$710,017,793
HUMAN GENOME RESEARCH	93.172	1-R01-HG-009655-01				\$425,536	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	7-R01-DC-013243-06			-\$7,171	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-013588-01A1			\$15,172	\$15,172	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-013588-01A1				-\$1,133	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-015359-01A1			\$35,867	\$411,105	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-016800-01A1			\$47,346	\$695,000	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-013961-01A1			\$59,779	\$321,039	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R01-DC-006213-11A1			\$152,724	\$560,780	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		NORTHWESTERN UNIVERSITY	60044484 PENN	-\$41,443	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		TEMPLE UNIVERSITY	253763-UPENN	-\$8,962	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	4-R01-DC-012780-04				-\$3,128	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R01-DC-009224-07A1				-\$2,516	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-F31-DC-013945-01A1				-\$1,136	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	4-R01-DC-012511-04				-\$901	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R01-DC-006254-11A1				\$13	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-017144-01A1				\$183	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-015527-01A1				\$283	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		MONELL CHEMICAL SENSES CENTER	NIH033806MENNE	\$17,487	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		NORTHWESTERN UNIVERSITY	60049678 UP	\$19,692	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R13-DC-010549-11			\$19,820	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	10858SC	\$30,322	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-F31-DC-016192-01A1			\$33,220	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-F31-DC-016524-01			\$34,508	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-F31-DC-017054-01A1			\$45,137	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-018075-01A1			\$57,628	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		NORTHWESTERN UNIVERSITY	SP0028600-PROJ0014095	\$59,226	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		MEDICAL COLLEGE OF WISCONSIN	SUB TO R01DC016622	\$80,970	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1R01DC018525-01			\$85,569	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	7-R01-DC-010014-10			\$92,359	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-K08-DC-014299-01			\$141,175	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-T32-DC-016903-01			\$183,082	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		TEMPLE UNIVERSITY	262389 UPENN	\$197,417	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		NORTHWESTERN UNIVERSITY	SP0028600-PROJ0015132	\$284,661	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R01-DC-006254-16A1			\$295,314	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-014464-01			\$300,973	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-014479-01			\$301,957	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1R01DC017690-01A1			\$317,521	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-015527-01A1			\$386,754	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R01-DC-009209-11			\$403,185	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-016309-01A1			\$405,938	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1-R01-DC-017144-01A1			\$441,980	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2-R01-DC-012854-06			\$611,979	\$6,785,059	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL RESEARCH SERVICE AWARD IN PRIMARY CARE MEDICINE	93.186	6 T32HP10026-23-01			\$465,509	\$465,509	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	1-UH2-AT-007797-01			\$97,377	\$359,610	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213		NEW YORK UNIVERSITY	17-AO-00-008501	\$49,554	\$632,946	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213		UNIVERSITY OF MINNESOTA	A0006743902	\$223,782	\$632,946	RESEARCH AND DEVELOPMENT	\$710,017,793
FAMILY PLANNING SERVICE	93.217		FAMILY HEALTH COUNCIL OF CENTRAL PA	FHPAD36160	\$40,201	\$40,201	OTHER PROGRAMS	\$15,539,552
NATIONAL RESEARCH SERVICE AWARDS HEALTH SERVICES RESEARCH TRAINING	93.225	1-T32-HS-026116-01			\$571,053	\$571,053	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R01-HS-024266-01			\$1,072	\$1,072	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R01-HS-023615-01			\$6,942	\$19,431	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R01-HS-023794-01			\$26,097	\$87,103	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	7-R01-HS-021491-04			\$72,283	\$114,458	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R01-HS-024918-01			\$186,796	\$484,924	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R21-HS-023805-01A1			\$4,085	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		UNIVERSITY OF CHICAGO	FP063214-A	\$5,565	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		COLUMBIA UNIVERSITY	1(GG014621-01)	\$9,959	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		ARBOR RESEARCH COLLABORATIVE FOR HEALTH	SUB TO R01-HS025756	\$15,878	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		CHILDREN'S HOSPITAL OF PHILADELPHIA	3200220120	\$25,122	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R18-HS-026862-01A1			\$25,242	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R36-HS-027142-01			\$26,802	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		EMORY UNIVERSITY	A015673	\$26,932	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		JOHNS HOPKINS UNIVERSITY	2004496574	\$30,069	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		EMORY UNIVERSITY	A242409	\$30,500	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R01-HS-024106-01			\$31,003	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES	51981 - UPENN	\$43,751	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		CORNELL UNIVERSITY	83742-11053	\$45,695	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201800422	\$50,003	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		UNIVERSITY OF IOWA	S00848-01	\$50,652	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		YALE UNIVERSITY	GR103820 (CON-80001346)	\$53,832	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		CHILDREN'S HOSPITAL OF PHILADELPHIA	ACTIVITY#320133072	\$97,985	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-R01-HS-025184-01			\$430,787	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1-K12-HS-026372-01			\$443,293	\$2,154,143	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-U01-HL-125388-01A1			\$27,801	\$1,081,681	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	2-P01-HL-094307-06A1			\$385,868	\$2,664,088	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-R01-HL-134015-01			\$431,955	\$710,518	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-R01-HL-143790-01			\$470,038	\$689,002	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	2-T32-HL-110952-06			\$539,208	\$542,740	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-K23-HL-141581-01A1				\$5,414	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	2-R01-HL-047600-20A1				\$18,095	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233		CHILDREN'S HOSPITAL OF PHILADELPHIA	8901440619	\$20,171	\$7,805,961	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-K99-HL-147212-01			\$67,625	\$7,805,961	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233		UNIVERSITY OF NEVADA, LAS VEGAS	GR09951	\$79,305	\$7,805,961	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-R01-HL-123331-01A1			\$193,034	\$7,805,961	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-R25-HL-120874-01			\$199,599	\$7,805,961	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1-R01-HL-122754-01A1			\$226,740	\$7,805,961	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1R01HL149133-01			\$330,683	\$7,805,961	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	2-T32-HL-007953-19			\$366,925	\$7,805,961	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	2-T32-HL-007713-26A1			\$610,341	\$7,805,961	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	7-K23-MH-106362-04			-\$7,980	\$90,477	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R34-MH-104407-01				\$86	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-120739-01			\$7,792	\$97,200	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-119219-01A1			\$7,794	\$583,120	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1R01MH118203-01A1			\$8,085	\$257,102	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	7-R01-MH-103910-06			\$8,862	\$85,679	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-108996-01A1			\$9,201	\$169,948	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	4-R01-MH-098260-03			\$10,194	\$241,557	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-075916-05A1			\$11,512	\$11,933	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-116884-01A1			\$17,710	\$272,883	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-116362-01			\$17,748	\$156,541	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-061975-12A1			\$40,328	\$58,939	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R34-MH-108437-01A1			\$41,181	\$90,388	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-111389-01			\$43,398	\$405,914	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1UF1MH121944-01			\$45,777	\$660,156	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-112070-01A1			\$50,000	\$723,727	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R37-MH-109728-01			\$55,926	\$772,599	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-109382-01A1			\$76,371	\$694,164	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-117807-01A1			\$97,705	\$412,047	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-108551-01			\$101,009	\$711,634	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-P50-MH-113840-01			\$101,889	\$2,081,892	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-107276-01A1			\$134,348	\$652,122	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-120482-01			\$165,701	\$528,678	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	2-P30-MH-097488-06			\$172,597	\$1,548,778	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-106967-01A1			\$199,627	\$516,146	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-108627-01			\$218,324	\$413,314	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-115557-01			\$222,133	\$446,431	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	R01MH111602			\$323,338	\$492,763	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-107452-01A1			\$403,062	\$749,779	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R56-MH-118550-01			\$418,670	\$624,476	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-098742-06A1			\$423,720	\$776,734	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	7-U19-MH-106434-02			\$2,114,779	\$2,591,693	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-P50-MH-099910-01				-\$29,367	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-107703-01				-\$15,430	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-104134-01				-\$14,024	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-109298-01A1				-\$7,331	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		BETH ISRAEL MEDICAL CENTER	01027167	-\$2,392	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MENTAL HEALTH RESEARCH GRANTS	93.242	1UF1MH121944-01				\$11	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-118489-01A1				\$12	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-2001-4609	\$18	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-106967-01A1				\$323	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-109382-01A1				\$323	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-098742-06A1				\$323	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

MENTAL HEALTH RESEARCH GRANTS	93.242		YALE UNIVERSITY	GR104299 (CON-80001421)	\$466	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-DP2-MH-107055-01			\$1,677	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		JOHNS HOPKINS UNIVERSITY	145276	\$2,222	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F31-MH-114609-01A1			\$3,087	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-123550-01			\$3,645	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3209760321	\$3,684	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F31-MH-115709-01A1			\$4,508	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F31-MH-114528-01			\$5,115	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			PENNSYLVANIA STATE UNIVERSITY COLLEGE OF MEDICINE	UPENNMH108558	\$6,247	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F31-MH-120925-01A1			\$6,330	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	2-T32-MH-019112-24			\$6,450	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF CALIFORNIA, SAN DIEGO	118744601	\$6,993	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		OHIO STATE UNIVERSITY	60067395	\$7,251	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3210640821	\$7,571	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			MASSACHUSETTS GENERAL HOSPITAL	227381	\$8,858	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		JOHNS HOPKINS UNIVERSITY	2003487677	\$9,185	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		THOMAS JEFFERSON UNIVERSITY	080-19250-536601	\$9,494	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		MICHIGAN STATE UNIVERSITY	RC105383UOPENN	\$9,783	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		TEMPLE UNIVERSITY	260864-PENN	\$9,964	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	102875C	\$10,166	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-087950-06A1			\$10,338	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF MASSACHUSETTS	WAO0320041/RFS2016010	\$10,606	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-K99-MH-117274-01			\$12,237	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			ACLARIS MEDICAL, LLC	R43MH107089-S1	\$12,693	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-K23-MH-107831-01A1			\$13,417	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-123002-01			\$15,150	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			COLUMBIA UNIVERSITY	3 (GG009422	\$15,196	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			DREXEL UNIVERSITY	232616	\$15,536	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		HENRY FORD HEALTH SYSTEM	B11175_UPENN	\$17,531	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF ALABAMA AT BIRMINGHAM	000518108-003	\$17,676	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			WASHINGTON UNIVERSITY IN ST. LOUIS	WU-20-422	\$17,902	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILD MIND INSTITUTE BIOBANK	1R21MH118556 SUB1	\$18,455	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	2-T32-MH-017168-31			\$19,951	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF WASHINGTON	UWSC10949	\$20,248	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F30-MH-122076-01			\$23,633	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF UTAH	P10048074	\$24,594	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-120174-01A1			\$26,450	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			PROMPTWORKS	SUB TO R32MH121205	\$27,058	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3201571123	\$31,215	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			BOISE STATE UNIVERSITY	8424-PO133997	\$33,564	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3200290221	\$41,962	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-100923-01A1			\$48,159	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5111526	\$49,635	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	7-K23-MH-102360-06			\$49,669	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-111166-01A1			\$50,146	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-106175-01A1			\$54,330	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F30-MH-118871-01			\$55,250	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3201070320	\$55,565	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	2-T32-MH-065218-11			\$56,151	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-120890-01			\$56,204	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-115661-01A1			\$58,635	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1F32MH113334-01A1			\$60,366	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-114506-01			\$60,376	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-117924-01A1			\$61,361	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF WASHINGTON	UWSC11446	\$62,011	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	116965C	\$64,474	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-F32-MH-115434-01			\$65,240	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF CALIFORNIA, LOS ANGELES	1580 G WB602	\$69,795	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-118369-01A1			\$74,380	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
			ARIZONA STATE UNIVERSITY	18-285	\$74,574	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF WASHINGTON	UWSC9095	\$77,349	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

MENTAL HEALTH RESEARCH GRANTS	93.242	1-R34-MH-108818-01			\$77,873	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.	26657	\$80,374	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201790521	\$82,711	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		COLUMBIA UNIVERSITY	1(GG011930)	\$83,544	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-118170-01			\$85,316	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		NORTHWESTERN UNIVERSITY	60047194 UP	\$92,390	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1R21MH122239-01			\$93,755	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF CALIFORNIA, LOS ANGELES	2000 G VA473	\$95,248	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF ILLINOIS AT CHICAGO	16626	\$97,595	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		RUTGERS UNIVERSITY	SUB TO R01MH109520	\$103,534	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	10288SC	\$106,506	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		DREXEL UNIVERSITY	800172	\$107,883	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-K01-MH-121777-01			\$122,130	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-K23-MH-118580-01A1			\$134,515	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-119185-01A1			\$138,126	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		ARIZONA STATE UNIVERSITY	SUB TO U01MH121260	\$140,112	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		COLUMBIA UNIVERSITY	1(GG011969-01)	\$144,247	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R25-MH-119043-01			\$151,888	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-118489-01A1			\$174,659	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R21-MH-118037-01			\$195,810	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		PALO ALTO VETERANS INSTITUTE FOR RESEARCH	WIS0003-05	\$196,175	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		YALE UNIVERSITY	GR107872 (CON-80002099)	\$198,988	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-042191-24A1			\$206,730	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	2-T32-MH014654-40			\$207,701	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-T32-MH-109433-01A1			\$218,275	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - MENTAL HEALTH RESEARCH GRANTS	93.242	7-K08-MH-112120-04			\$251,551	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-111719-01A1			\$255,900	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-T32-MH-106442-01A1			\$260,460	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		NEW YORK UNIVERSITY GROSSMAN SCHOOL OF MEDICINE	19-00-00-1003623	\$266,250	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	7-R01-MH-105128			\$279,310	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-120811-01			\$298,600	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		EMORY UNIVERSITY	A051228	\$327,183	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-U01-MH-119738-01			\$330,943	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-087950-06A1			\$331,782	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-120269-01			\$348,905	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242		ALLEN INSTITUTE FOR BRAIN SCIENCE	2017-0567	\$365,846	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-109498-01			\$371,984	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-107571-01A1			\$381,106	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	4-R00-MH-111836-03			\$394,626	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	2-R01-MH-055687-21			\$400,945	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-U01-MH-109991-01			\$428,065	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-110939-01A1			\$435,044	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-112847-01			\$453,523	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-117014-01A1			\$559,303	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-115030-01			\$572,125	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-RF1-MH-116920-01			\$587,358	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-110180-01A1			\$609,595	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-111886-01			\$622,879	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-113565-01A1			\$696,329	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-109260-01A1			\$700,015	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL HEALTH RESEARCH GRANTS	93.242	1-R01-MH-113550-01A1			\$929,406	\$34,398,262	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243		CITY OF PHILADELPHIA	SUB TO SAMHSA	\$31	\$1,297,877	OTHER PROGRAMS	\$15,539,552
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243		GEORGIA STATE UNIVERSITY	SP00011772-01	\$2,223	\$1,297,877	OTHER PROGRAMS	\$15,539,552
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243		DELAWARE, STATE OF	0417124	\$28,465	\$1,297,877	OTHER PROGRAMS	\$15,539,552
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243		CITY OF PHILADELPHIA	1720075-03/YR4	\$51,822	\$1,297,877	OTHER PROGRAMS	\$15,539,552
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243		CITY OF PHILADELPHIA	1720535	\$74,855	\$1,297,877	OTHER PROGRAMS	\$15,539,552
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243		CITY OF PHILADELPHIA	SUB TO SAMHSA	\$105,633	\$1,297,877	OTHER PROGRAMS	\$15,539,552
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243		ADAMS COUNTY, PENNSYLVANIA	SUB TO 1H79SM081196-01	\$254,333	\$1,297,877	OTHER PROGRAMS	\$15,539,552

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

FIRST RESPONDERS - COMPREHENSIVE NALOXONE DISTRIBUTION AND RECOVERY SERVICE INITIATIVE	93.243	1H795PO080317-01			\$286,465	\$1,297,877	OTHER PROGRAMS	\$15,539,552	
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243	1H79TI081596-01			\$494,050	\$1,297,877	OTHER PROGRAMS	\$15,539,552	
ADVANCED NURSING EDUCATION WORKFORCE GRANT PROGRAM	93.247	1-D09-HP-28672-01-00			\$37,187	\$387,405	RESEARCH AND DEVELOPMENT	\$710,017,793	
ADVANCED NURSING EDUCATION WORKFORCE GRANT PROGRAM	93.247	1 T94HP30898-0-100			\$350,218	\$387,405	RESEARCH AND DEVELOPMENT	\$710,017,793	
OCCUPATIONAL SAFETY AND HEALTH PROGRAM	93.262	2-T03-OH-008628-11			\$2,160	\$163,058	RESEARCH AND DEVELOPMENT	\$710,017,793	
OCCUPATIONAL SAFETY AND HEALTH PROGRAM	93.262	2 T03OH008628-15-00			\$160,898	\$163,058	RESEARCH AND DEVELOPMENT	\$710,017,793	
NURSE FACULTY LOAN PROGRAM ISSUED DURING FY20	93.264				\$471,111	\$2,373,466	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701	
NURSE FACULTY LOAN PROGRAM OUTSTANDING AS OF 07/01/19	93.264				\$1,902,355	\$2,373,466	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701	
HEALTH SYSTEMS STRENGTHENING AND HIV/AIDS PREVENTION, CARE AND TREATMENT UNDER THE PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF	93.266	7-R01-EB-022574-03			\$154,853	\$292,317	RESEARCH AND DEVELOPMENT	\$710,017,793	
HEALTH SYSTEMS STRENGTHENING AND HIV/AIDS PREVENTION, CARE AND TREATMENT UNDER THE PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF	93.266		BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	60648.2005114.669202		\$16,169	\$308,486	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-022595-01A1			\$60,316	\$154,151	RESEARCH AND DEVELOPMENT	\$710,017,793	
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-022986-01A1			\$116,072	\$315,698	RESEARCH AND DEVELOPMENT	\$710,017,793	
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-024941-01			\$161,292	\$806,716	RESEARCH AND DEVELOPMENT	\$710,017,793	
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-026297-01A1				-\$12,849	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273	1-F32-AA-024347-01A1				-\$2,120	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273	4-K08-AA-021424-04				-\$749	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273		COLUMBIA UNIVERSITY	2(GG014243-01)		\$10,157	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273		UNIVERSITY OF ROCHESTER	417591G / URFAO: GR510935		\$19,148	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	105095C		\$19,494	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273	1-F31-AA-026766-01A1				\$21,479	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273		RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.	PO# 140111		\$29,523	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273		PUBLIC HEALTH MANAGEMENT CORPORATION	7617061803		\$33,066	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273		MASSACHUSETTS GENERAL HOSPITAL	233136		\$56,989	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273		UNIVERSITY OF NEW MEXICO	028372-874D		\$57,826	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273	1-K23-AA-023894-01				\$119,236	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-023192-01				\$200,513	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273		YALE UNIVERSITY	GR104469 (CON-80001475)		\$233,925	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273	4-R01-AA-021164-05				\$257,235	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-026267-01A1				\$367,323	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273	1-U01-AA-025931-01A1				\$396,257	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-026302-01				\$416,393	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273	1-DP1-AA-028409-01				\$429,525	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
ALCOHOL RESEARCH PROGRAMS	93.273	1-R01-AA-027202-01A1				\$467,064	\$4,396,000	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R21-DA-043983-01A1			\$1,118	\$170,982	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-049514-01			\$8,929	\$545,953	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	4-R01-DA-033670-05			\$26,792	\$32,510	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-041180-01A1			\$42,913	\$449,909	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-040972-01A1			\$54,313	\$419,895	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-049545-01			\$71,725	\$416,900	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-048001-01			\$102,113	\$534,826	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-R01-DA-029840-06A1			\$124,181	\$278,679	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-P30-DA-046345-01A1			\$193,438	\$973,106	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-037289-01A1			\$243,150	\$388,881	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-U54-DA-039002-01			\$263,514	\$287,437	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-R01-DA-035868-04A1			\$382,467	\$610,703	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-U10-DA-013043-11				-\$57,365	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-046619-01				-\$18,667	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1R21DA044017-01A1				-\$2,075	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R21-DA-043993-01A1				-\$764	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-049514-01				\$323	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-040670-01A1				\$932	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1R01DA045604-01A1				\$2,056	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		NEW YORK UNIVERSITY	19-A0-00-1002274		\$3,795	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		SIMON FRASER UNIVERSITY	SUB TO 3R01DA041747		\$4,034	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		YALE UNIVERSITY	GR105496 (CON-80001678)		\$8,443	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		UNIVERSITY OF MARYLAND	1802582		\$12,515	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R21-DA-050761-01				\$20,996	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		JOHNS HOPKINS UNIVERSITY	2002753634		\$21,392	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		UNIVERSITY OF ROCHESTER	417660G / URFAO:GR510990		\$21,735	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		TEMPLE UNIVERSITY	264420-UPENN		\$22,418	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		UNIVERSITY OF FLORIDA	SUB00002214		\$23,851	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		YALE UNIVERSITY	GR109740 (CON-80002398)		\$26,621	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		MCLEAN HOSPITAL	401655		\$29,563	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		RHODE ISLAND HOSPITAL	7017137280		\$32,201	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		WISTAR INSTITUTE	25631-02-324	\$47,692	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		UNIVERSITY OF MICHIGAN	SUBK00011012	\$49,451	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-037897-01A1			\$55,292	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		CORNELL UNIVERSITY	183469-2	\$56,815	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R21-DA-045792-01A1			\$82,909	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		UNIVERSITY OF MICHIGAN	3003985347	\$88,919	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	4-R01-DA-036503-04			\$92,193	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R21-DA-046760-01A1			\$97,876	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-K01-DA-048134-01			\$101,356	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-036572-01			\$102,119	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1R21DA049572-01			\$129,752	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		WISTAR INSTITUTE	25621-02-324	\$133,417	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-K24-DA-029062-06			\$133,979	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-K01-A047417-01A1			\$137,339	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		GEISINGER HEALTH SYSTEM	626510UP01	\$142,106	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		MCLEAN HOSPITAL	SUB TO UG1DA015831	\$143,061	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-K23-DA-038726-01A1			\$149,139	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-K01-DA-040023-01A1			\$170,580	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-K24-DA-045244-01A1			\$173,786	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-K23-DA-048167-01			\$180,600	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	7-R01-DA-039457-02			\$185,713	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R21-DA-046364-01A1			\$199,169	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		WEILL CORNELL MEDICAL COLLEGE	15070983-02	\$241,617	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R34-DA-050297-01			\$255,335	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-R01-DA-033641-06			\$257,352	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		SUNNYBROOK RESEARCH INSTITUTE	2017-1218	\$287,325	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5-U34-DA-045177-01A1			\$309,294	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-T32-DA-028874-08			\$342,147	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	4-R00-DA-043609-03			\$347,633	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-041402-01			\$397,828	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-040670-01A1			\$410,028	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-044205-01A1			\$416,059	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-UG3-DA-049694-01			\$432,652	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-0P1-DA-044250-01			\$467,178	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-041409-01A1			\$489,593	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2-R01-DA-037897-05A1			\$490,586	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-042682-01			\$495,394	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-039215-01A1			\$536,333	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1-R01-DA-044906-01			\$719,780	\$14,810,182	RESEARCH AND DEVELOPMENT	\$710,017,793
CENTERS FOR DISEASE CONTROL AND PREVENTION INVESTIGATIONS AND TECHNICAL ASSISTANCE	93.283		HARVARD PILGRIM HEALTH CARE	SUB TO 3U54CK000172-03SI	\$2,291	\$2,291	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1U24EB028941-01			\$25,468	\$209,468	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-018464-01A1			\$60,737	\$70,094	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R21-EB-027397-01			\$61,461	\$144,147	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R13-EB-021825-01A1				-\$843	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-U01-EB-016027-01A1				-\$258	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R13-EB-028135-01				\$9,456	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		POLYURUM LLC	SUB TO 1R41EB023169	\$11,377	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2-T32-EB-009384-06			\$14,430	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		UNIVERSITY OF CONNECTICUT HEALTH CENTER	UCHC7-117331099	\$15,041	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		BOSTON UNIVERSITY	4500002478	\$20,676	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		UNIVERSITY OF CALIFORNIA, SANTA BARBARA	KK1614	\$20,770	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-F31-EB-029309-01			\$24,590	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		OLD DOMINION UNIVERSITY RESEARCH FOUNDATION	16-249-100594-010	\$26,883	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		UNIVERSITY OF MIAMI	SPC-000724	\$26,951	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-028764-01			\$29,890	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-F31-EB-024378-01A1			\$30,065	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		UNIVERSITY OF CHICAGO	AWD100072 (SUB0000207)	\$30,257	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		DARTMOUTH COLLEGE	R1035	\$42,869	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		INDIANA UNIVERSITY	8165-UP	\$47,764	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-029238-01A1			\$63,417	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		ALPHATHERA	SUB TO R44 EB023750-02	\$75,840	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-029767-01			\$100,314	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-029363-01			\$144,225	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R21-EB-027407-01			\$151,688	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R21-EB-023989-01A1			\$157,870	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-028162-01			\$165,514	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		CHILDREN'S HOSPITAL OF PHILADELPHIA	3200920521/PO 962704-RSUB	\$166,137	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R21-EB-022687-01A1			\$168,307	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-021293-01A1			\$183,386	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-T32-EB-020087-01A1			\$193,276	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2-T32-EB-004311-11			\$206,583	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2-T32-EB-009384-11			\$245,449	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-017255-01A1			\$286,953	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-028320-01			\$344,665	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-022573-03			\$409,759	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-026945-01			\$421,607	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-022612-01			\$436,904	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-026988-01			\$470,129	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-023274-01			\$498,391	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2-R01-EB-017753-05			\$512,787	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1-R01-EB-026892-01			\$554,836	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2-P41-EB-015893-31			\$1,045,289	\$7,776,953	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1-R01-MD-011518-01A1			\$1,448	\$219,788	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1-R01-MD-013859-01			\$74,516	\$533,102	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	7-R01-MD-013558-03			\$90,136	\$431,470	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1-R01-MD-011679-01			\$229,165	\$507,650	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1-R01-MD-013623-01			\$302,951	\$531,631	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1-U01-MD-011274-01			\$1,303,317	\$1,861,735	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		MEDICAL UNIVERSITY OF SOUTH CAROLINA	MUSC18-024-8C186	\$1,531	\$4,681,508	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1-F31-MD-013358-01			\$2,027	\$4,681,508	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		MEDICAL UNIVERSITY OF SOUTH CAROLINA	A00-2768-5004	\$35,051	\$4,681,508	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		UNIVERSITY OF PITTSBURGH	CNVAA00047269 (127145-6)	\$36,497	\$4,681,508	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201001122	\$37,149	\$4,681,508	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		WASHINGTON UNIVERSITY IN ST. LOUIS	WU-20-107	\$52,000	\$4,681,508	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		MEDICAL UNIVERSITY OF SOUTH CAROLINA	MUSC16-081-8C186	\$134,160	\$4,681,508	RESEARCH AND DEVELOPMENT	\$710,017,793
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		RAND CORPORATION	9920170019	\$297,717	\$4,681,508	RESEARCH AND DEVELOPMENT	\$710,017,793
TRANS-NIH RESEARCH SUPPORT	93.310		DREXEL UNIVERSITY	800134	\$15,458	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793
TRANS-NIH RESEARCH SUPPORT	93.310		NEW YORK UNIVERSITY	15-A0-00-004321-01	\$28,793	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793
TRANS-NIH RESEARCH SUPPORT	93.310		PRINCETON UNIVERSITY	SUB0000255	\$65,557	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793
TRANS-NIH RESEARCH SUPPORT	93.310	1-DP2-MH-110247-01			\$136,321	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

			CHILDREN'S HOSPITAL OF PHILADELPHIA	3201240619	\$193,828	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793	
TRANS-NIH RESEARCH SUPPORT	93.310								
TRANS-NIH RESEARCH SUPPORT	93.310	1DP2TR002776-01			\$208,428	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793	
TRANS-NIH RESEARCH SUPPORT	93.310	1-DP5-OD-021391-01			\$232,591	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793	
TRANS-NIH RESEARCH SUPPORT	93.310	1DP5OD028144-01			\$327,893	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793	
TRANS-NIH RESEARCH SUPPORT	93.310	1-DP5-OD-026420-01			\$389,390	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793	
TRANS-NIH RESEARCH SUPPORT	93.310	1-DP5-OD-026386-01			\$462,398	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793	
TRANS-NIH RESEARCH SUPPORT	93.310	1-R01-GM-137425-01			\$624,909	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793	
TRANS-NIH RESEARCH SUPPORT	93.310	1-R01-AR-075337-01			\$798,811	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793	
			UNIVERSITY OF CALIFORNIA, DAVIS	20150115-01	\$1,042,300	\$4,526,677	RESEARCH AND DEVELOPMENT	\$710,017,793	
TRANS-NIH RESEARCH SUPPORT	93.310								
HEALTH PROFESSIONS STUDENT LOANS, INCLUDING PRIMARY CARE LOANS/LOANS FOR DISADVANTAGED STUDENTS	93.342	4 E31HP27260-00			\$2,376	\$16,294,097	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701	
LDS DENTAL OUTSTANDING AS OF 07/01/2019	93.342				\$5,444	\$16,294,097	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701	
LDS MEDICAL ISSUED AFTER 07/01/2019	93.342				\$29,233	\$16,294,097	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701	
HPL VET ISSUED AFTER 07/01/2019	93.342				\$65,000	\$16,294,097	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701	
HPL MEDICAL OUTSTANDING AS OF 07/01/2019	93.342				\$171,339	\$16,294,097	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701	
HPL DENTAL ISSUED AFTER 07/01/2019	93.342				\$1,250,000	\$16,294,097	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701	
LDS MEDICAL OUTSTANDING AS OF 07/01/2019	93.342				\$2,212,165	\$16,294,097	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701	
HPL VET OUTSTANDING AS OF 07/01/2019	93.342				\$3,313,443	\$16,294,097	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701	
HPL DENTAL OUTSTANDING AS OF 07/01/2019	93.342				\$9,245,097	\$16,294,097	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701	
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES COVID-19 - NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1-UL1-TR-001879-01			\$2,663,643	\$10,475,285	RESEARCH AND DEVELOPMENT	\$710,017,793	
			BOSTON UNIVERSITY	4500002228		\$304	\$11,647,392	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350		UNIVERSITY OF PITTSBURGH	0056222 (131558-2)		\$332	\$11,647,392	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350		BOSTON UNIVERSITY	4500002228		\$147,943	\$11,647,392	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3201810721		\$158,977	\$11,647,392	RESEARCH AND DEVELOPMENT	\$710,017,793
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5-TL1-TR-001880-02			\$864,551	\$11,647,392	RESEARCH AND DEVELOPMENT	\$710,017,793	
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	2-P40-OD-010939-34A1			\$41,137	\$1,151,215	RESEARCH AND DEVELOPMENT	\$710,017,793	
RESEARCH INFRASTRUCTURE PROGRAMS	93.351		COLUMBIA UNIVERSITY	1(GG012813)		\$28,426	\$2,467,932	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	7-K01-OD-019729-06				\$95,921	\$2,467,932	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	7-R03-OD-026599-02				\$205,440	\$2,467,932	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	1S100D026860-01				\$236,930	\$2,467,932	RESEARCH AND DEVELOPMENT	\$710,017,793
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	1-S10-OD-025098-01A1				\$750,000	\$2,467,932	RESEARCH AND DEVELOPMENT	\$710,017,793
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-U54-CA-244711-01			\$30,288	\$592,438	RESEARCH AND DEVELOPMENT	\$710,017,793	
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-P01-CA-210944-01			\$52,387	\$1,866,376	RESEARCH AND DEVELOPMENT	\$710,017,793	
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-R33-CA-225310-01			\$138,387	\$551,394	RESEARCH AND DEVELOPMENT	\$710,017,793	
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-P01-CA-214278-01			\$502,465	\$2,848,781	RESEARCH AND DEVELOPMENT	\$710,017,793	
			HUTCHINSON (FRED) CANCER RESEARCH CENTER	0000920801		-\$7,002	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0000916484		\$2,844	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		MORRIS ANIMAL FOUNDATION	D17CA-501		\$18,569	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - 21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-P01-CA-214278-01				\$24,521	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3201380619		\$28,273	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		WISTAR INSTITUTE	25451-06-314; NATHANSON		\$51,546	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		WISTAR INSTITUTE	25451-05-314; XU		\$83,184	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
			HUTCHINSON (FRED) CANCER RESEARCH CENTER	0000921427		\$160,206	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201460819-XX		\$172,428	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	SUB TO 1U01CA232563-01		\$283,648	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201460819-XX / PO 20028898-RSUB		\$292,070	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-U01-CA-232836-01A1				\$310,213	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1-U24-CA-224122-01				\$400,623	\$7,680,112	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	1-R01-NR-016002-01				\$246,542	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	2-R01-NR-015639-04			\$33,351	\$443,209	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	7-R01-NR-012213-05			\$65,097	\$467,682	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	1-R01-NR-014855-01			\$185,194	\$747,995	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
			COLUMBIA UNIVERSITY	1(GG011577-01)		-\$2,202	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	2-T32-NR-009356-06A1				\$440	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

NURSING RESEARCH	93.361	1-R01-NR-018425-01A1			\$4,026	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	2-T32-NR-007104-16			\$9,736	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF NORTH CAROLINA AT					
			CHAPEL HILL	5111361	\$10,436	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361		UNIVERSITY OF WASHINGTON	UWSC10149	\$16,929	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF					
			PHILADELPHIA	3201511123	\$18,415	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	2R01NR014784-06			\$18,889	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361		UNIVERSITY OF WASHINGTON	UWSC10763	\$23,236	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361		COLUMBIA UNIVERSITY	2(GG014705-01)	\$24,417	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361		DREXEL UNIVERSITY	800066	\$26,669	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	1-F31-NR-017554-01A1			\$30,445	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	2-T32-NR-007100-16			\$30,737	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361		JOHNS HOPKINS UNIVERSITY	2004317284	\$30,867	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	1-F31-NR-018374-01			\$44,171	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
			BRIGHAM AND WOMEN'S HOSPITAL	117914	\$44,448	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	1-F31-NR-018104-01			\$45,077	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361		UNIVERSITY OF IOWA	W000711747	\$50,835	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	1-F31-NR-018097-01A1			\$52,894	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF COLORADO DENVER	FY18.105.016	\$56,444	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF					
			PHILADELPHIA	3200390519	\$102,824	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	1-K23-NR-017663-01A1			\$103,036	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	1-K23-NR-018487-01			\$115,540	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	1-K23-NR-017209-01A1			\$143,881	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	1-R01-NR-017853-01A1			\$353,500	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	2-T32-NR-007104-21			\$445,023	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	1-R01-NR-018196-01			\$491,174	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	2-T32-NR-009356-11			\$498,153	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING RESEARCH	93.361	1-R01-NR-015226-01A1			\$625,752	\$5,321,220	RESEARCH AND DEVELOPMENT	\$710,017,793
NURSING STUDENT LOAN GRADUATE OUTSTANDING NEW LOANS ISSUED DURING 2020	93.364				\$83,200	\$3,837,800	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701
NURSING STUDENT LOAN GRADUATE OUTSTANDING LOANS ISSUED AS OF 07/01/2019	93.364				\$455,776	\$3,837,800	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701
NURSING STUDENT LOAN UNDERGRADUATE NEW LOANS ISSUED DURING 2020	93.364				\$619,600	\$3,837,800	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701
NURSING STUDENT LOAN UNDERGRADUATE OUTSTANDING LOANS ISSUED AS OF 07/01/2019	93.364				\$2,679,224	\$3,837,800	STUDENT FINANCIAL ASSISTANCE CLUSTER	\$250,258,701
NATIONAL AND STATE TOBACCO CONTROL PROGRAM	93.387		CLEVELAND CLINIC FOUNDATION	541-SUB	-\$8,292	-\$8,292	RESEARCH AND DEVELOPMENT	\$710,017,793
			MASSACHUSETTS GENERAL					
			HOSPITAL	220778	\$77,497	\$77,497	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONSTRUCTION	93.392							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-215518-01A1			\$10,797	\$462,134	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-202262-01A1			\$13,999	\$608,396	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-206058-01			\$23,404	\$613,545	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-213645-01A1			\$45,634	\$93,752	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R21-CA-227613-01A1			\$49,194	\$176,011	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-184315-01			\$49,338	\$380,831	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2-R01-CA-138835-06A1			\$61,967	\$198,855	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1R01CA215587-01			\$73,211	\$604,270	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-190871-01			\$85,940	\$187,040	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-227188-01A1			\$92,368	\$414,170	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-196131-01A1			\$102,523	\$164,771	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	4-P01-CA-174439-04			\$112,793	\$407,120	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-207513-01			\$130,831	\$479,116	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-202699-01A1			\$191,896	\$640,225	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-204193-01A1			\$418,883	\$675,946	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-UM1-CA-183711-01			-\$8,464	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF CALIFORNIA, DAVIS	201603696-14	-\$24	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-202699-01A1			\$33	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-202262-01A1			\$164	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CANCER CAUSE AND PREVENTION RESEARCH	93.393		ROCKEFELLER UNIVERSITY	1-P01-CA-196539-01	\$1,968	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	4-R01-CA-172921-04			\$2,928	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393		OHIO STATE UNIVERSITY	60064995	\$8,019	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF VERMONT	32088SUB52367	\$11,724	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2R01CA138835-11			\$12,254	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF SOUTHERN					
			CALIFORNIA	125902890	\$16,581	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
			RESEARCH FOUNDATION FOR THE					
			STATE UNIVERSITY OF NEW YORK	SUB TO 1R01CA206193	\$17,527	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393		THOMAS JEFFERSON UNIVERSITY	080-03800-527301	\$19,567	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393		UNIVERSITY OF MICHIGAN	3004298102	\$20,749	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-174761-01A1			\$28,256	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393		YALE UNIVERSITY	GR108743(CON-80002262)	\$32,801	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

CANCER CAUSE AND PREVENTION RESEARCH	93.393	NORTHWESTERN UNIVERSITY	60038259 UP	\$36,105	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	UNIVERSITY OF CALIFORNIA, LOS ANGELES	1647 G CA089	\$45,950	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-F99-CA-234842-01		\$48,984	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-249210-01		\$50,334	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	4-R01-CA-171979-04		\$51,502	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	FOX CHASE CANCER CENTER	FCCC 15086-01	\$61,735	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	MAYO CLINIC ROCHESTER	THE-188223-04	\$62,007	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	MAYO CLINIC ROCHESTER	63846738	\$68,041	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	UNIVERSITY OF MISSOURI-COLUMBIA	C00053910-3	\$71,794	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-178856-01A1		\$74,541	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-230800-01A1		\$80,191	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	HARVARD UNIVERSITY	117202-5111676	\$87,685	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	7-R01-CA-178744-06		\$90,771	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	UNIVERSITY OF UTAH	10044180-01	\$111,098	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	UNIVERSITY OF SOUTHERN CALIFORNIA	120627049	\$137,741	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	ROCKEFELLER UNIVERSITY	1-P01-CA-196539-01	\$143,934	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	HARVARD MEDICAL SCHOOL	1057501	\$200,075	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-189743-01A1		\$217,458	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-243914-01		\$249,928	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2-R01-CA-092900-15		\$260,523	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	YALE UNIVERSITY	M17A12539(A10702)	\$265,582	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	MAYO CLINIC ROCHESTER	UOP-225625	\$282,383	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-187718-01A1		\$335,296	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-R01-CA-190415-01		\$337,438	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2-R01-CA-078831-20		\$365,297	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2-R01-CA-174904-06A1		\$384,839	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	QUANTITATIVE RADIOLOGY SOLUTIONS, LLC	SUB TO CA199735	\$410,652	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1-UM1-CA-239745-01		\$836,438	\$11,638,597	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-196528-01A1		\$4,626	\$729,702	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R21-CA-27056-01		\$6,960	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-197000-01A1		\$9,914	\$449,382	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-191207-01A1		\$14,384	\$497,404	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-204261-01A1		\$19,602	\$458,926	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-193556-01A1		\$46,173	\$713,608	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-207643-01		\$58,806	\$429,256	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-229502-01		\$76,233	\$495,683	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2-R01-CA-161749-05		\$108,973	\$475,888	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-227142-01		\$141,327	\$555,989	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-227485-01A1		\$288,631	\$481,612	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	4-R01-CA-175480-04		\$-1,015	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-229502-01		\$453	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R21-CA-198563-01		\$888	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	60723.2006384.669301	\$6,862	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CASE WESTERN RESERVE UNIVERSITY	SUB TO RESS10429	\$7,873	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U24CA196172-01-UPA1	\$9,679	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CASE WESTERN RESERVE UNIVERSITY	RESS14087	\$12,016	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	MD ANDERSON CANCER CENTER	SUB TO UH2CA207101	\$15,129	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	UNIVERSITY OF MASSACHUSETTS	WA00397956/OSP2016156	\$16,064	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	UNIVERSITY OF CONNECTICUT HEALTH CENTER	UCHC7-118312410	\$18,700	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U24CA196172-03-UPA3	\$19,071	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	RUTGERS UNIVERSITY	0347	\$20,162	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CASE WESTERN RESERVE UNIVERSITY	RESS11172	\$35,099	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	AMERICAN COLLEGE OF RADIOLOGY	1672	\$40,520	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	JOHNS HOPKINS UNIVERSITY	SUB TO U01CA210170	\$48,061	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1R01CA228457-01A1		\$53,342	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-238552-01A1		\$59,126	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	GMO200103	\$63,008	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	107245C	\$63,934	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5114713	\$69,579	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	THOMAS JEFFERSON UNIVERSITY	080-30000-522601	\$70,140	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		BRIGHAM AND WOMEN'S HOSPITAL	114835	\$75,236	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-250102-01			\$87,577	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		JBS SCIENCE, INC.	R44CA165312-UP	\$103,641	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R21-CA-223358-01			\$137,487	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-U01-CA-242871-01			\$150,938	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		MAYO CLINIC ROCHESTER	THE-216870	\$159,174	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-201328-01A1			\$354,541	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R33-CA-206907-01A1			\$367,526	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-226412-01			\$373,410	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-236362-01			\$374,875	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-211337-01			\$408,363	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-204446-01A1			\$428,830	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2-R01-CA-113941-10			\$435,121	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-U24-CA-231858-01			\$443,474	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-193050-01			\$461,544	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-U24-CA-189523-01A1			\$513,531	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-225874-01A1			\$547,603	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1-R01-CA-223816-01A1			\$760,682	\$12,158,613	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-197332-01			-\$276	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-238237-01A1			\$1,542	\$112,147	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-229305-01A1			\$23,530	\$606,545	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	2-P01-CA-087971-11A1			\$23,648	\$791,502	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-219871-01A1			\$73,302	\$478,410	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-219006-01A1			\$146,368	\$542,087	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		GOG FOUNDATION	27469-025		-\$377,640	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER TREATMENT RESEARCH	93.395	4-R01-CA-168900-05				-\$1,022	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CANCER TREATMENT RESEARCH	93.395	2-P01-CA-087971-11A1				\$153	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER TREATMENT RESEARCH	93.395		JOHNS HOPKINS UNIVERSITY	ABTC 1202	\$400	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		OREGON HEALTH & SCIENCE UNIVERSITY	1005019_UPA	\$521	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	1UG1CA189828-01-UPA1	\$607	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		JOHNS HOPKINS UNIVERSITY	ABTC1604	\$721	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		PENNSYLVANIA STATE UNIVERSITY COLLEGE OF MEDICINE	UPENNRCORP4-STURGEON	\$1,696	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	1-UG-1CA-189828-01-UPA2	\$1,745	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		JOHNS HOPKINS UNIVERSITY	ABTC1401	\$2,000	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		NRG ONCOLOGY	NRG-XIAO-GY6	\$2,500	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	SUB TO UG1CA189828	\$3,618	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		JOHNS HOPKINS UNIVERSITY	ABTC1602	\$4,033	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U-10-CA-180820-06UPA5C	\$5,250	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R21-CA-205063-01A1			\$5,841	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		NRG ONCOLOGY	NRG-BURGER-GY96	\$6,000	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		NRG ONCOLOGY		\$6,761	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		CHILDREN'S HOSPITAL OF PHILADELPHIA	95000870216-XX	\$7,472	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		MOUNT SINAI MEDICAL CENTER	0254-3503-4605	\$7,826	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		CHILDREN'S HOSPITAL OF PHILADELPHIA	9500130220-XX	\$9,000	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		WSTAR INSTITUTE	24921-06-314; GEORGE	\$9,159	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06UPA6C	\$9,573	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
COVID-19 - CANCER TREATMENT RESEARCH	93.395		WSTAR INSTITUTE	24926-04-314	\$10,130	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U 10CA180820-06-U PA3C	\$10,894	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		JOHNS HOPKINS UNIVERSITY	SUB TO U01CA137443	\$11,000	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		UNIVERSITY OF SOUTHERN CALIFORNIA	107587057	\$13,517	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		CHILDREN'S HOSPITAL OF PHILADELPHIA	SUB TO U10CA180886	\$14,942	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		NRG ONCOLOGY	NRG-LANGER-GY6	\$15,000	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		NRG ONCOLOGY	NRG-PRYMA-GY6	\$15,000	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		CHILDREN'S HOSPITAL OF PHILADELPHIA	9500080220-XX	\$15,115	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		FRONTIER SCIENCE & TECHNOLOGY RESEARCH FDN	ECOG PURCHASE SERVICE AGREEMENT	\$15,852	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-174976-01A1			\$15,930	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06-UPA2C	\$17,832	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06-UPA2A	\$18,333	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

CANCER TREATMENT RESEARCH	93.395	ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06UPA1C	\$19,999	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	WISTAR INSTITUTE	24925-14-314; WINKLER	\$20,945	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	HUTCHINSON (FRED) CANCER RESEARCH CENTER	0000843306	\$28,000	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	BRIGHAM AND WOMEN'S HOSPITAL	121298	\$29,922	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	INDIANA UNIVERSITY	IN-4687956-UP	\$30,689	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	CHILDREN'S HOSPITAL OF PHILADELPHIA	3208130624	\$30,689	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	CUREBIOTECH, INC.	SUB TO 2R44CA217489	\$39,090	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	JOHNS HOPKINS UNIVERSITY	ABTC1603	\$44,615	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	UNIVERSITY OF CALIFORNIA, LOS ANGELES	1568 G TA812	\$46,541	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER	3RFFW6	\$48,167	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	JOHNS HOPKINS UNIVERSITY	ABTC 1501 (BMS# CA209-596)	\$48,866	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	CHILDREN'S HOSPITAL OF PHILADELPHIA	SUB TO 2U10CA180886	\$61,626	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	UNIVERSITY OF CALIFORNIA, LOS ANGELES	1670 G WC216	\$64,570	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	2-R01-CA-085831-11A1		\$70,446	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	UNIVERSITY OF CALIFORNIA, LOS ANGELES	1568 G WA742	\$70,894	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-181429-01A1		\$74,511	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-02-UPA10	\$79,781	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	WISTAR INSTITUTE	24926-13-314	\$86,042	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	UNIVERSITY OF NEBRASKA	34-2005-2096-001	\$91,615	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	WISTAR INSTITUTE	24672-02-366	\$91,742	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R21-CA-239127-01A1		\$91,756	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	4-R00-CA-226399-03		\$93,581	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	RADIATION THERAPY ONCOLOGY GROUP	1818	\$111,063	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R21-CA-224267-01A1		\$112,875	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06-U PA3A	\$116,194	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	U10CA180820-06UPA1A	\$120,000	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	MASSACHUSETTS GENERAL HOSPITAL	231928	\$122,845	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	WISTAR INSTITUTE	SUB TO P01CA114046	\$126,669	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R21-CA-223366-01A1		\$127,429	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-247803-01		\$132,143	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	LINNAEUS THERAPEUTICS	SUB TO 2R44CA228695	\$139,220	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	NRG ONCOLOGY	04-225-0712	\$144,165	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R21-CA-216552-01A1		\$188,872	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	RTOG FOUNDATION, INC.	UPENN-NCTN-YR6-11	\$192,634	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-182747-01A1		\$231,987	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-219034-01A1		\$253,259	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	WISTAR INSTITUTE	24926-04-314	\$262,707	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	2-R01-CA-019033-41		\$288,170	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-198015-01		\$292,934	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	7R01CA102613-12		\$338,871	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	R37-CA-215436		\$349,926	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	AMERICAN COLLEGE OF RADIOLOGY	1823	\$444,659	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-201071-01A1		\$505,175	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-241762-01		\$617,057	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-208273-01A1		\$668,595	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-R01-CA-229803-01		\$799,957	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER TREATMENT RESEARCH	93.395	1-P01-CA-217805-01A1		\$2,460,578	\$13,341,067	RESEARCH AND DEVELOPMENT	\$710,017,793	
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-237243-01A1		\$3,672	\$290,752	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-228339-01		\$26,169	\$258,213	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	2-P01-CA-104838-11		\$40,185	\$185,312	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	4-P01-CA-165997-04		\$41,077	\$87,791	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-206012-01		\$108,818	\$382,870	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	2-P01-CA-165997-06A1		\$138,273	\$674,338	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	2-P01-CA-098101-11		\$168,706	\$195,908	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-237170-01		\$214,987	\$369,023	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-158301-06A1		\$238,187	\$426,858	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-198089-01		\$305,719	\$515,584	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-U01-CA-227550-01		\$463,312	\$891,573	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-184867-01			-\$121	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-168654-06			\$17	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-232743-01A1			\$125	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

COVID-19 - CANCER BIOLOGY RESEARCH	93.396	2-P01-CA-165997-06A1			\$173	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396		BRIGHAM AND WOMEN'S HOSPITAL	118617	\$4,829	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
			MEMORIAL SLOAN-KETTERING					
CANCER BIOLOGY RESEARCH	93.396		CANCER CENTER	BD526705	\$11,640	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396		WISTAR INSTITUTE	25651-02-366	\$21,756	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF					
CANCER BIOLOGY RESEARCH	93.396		PHILADELPHIA	3201080320	\$23,110	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	2R01CA174761-06A1			\$28,097	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396		WISTAR INSTITUTE	25421-02-382	\$28,180	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-181633-01A1			\$51,110	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396		UNIVERSITY OF VIRGINIA	GB10749	\$59,734	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396		WISTAR INSTITUTE	25241-02-370	\$62,551	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396		AQD LIFE SCIENCES	R41CA221595-UP	\$64,285	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396		BRIGHAM AND WOMEN'S HOSPITAL	118360	\$70,579	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396		MEDICAL COLLEGE OF WISCONSIN	SUB TO 7R01CA188575	\$85,338	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-240814-01A1			\$87,353	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-182675-01A1			\$98,292	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
			MASSACHUSETTS INSTITUTE OF					
CANCER BIOLOGY RESEARCH	93.396		TECHNOLOGY	5710004020	\$105,774	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	4-R00-CA-190658-03			\$107,126	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396		UNIVERSITY OF OKLAHOMA	RS20150916-01	\$109,333	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396		WISTAR INSTITUTE	25571-02-364;SHENOY/RAJ	\$110,108	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-245323-01			\$115,011	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R50-CA-221841-01			\$116,669	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-237200-01A1			\$119,633	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
			SANFORD BURNHAM PREBYS					
CANCER BIOLOGY RESEARCH	93.396		MEDICAL DISCOVERY INSTITUTE	SUB TO P01CA128814	\$140,415	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-243520-01A1			\$149,598	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	7-R01-CA-227124-02			\$180,520	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
			SANFORD BURNHAM PREBYS					
CANCER BIOLOGY RESEARCH	93.396		MEDICAL DISCOVERY INSTITUTE	59953-13198-UPENN	\$187,831	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R21-CA-213234-01			\$193,820	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-189765-01A1			\$208,969	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-193602-01A1			\$230,132	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-187392-01A1			\$238,523	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	4-R00-CA-212302-03			\$240,949	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396		WISTAR INSTITUTE	25491-02-363	\$247,954	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-219083-01			\$294,625	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-118374-07A1			\$319,712	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-197916-01A1			\$342,682	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-235760-01A1			\$344,761	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-229688-01A1			\$349,557	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-234005-01A1			\$357,582	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-168654-06			\$362,314	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-226983-01			\$377,497	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-231021-01A1			\$386,796	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-196232-01A1			\$401,139	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R37-CA-234027-01			\$462,879	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-148774-06			\$496,172	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R01-CA-222503-01A1			\$606,452	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-098371-11			\$618,578	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	2-R01-CA-143296-06A1			\$630,390	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
			KAISER PERMANENTE	RNG209451-PENN-01	\$709,116	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER BIOLOGY RESEARCH	93.396	1-R35-CA-220483-01			\$850,786	\$15,688,673	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397	1-U54-CA-163313-01			-\$27,851	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397	1-U54-CA-193417-01			\$38,937	\$1,683,915	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397	2-P30-CA-016520-40			\$289,500	\$8,097,337	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397	1-U54-CA-190158-01			\$411,515	\$731,069	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CANCER CENTERS SUPPORT GRANTS	93.397	1-U54-CA-193417-01			\$1,348	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CANCER CENTERS SUPPORT GRANTS	93.397	2-P30-CA-016520-40			\$4,366	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
			MD ANDERSON CANCER CENTER	SUB TO P50CA221707	\$20,000	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		COLUMBIA UNIVERSITY	1(GG012789-18) PROJECT 2	\$20,349	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	25501-02-381	\$26,221	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		COLUMBIA UNIVERSITY	2(GG012789-04)	\$39,388	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	24961-02-314	\$40,502	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	SUB TO 5-P50-CA174523	\$41,982	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		COLUMBIA UNIVERSITY	3(GG012789-03)	\$47,365	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	24961-06-314	\$64,129	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	24961-05-314	\$72,137	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		MAYO CLINIC ROCHESTER	UOP-182363	\$74,484	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		COLD SPRING HARBOR LABORATORY	25103074	\$84,065	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	24961-04-314	\$88,384	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS**

Fiscal Period 7/1/2019 - 6/30/2020

CANCER CENTERS SUPPORT GRANTS	93.397		WISTAR INSTITUTE	24961-10-314		\$103,256	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		JOHNS HOPKINS UNIVERSITY	2003261994		\$150,569	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CENTERS SUPPORT GRANTS	93.397		JOHNS HOPKINS UNIVERSITY	2004131859		\$659,565	\$12,022,580	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	2-K12-CA-076931-16A1			\$131,579	\$133,631	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-K22-CA-193661-01A1				-\$9,784	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-189661-01				-\$2,064	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F32-CA-206264-01				-\$692	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F32-CA-221094-01				-\$307	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-206381-01				\$525	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-206453-01				\$1,144	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CANCER RESEARCH MANPOWER	93.398	1-K08-CA-194256-01				\$3,259	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F99-CA-222741-01				\$4,054	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-206338-01				\$5,338	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-220844-01A1				\$12,129	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-217004-01				\$16,399	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-213915-01				\$18,836	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-250267-01				\$19,119	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-247348-01				\$23,581	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-239424-01A1				\$23,934	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-225069-01A1				\$29,290	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F30-CA-236464-01A1				\$29,740	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F30-CA-221385-01				\$29,766	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F30-CA-224970-01				\$31,318	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F30-CA-232388-01				\$31,890	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-217070-01				\$35,408	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-236269-01				\$36,462	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F30-CA-236129-01				\$36,988	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F32-CA-232466-01A1				\$37,780	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-232468-01				\$43,304	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-243294-01				\$44,474	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-239428-01				\$44,492	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-232551-01A1				\$44,765	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-239514-01				\$45,018	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F31-CA-228455-01				\$45,070	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F32-CA-221010-01A1				\$58,348	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F32-CA-228285-01				\$58,651	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-F32-CA-221093-01				\$66,778	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	4-K00-CA-212455-03				\$72,948	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	4-K00-CA-212437-02				\$75,748	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	2-R25-CA-140116-06				\$119,312	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-194256-01				\$127,320	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-241084-01				\$144,801	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-K07-CA-218366-01A1				\$148,530	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-K23-CA-187185-01A1				\$151,876	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-230157-01A1				\$153,777	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-215312-01A1				\$160,409	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-234335-01				\$174,844	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-230170-01A1				\$190,636	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-K22-CA-214849-01				\$209,123	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	1-K08-CA-234326-01				\$260,199	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	2-T32-CA-115299-11				\$260,350	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	2-T32-CA-009615-26				\$413,245	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	2-T32-CA-009140-41A1				\$526,333	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER RESEARCH MANPOWER	93.398	2-T32-CA-009679-26A1				\$559,427	\$4,747,522	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399	1-R01-CA-226888-01A1			\$109,436	\$589,911	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399		NRG ONCOLOGY	NRG ONCOLOGY FOUNDATION		-\$242,038	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CANCER CONTROL	93.399	1-R01-CA-244074-01				\$25	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399		NRG ONCOLOGY	UPENN CC003 - NCORP-02		\$4,936	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399		OREGON HEALTH & SCIENCE UNIVERSITY	1014562_UPENN		\$17,608	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	UG1CA189828-06UPA5		\$19,917	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	UG1CA189828-06-UPA3		\$21,779	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	UG1CA89828-06-UPA4		\$35,023	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399		ECOG-ACRIN MEDICAL RESEARCH FOUNDATION, INC	UG1CA189828-06-UPA3		\$45,850	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399		NRG ONCOLOGY	NCORPC003-UPENN-GY6		\$53,070	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399	1R01CA236468-01A1				\$117,574	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399	1-R1-CA-239177-01A1				\$125,603	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399	1-R01-CA-225929-01A1				\$233,684	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399	1-R01-CA-241661-01				\$253,682	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CANCER CONTROL	93.399	1-R01-CA-244074-01				\$360,017	\$1,638,641	RESEARCH AND DEVELOPMENT	\$710,017,793
AMERICAN INDIAN CHRONIC RENAL INSUFFICIENCY COHORT STUDY AI-CRIC	93.47		UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER	3RGL2		\$220,704	\$220,704	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

AFFORDABLE CARE ACT (ACA) MATERNAL, INFANT AND EARLY CHILDHOOD HOME VISITING PROGRAM	93.505		UNITED WAY OF LANCASTER COUNTY	4100070241		\$1,129,646	\$1,129,646	OTHER PROGRAMS	\$15,539,552
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630		TEMPLE UNIVERSITY	261591-UPENN		\$45,000	\$45,000	OTHER PROGRAMS	\$15,539,552
SOCIAL SERVICES BLOCK GRANT	93.667		CITY OF PHILADELPHIA	1720075-03/YR4		\$200,398	\$200,398	OTHER PROGRAMS	\$15,539,552
TRANS-NIH RECOVERY ACT RESEARCH SUPPORT	93.701	1-P30-CA-147859-01				-\$364	-\$364	RESEARCH AND DEVELOPMENT	\$710,017,793
MENTAL AND BEHAVIORAL HEALTH EDUCATION AND TRAINING GRANTS	93.732	1 M01HP31346-01-00				\$317,639	\$317,639	RESEARCH AND DEVELOPMENT	\$710,017,793
ELDER ABUSE PREVENTION INTERVENTIONS PROGRAM	93.747		UNIVERSITY OF SOUTHERN CALIFORNIA	99922430		\$3,479	\$3,479	RESEARCH AND DEVELOPMENT	\$710,017,793
MEDICAL ASSISTANCE PROGRAM	93.778		CITY OF PHILADELPHIA	1720074-03/YR4		\$159,880	\$159,880	OTHER PROGRAMS	\$15,539,552
			COMMONWEALTH OF PENNSYLVANIA	4100086433					
OPIOID STR	93.788					\$73,994	\$293,105	OTHER PROGRAMS	\$15,539,552
OPIOID STR	93.788	1H79T1081692-01				\$219,111	\$293,105	OTHER PROGRAMS	\$15,539,552
CARDIOVASCULAR DISEASES RESEARCH	93.837	7-R01-HL-116280-04				-\$1,173	\$40,706	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-U10-HL-110338-01				-\$314	\$85,352	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-T32-HL-110952-01A1				-\$28	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-135090-01A1				\$8,185	\$461,829	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R21-HL-120751-01				\$11,887	\$285,280	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	4-R01-HL-115041-04				\$12,369	\$16,402	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-131626-01				\$17,049	\$550,145	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		KENT STATE UNIVERSITY	403013-UPENN		\$23,002	\$42,649	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-131613-01A1				\$31,839	\$487,969	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-128465-01				\$37,143	\$591,417	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R01-HL-103419-06A1				\$50,164	\$709,244	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-138306-01A1				\$59,129	\$165,777	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-121510-01A1				\$81,253	\$394,829	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-147256-01				\$89,466	\$319,993	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-UM1-HL-088957-11				\$92,400	\$478,590	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R34-HL-146927-01				\$93,759	\$266,578	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-137984-01A1				\$101,085	\$565,667	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-133339-01A1				\$150,516	\$485,007	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R21-HL-141802-01				\$182,788	\$235,354	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-133218-01A1				\$242,670	\$652,477	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R01-HL-073021-10A1				\$261,141	\$403,325	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R01-HL-107904-05				\$276,887	\$637,738	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R01-HL-103723-05				\$281,059	\$420,641	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-142893-01				\$284,055	\$543,389	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	7-R01-HL128349-03				\$286,206	\$666,595	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-136719-01				\$316,165	\$789,404	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-134905-01				\$479,952	\$961,932	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	7-R01-HL-134647-02				\$594,086	\$765,785	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		MOUNT SINAI MEDICAL CENTER	0255-3102-4605		-\$16,645	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		MOUNT SINAI MEDICAL CENTER	0255-3101-4609		-\$15,240	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		MOUNT SINAI MEDICAL CENTER	MT SINANI LVAD		-\$1,643	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F30-HL-136127-01A1				-\$263	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		LAM FOUNDATION	SUB TO U54HL127672		-\$99	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F32-HL-134564-01A1				-\$89	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-007891-16				-\$74	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R03-HL-135227-01				-\$28	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-1521-4609		-\$18	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-007843-21				\$140	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-140176-01				\$311	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF COLORADO	SUB TO R24-HL-123767		\$511	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-122843-01A1				\$569	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-131626-01				\$973	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-149891-01				\$1,010	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-134325-01				\$1,171	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		FLOBIO LLC	1276778		\$1,874	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		MEDICAL COLLEGE OF WISCONSIN UNIVERSITY OF CALIFORNIA, RIVERSIDE	S-000856		\$1,878	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA	2101260619-XX		\$2,853	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-3108-4605 (0255-A342-4605) TR		\$3,303	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-152446-01				\$3,645	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-152086-01				\$3,645	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141759-01				\$5,063	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F30-HL-134255-01				\$5,690	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		WAKE FOREST UNIVERSITY	WFUHS 116558		\$7,084	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	61695.2007934.669303		\$8,204	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		COLUMBIA UNIVERSITY	1(GG012838-01)		\$8,253	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA	3259060221	\$8,256	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-A343-4605	\$8,998	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-142153-01	DUKE UNIVERSITY	HFN-LIFE 177494/218214/226028	\$9,516	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		DUKE UNIVERSITY	HFN-LIFE 177494/218214/226028	\$9,538	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		GEORGE WASHINGTON UNIVERSITY	SUB TO U24HL140168	\$10,026	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF CINCINNATI	010575-002	\$10,559	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-A342-4605	\$11,017	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		THOMAS JEFFERSON UNIVERSITY	080-18007-524201	\$11,402	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		YALE UNIVERSITY	SUB TO R01HL125918-05	\$12,122	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	GMO 190906	\$12,307	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	131950	\$13,047	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		BRIGHAM AND WOMEN'S HOSPITAL	SUB TO 5-P50-HL-1123349-02	\$13,476	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-132349-01			\$14,247	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F30-HL-142186-01A1			\$15,002	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA	3200120320	\$15,129	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		RESEARCH TRIANGLE INSTITUTE	14-312-0214047-52918L	\$15,383	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		RESEARCH TRIANGLE INSTITUTE	NUMOM2B-HHS / U10HL1199930215	\$17,855	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		EMORY UNIVERSITY	A258184	\$18,447	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF CONNECTICUT	UCHC7-122008437	\$19,253	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201170622	\$19,826	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA	GRT-0000005	\$20,135	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		ONOCOR	SUB TO R41HL139309	\$20,195	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-3106-4605	\$20,945	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF PITTSBURGH	SUB TO 1-R01-HL-130261-01	\$23,964	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		BRIGHAM AND WOMEN'S HOSPITAL	115809	\$26,534	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-132999-01			\$26,948	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA	320823.1222	\$28,075	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F30-HL-142138-01			\$29,415	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		YALE UNIVERSITY	GR105897 (CON-80001728)	\$31,956	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-149891-01			\$32,658	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	7-R01-HL-058493-21			\$34,910	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF SOUTH CAROLINA	18-3554	\$36,086	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		PROLIFAGEN, LLC	SUB TO R43HL145845	\$37,759	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF MINNESOTA	N006187419	\$38,304	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-147416-01			\$38,417	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF DELAWARE	47649	\$38,592	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-149162-01			\$39,090	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		RUTGERS UNIVERSITY	8254	\$39,435	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		COLUMBIA UNIVERSITY	2(GG013569)	\$39,835	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		OHIO STATE UNIVERSITY	6008444	\$40,126	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		BRIGHAM AND WOMEN'S HOSPITAL	SUB TO 1U01HL23336/AS332/AS333	\$42,836	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	SUB TO R01-HL-141841	\$43,039	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-143857-01			\$43,164	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-146077-01			\$44,340	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-142160-01			\$44,372	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F31-HL-142238-01A1			\$45,268	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-148103-01A1			\$46,208	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		OSCIFLEX, LLC	SEH2019-1	\$48,532	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF TEXAS AT AUSTIN	UTA18-00758	\$50,118	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF ILLINOIS	097337-17723	\$51,627	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-145121-01A1			\$53,779	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201690324	\$55,288	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		MASSACHUSETTS GENERAL HOSPITAL	234357	\$58,277	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-F32-HL-145923-01A1			\$60,896	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-151345-01			\$62,032	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF MASSACHUSETTS	OSP2017185	\$63,020	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA	3207950619	\$63,572	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL151292-01			\$63,845	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		DUKE UNIVERSITY	2035542	\$65,638	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-098054-11			\$69,436	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		PROHIBIX, LLC	SUB TO 1 R41 HL140645-01A1	\$70,050	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA	ACTIVITY #3201170622	\$78,204	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		ROCHESTER INSTITUTE OF TECHNOLOGY	31998-01	\$79,871	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-130551-01			\$82,332	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	4-R00-HL-141678-03			\$97,352	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		THOMAS JEFFERSON UNIVERSITY	080-31050-523802	\$105,162	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		YALE UNIVERSITY	GR102136 (CON-80001158)	\$105,518	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		MASSACHUSETTS GENERAL HOSPITAL	SUB TO1R01HL130539-01A1	\$113,171	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K25-HL-145092-01A1			\$120,619	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1K01HL143153-01			\$131,372	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF ALABAMA AT BIRMINGHAM	000503570-010	\$132,652	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		INDIANA UNIVERSITY	IN4667766PENN	\$134,217	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		COLUMBIA UNIVERSITY	1(GG012810-01)	\$134,593	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-128837-01A1			\$134,648	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R25-HL-084665-11			\$135,747	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K01-HL-141643-01			\$139,111	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K08-HL-138269-01			\$140,440	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-A342-4605	\$143,935	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K08-HL-136858-01A1			\$154,620	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-146662-01A1			\$166,963	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-125723-01A1			\$169,487	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-143161-01A1			\$171,024	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K08-HL-136890-01			\$176,182	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	4-R00-HL-131817-03			\$182,573	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-134904-01			\$183,079	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF KENTUCKY	3200000734-18-040	\$184,476	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-140176-01			\$187,030	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K08-HL-132101-01			\$188,296	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-118018-01A1			\$192,680	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-126874-01A1			\$192,840	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA	2101260619-XX	\$207,400	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-K23-HL-133843-01			\$208,798	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-147379-01			\$210,563	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-126797-01A1			\$228,937	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-133080-01			\$265,180	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-DP2-HL-142044-01			\$278,373	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-134853-01			\$296,430	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-148769-01			\$300,223	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R56-HL-136730-01A1			\$302,937	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-145437-01			\$308,699	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-118195-01A1			\$327,850	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		CHILDREN'S HOSPITAL OF PHILADELPHIA	FP1897_SUB01_01	\$328,095	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-133502-01			\$338,792	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-139783-01A1			\$344,562	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-131557-01			\$344,975	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141844-01A1			\$345,414	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-129150-01A1			\$346,825	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-007586-31			\$351,042	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-134923-01			\$370,672	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-126788-01A1			\$373,891	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-132349-01			\$379,127	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-137232-01A1			\$394,166	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141462-01A1			\$399,553	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141232-01A1			\$400,358	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-007891-21A1			\$407,146	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R61-HL-146390-01			\$413,187	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-DP2-HL-147123-01			\$434,661	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141294-01			\$454,431	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		BOSTON UNIVERSITY	4500003022	\$462,022	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-132999-01			\$465,392	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-098054-096A1			\$477,663	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837		UNIVERSITY OF WASHINGTON	UWSC8520	\$486,460	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-139358-01			\$490,860	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-007843-21			\$492,556	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

CARDIOVASCULAR DISEASES RESEARCH	93.837	2-T32-HL-007954-16			\$597,569	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141759-01			\$598,383	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-R01-HL-108119-06A1			\$645,423	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-141912-01A1			\$648,311	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R61-HL-141440-01			\$689,120	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R01-HL-129805-01A1			\$715,744	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R35-HL-145203-01			\$797,789	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	1-R35-HL-140018-01			\$864,463	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
CARDIOVASCULAR DISEASES RESEARCH	93.837	2-P01-HL-059407-16A1			\$1,352,007	\$37,407,223	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	2-R01-HL-087115-06A1			\$843	\$5,813	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-137006-01			\$18,592	\$652,144	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-143364-01A1			\$26,636	\$716,334	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-U01-HL-129998-01			\$27,654	\$774,418	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-137915-01			\$29,750	\$531,415	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-133889-01A1			\$128,426	\$318,410	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-UG3-HL-141736-01			\$137,809	\$1,326,843	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-141992-01			\$156,393	\$390,703	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-133433-01A1			\$186,913	\$629,634	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-142269-01			\$285,495	\$671,700	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-U01-HL-145435-01			\$450,086	\$1,058,479	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	4-R01-HL-119436-04				\$-86,307	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-120872-01A1				\$-41,456	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838		LIGNAMED	N/A		\$-4,655	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R56-HL-127020-01A1				\$-4,475	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	4-K23-HL-116656-04				\$-91	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838		JOHNS HOPKINS UNIVERSITY	2002773100		\$-1	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1R01HL146386-01A1				\$201	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - LUNG DISEASES RESEARCH	93.838	1R01HL148821-01				\$473	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - LUNG DISEASES RESEARCH	93.838	2-R01-HL-087825-11A1				\$1,098	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - LUNG DISEASES RESEARCH	93.838	1-R38-HL-143613-01				\$2,433	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1R01HL151467-01				\$3,334	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - LUNG DISEASES RESEARCH	93.838	1-R01-HL-137006-01				\$4,012	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-F30-HL-145907-01A1				\$11,332	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1R13HL144010-01				\$17,550	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838		CHILDREN'S HOSPITAL OF ANGELES	RGF010323-B		\$19,991	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838		ALBANY MEDICAL COLLEGE	515502-01		\$20,303	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K08-HL-132099-01A1				\$20,944	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-F31-HL-140785-01				\$22,953	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-153539-01				\$25,994	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	2-R01-HL-102016-05A1				\$28,196	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-F32-HL-144145-01				\$36,866	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-F31-HL-149338-01				\$39,943	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K01-HL-149851-01				\$47,673	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838		MEDICAL UNIVERSITY OF SOUTH CAROLINA	MUSC18-066-8D441		\$53,562	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K99-HL-141678-01				\$72,677	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838		BOSTON UNIVERSITY	4500003055		\$75,198	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R03-HL-144890-01				\$87,303	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838		THOMAS JEFFERSON UNIVERSITY	080-18007-533801		\$93,112	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	102535C		\$94,907	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	2-K24-HL-103844-06				\$95,354	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	2-K24-HL-115354-06				\$103,257	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R38-HL-143613-01				\$112,914	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	4-R18-HL-116285-04				\$113,133	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K99-HL-141684-01				\$122,488	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K24-HL-143289-01				\$127,073	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1R5GHL139559-01A1				\$130,439	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838		ALBERT EINSTEIN COLLEGE OF MEDICINE, INC	311072		\$133,947	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K23-HL-146894-01				\$134,563	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201040419		\$135,331	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K23-HL-146970-01				\$136,815	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-125462-01A1				\$142,389	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201160619		\$151,967	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K23-HL-140482-01				\$152,626	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-150147-01				\$155,383	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - LUNG DISEASES RESEARCH	93.838	1-U01-HL-148857-01				\$164,909	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838		LIGNAMED	SUB TO R44HL140680		\$165,654	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K08-HL-136698-01A1				\$167,412	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K23-HL-141584-01				\$178,181	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K23-HL-132065-01A1				\$180,831	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

			CHILDREN'S HOSPITAL OF PHILADELPHIA	3200850618	\$189,860	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-127969-01A1			\$192,606	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K23-HL-141639-01			\$194,569	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-K23-HL-143181-01			\$203,578	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	7-K01-HL-135459-03			\$235,498	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-144859-01			\$334,633	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
			CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	137990	\$375,164	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-139066-01			\$384,605	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-128398-01			\$398,794	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	2-R01-HL-087825-11A1			\$501,035	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-141608-01A1			\$542,155	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-142258-01A1			\$599,180	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1R01HL148821-01			\$665,702	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R61-HL-137063-01			\$666,627	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-U01-HL-148857-01			\$671,870	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-124986-01A1			\$829,285	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
LUNG DISEASES RESEARCH	93.838	1-R01-HL-137389-01A1			\$865,573	\$18,374,363	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-P01-HL-040387-26A1			\$10,457	\$411,155	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-R01-HL-091724-24			\$18,934	\$413,129	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1R01HL142976-01			\$28,022	\$649,268	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-141408-01			\$48,437	\$600,967	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-142122-01			\$57,842	\$510,134	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-U01-HL-131053-01A1			\$68,313	\$829,704	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-P01-HL-120846-01A1			\$80,203	\$88,217	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-134839-01			\$195,261	\$471,054	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		UNIVERSITY OF MICHIGAN	SUBK00009066		\$16,689	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-F31-HL-150952-01			\$2,110	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3200770621/962617-RSUB	\$3,577	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-T32-HL-007775-21			\$3,580	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	GRT-00000215	\$3,805	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-139552-01A1			\$12,950	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-T32-HL-007439-36			\$16,833	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		THOMAS JEFFERSON UNIVERSITY	080-18060-S17002	\$20,105	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		WISTAR INSTITUTE	25561-02-366	\$20,830	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		UNIVERSITY OF MICHIGAN	3004935104	\$24,722	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		RUTGERS UNIVERSITY	SUB0151	\$27,087	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		UNIVERSITY OF NEW HAMPSHIRE	18-016	\$30,487	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-F31-HL-139091-01			\$30,826	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-F31-HL-140774-01			\$35,116	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3200650121	\$44,686	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-K99-HL-148646-01			\$60,431	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-T32-HL-007775-26			\$79,600	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3201710624	\$83,801	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R21-HL-144224-01			\$98,722	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-146722-01A1			\$110,066	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-P01-HL-146373-01A1			\$122,184	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3210081122	\$127,864	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-R01-HL-065449-15A1			\$128,196	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3200961121	\$151,134	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-UG1-HL-069286-17			\$201,075	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3200770621/962617-RSUB	\$217,853	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-128895-01			\$270,333	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-T32-HL-007971-16A1			\$287,817	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-R01-HL-124106-05A1			\$306,521	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-143806-01			\$313,181	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-145754-01			\$386,405	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-R01-HL-111501-06A1			\$390,856	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-136572-01			\$404,980	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		INDIANA UNIVERSITY	IN4687667UPENN	\$523,594	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-139552-01A1			\$587,945	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1-R01-HL-135254-01			\$620,950	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2-T32-HL-007439-41			\$788,626	\$10,495,787	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-P30-AR-069619-01			\$1,510	\$698,207	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R21-AR-070959-01			\$1,611	\$49,996	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-064153-01			\$6,424	\$34,761	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-066098-01A1			\$9,130	\$318,877	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R21-AR-071623-01A1			\$13,353	\$148,477	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	7-R01-AR-066101-03			\$20,067	\$139,435	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R21-AR-071559-01A1			\$43,253	\$123,440	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-068382-01			\$44,540	\$130,087	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-074948-01			\$53,225	\$263,528	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-069062-01			\$60,490	\$423,586	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-065995-01			\$63,028	\$63,028	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-065995-01				-\$3,013	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-071718-01A1			\$65,734	\$455,405	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-070750-01			\$67,540	\$465,587	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R01AR076392-01			\$78,013	\$312,970	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-070873-01A1			\$93,374	\$278,127	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-US4-AR-057319-17			\$94,333	\$280,200	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-073231-01			\$98,231	\$391,125	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-072363-01			\$113,366	\$218,765	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-075418-01			\$139,615	\$562,681	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-US4-AR-057319-13			\$309,045	\$399,054	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	4-R01-AR-064216-04				-\$40,326	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	4-R37-AR-047709-15				-\$36,252	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-T32-AR-007465-31				-\$4,955	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
UNIVERSITY OF CONNECTICUT									
HEALTH CENTER UCHC7-100457212									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-F31-AR-072461-01				-\$4,480	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-F31-AR-069982-01A1				\$21	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
BRIGHAM AND WOMEN'S HOSPITAL SUB TO 1U01AR068043									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$126	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
THOMAS JEFFERSON UNIVERSITY 080-23000-538001									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$211	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
DREXEL UNIVERSITY 900036									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$962	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
UNIVERSITY OF MICHIGAN SUBK00010500									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$1,237	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	7-R01-AR-066101-03				\$1,603	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
NEW YORK UNIVERSITY 14-A1-00-001693-01									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$5,460	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
UNIVERSITY OF DELAWARE MASSACHUSETTS GENERAL HOSPITAL 39762									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$6,610	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
HOSPITAL 231368									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	9-R01-AR-077362-09A1				\$11,974	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$13,071	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
UNIVERSITY OF SOUTHERN CALIFORNIA 116442662									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$15,883	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILDREN'S HOSPITAL OF PHILADELPHIA 3200760422									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$16,222	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
REVERAGEN BIOPHARMA CHILDREN'S HOSPITAL OF PHILADELPHIA SUB TO 1R43AR073541									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$17,211	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
SUB TO R01AR076241									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$20,260	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 0255-7261-4609									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$20,895	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
DREXEL UNIVERSITY 900024									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$22,111	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
UNIVERSITY OF MICHIGAN 3004881705									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K01-AR-066743-01A1				\$22,710	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$22,957	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
UNIVERSITY OF DELAWARE 42811									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$23,396	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-F31-AR-073103-01A1				\$30,079	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-F31-AR-075436-01				\$30,205	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R01AR075914-01A1				\$41,192	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	7-K08-AR-066661-01				\$49,161	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
UNIVERSITY OF MARYLAND-BALTIMORE COUNTY 1701828-1038									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-F32-AR-072478-01A1				\$53,058	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$55,391	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
NEW YORK UNIVERSITY 18-A1-00-1000572									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	4-T32-AR-007442-29				\$61,056	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$68,871	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
EMBODY SUB TO 1R43AR076841									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$74,405	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
NEW YORK UNIVERSITY 16-A0-00-005518-01									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R34-AR-074733-01A1				\$79,798	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$82,420	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
TEMPLE UNIVERSITY 258416-UP									
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$97,815	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R21-AR-074570-01A1				\$107,189	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

		UNIVERSITY OF TEXAS								
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH		93.846	SOUTHWESTERN MEDICAL CENTER		GMO180506	\$110,928	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K08-AR-070289-01				\$142,466	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH		93.846	BRIGHAM AND WOMEN'S HOSPITAL		119899					
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	7-K01-AR-069002-03				\$142,869	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R21AR074073-01A1				\$152,993	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K23-AR-073931-01				\$153,130	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K08-AR-075846-01				\$156,923	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-R01-AR-056624-11				\$163,699	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K23-AR-068433-01				\$163,761	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-K23-AR-071514-01				\$166,591	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	4-R00-AR-067283-03				\$170,948	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-T32-AR-007132-42				\$178,306	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-066663-01A1				\$188,196	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-R01-AR-056624-06				\$190,209	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-066741-01A1				\$211,306	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-068057-01A1				\$212,511	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-T32-AR-053461-11				\$232,212	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-068288-01				\$235,735	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$243,991	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH		93.846	THOMAS JEFFERSON UNIVERSITY		080-23000-527201					
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-069546-01				\$283,517	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-071399-01A				\$287,049	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-071340-01A1				\$320,164	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-071975-01				\$350,289	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-073809-01A1				\$360,253	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-R01-AR-050068-09A1				\$362,809	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2-T32-AR-007465-36				\$371,037	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-R01-AR-066567-01A1				\$398,070	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1-P30-AR-069589-01				\$435,895	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
ARTHROSIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846					\$820,993	\$13,927,891	RESEARCH AND DEVELOPMENT	\$710,017,793	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R21-DK-108045-01A1				-\$121	\$37,886	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-056645-17A1				\$3,026	\$5,522	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-101480-01A1				\$6,610	\$56,471	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U01-DK-123813-01				\$7,454	\$656,323	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-109492-01A1				\$7,700	\$21,293	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-117488-01				\$11,674	\$484,266	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-112812-01				\$11,778	\$265,294	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U01-DK-099919-01				\$12,408	\$177,292	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U01-DK-082316-07				\$16,379	\$35,756	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-106243-01A1				\$18,261	\$543,497	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-117208-01A1				\$18,686	\$166,741	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R21-DK-117297-01A1				\$23,787	\$160,713	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-105155-01A1				\$25,354	\$133,783	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-098656-06A1				\$28,398	\$513,584	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7-R01-DK-070869-12				\$31,792	\$227,119	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1U34DK120091-01				\$40,702	\$326,749	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-106027-01				\$44,537	\$154,822	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-113307-01				\$50,488	\$380,554	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-UC4-DK-116271-01				\$58,475	\$452,018	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-105689-01A1				\$60,046	\$203,419	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-UC4-DK-104196-01				\$66,261	\$66,261	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-UC4-DK-104196-01					-\$5,230	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-115762-01A1			\$66,461	\$433,735	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-116005-01A1			\$68,921	\$379,312	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-114054-01			\$74,821	\$243,549	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-104339-01			\$81,137	\$81,137	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-UM1-DK-100846-01			\$91,082	\$105,495	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-111558-01A1			\$120,214	\$401,801	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-083355-06A1			\$147,377	\$218,395	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U01-DK-106892-01			\$160,711	\$685,905	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U01-DK-103225-06			\$208,369	\$471,846	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-118431-01			\$230,069	\$299,060	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U01-DK-103225-01			\$237,037	\$362,628	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-111638-01A1			\$258,145	\$557,325	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-P30-DK-019525-41			\$291,480	\$1,915,377	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK116199-01			\$361,054	\$544,884	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U01-DK-100846-07			\$395,886	\$967,729	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-101629-01A1				-\$88,387	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R56-DK-103008-05A1				-\$33,922	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		GEORGIA STATE UNIVERSITY	SP00013024-01		-\$24,528	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		YALE UNIVERSITY	M17A12557(A10910)		-\$11,466	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MICHIGAN	3003289619		-\$8,240	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA	3200530322		-\$1,622	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MICHIGAN	SUB TO 1U54DK083912		-\$1,562	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		YALE UNIVERSITY	M13A11472 (A08744)		-\$240	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	4-P01-DK-049210-20				-\$60	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-108507-01				-\$38	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MICHIGAN	3003823855		\$15	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ILLINOIS	2011-06727-01-00		\$42	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-120757-01A1				\$51	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-109979-01				\$118	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-P30-DK-050306-21				\$148	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	51504.2000556.669324		\$190	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		VANDERBILT UNIVERSITY	VUMC 38846		\$266	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		NEW YORK BLOOD CENTER	2-P01-DK032094-24A1		\$270	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K23-DK-116935-01A1				\$349	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-107589-01A1				\$529	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA	3258760720		\$594	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	102565C		\$648	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007780-16				\$778	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA	GRT-00000106	\$821	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA	FP14249_SUB01_01/PO #960610RSUB	\$1,312	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JAEB CENTER FOR HEALTH RESEARCH	SUB TO 1R01DK122603	\$1,397	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		DREXEL UNIVERSITY	232664	\$1,630	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH COVID-19 - DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-060694-15			\$1,792	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-114103-01A1			\$1,872	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA	3200950818-XX/P 962748 -RSUB	\$2,035	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1F31DK126404-01			\$2,110	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ILLINOIS AT CHICAGO	17709	\$2,348	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R03-DK-110397-01A1			\$3,012	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F30-DK-112573-01			\$4,296	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MICHIGAN	SUBK00010724	\$4,455	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-114438-01			\$4,836	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-117124-01A1			\$5,043	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF WASHINGTON	UWSC8765	\$5,392	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		MEDICAL COLLEGE OF WISCONSIN	SUB TO 5R01DK083538	\$7,355	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-113666-01A1			\$8,270	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		NORTHWESTERN UNIVERSITY	60052783 UPA	\$8,937	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		DUKE CLINICAL RESEARCH INSTITUTE	203-7933	\$9,014	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF SOUTHERN CALIFORNIA	84029069	\$9,121	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R25-DK-066028-11			\$9,251	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	4-K24-DK-078228-10			\$9,656	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		COLUMBIA UNIVERSITY	1(GGG011642-03)	\$11,899	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MICHIGAN	SUBK00012114	\$12,043	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		WASHINGTON UNIVERSITY IN ST. LOUIS	WU-20-278	\$12,326	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF TENNESSEE	20-0671-PENN	\$12,449	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ALABAMA AT BIRMINGHAM	000518101-002	\$12,988	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		BAYLOR COLLEGE OF MEDICINE	SUB TO R01DK101500	\$13,058	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CASE WESTERN RESERVE UNIVERSITY	RES512826	\$13,632	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		VANDERBILT UNIVERSITY	VUMC81957	\$15,330	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF COLORADO DENVER	FY19.959.003	\$16,200	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF DELAWARE	38843	\$16,963	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	10791SC	\$18,268	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F30-DK-117546-01			\$19,484	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201760420	\$19,765	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JOHNS HOPKINS UNIVERSITY	2004065226	\$19,830	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-123886-01			\$19,845	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA	3209810920	\$20,540	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JOHNS HOPKINS UNIVERSITY	2004295590	\$20,784	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF PITTSBURGH	0062023(131994-1)	\$21,404	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R56-DK-119290-01			\$23,201	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MICHIGAN	SUBK00010054	\$23,652	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF PITTSBURGH	AWD00001317 (133760-01)	\$25,227	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		BRIGHAM AND WOMEN'S HOSPITAL	113077	\$26,050	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R21-DK-111755-01			\$26,441	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		COLUMBIA UNIVERSITY	1(GG011642-01)	\$26,548	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		HARVARD PILGRIM HEALTH CARE	PH000668A	\$27,615	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		MD ANDERSON CANCER CENTER	3001370497	\$28,220	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		MASSACHUSETTS GENERAL HOSPITAL	231761	\$29,116	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-111091-01			\$30,589	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-054481-18A1			\$30,786	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		GEORGE WASHINGTON UNIVERSITY	18-M94	\$31,359	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF WASHINGTON	UWSC 9063	\$31,633	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F30-DK-118827-01			\$32,122	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-122684-01A1			\$33,965	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F30-DK-120062-01			\$35,279	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-122677-01			\$36,961	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ILLINOIS AT CHICAGO	17647	\$37,110	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R03DK123543-01			\$40,526	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F30-DK-120096-01A1			\$42,948	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-117577-01A1			\$43,016	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-118816-01			\$43,782	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		DUKE UNIVERSITY	A032135	\$44,088	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-122683-01			\$44,765	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		NORTHWESTERN UNIVERSITY	60046420 UPENN	\$45,078	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-120162-01			\$45,802	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F30-DK-120135-01			\$47,072	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		COLUMBIA UNIVERSITY	2(GG015836-01)	\$47,706	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-106309-05			\$48,077	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F31-DK-122649-01			\$48,084	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K99-DK-119574-01			\$49,863	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		JOHNS HOPKINS UNIVERSITY	2004016695	\$50,047	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ILLINOIS AT CHICAGO	17483	\$54,555	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-117568-01A1			\$54,932	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		BROAD INSTITUTE OF MIT AND HARVARD	5000110-5500000842	\$55,002	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		NORTHWESTERN UNIVERSITY	60044864	\$55,326	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		TUFTS UNIVERSITY	101517-00002	\$55,465	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF UTAH	10030258-00	\$55,471	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R03-DK-120946-01			\$58,477	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-120211-01A1			\$58,859	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-118818-01A1			\$60,652	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		SAINT LOUIS UNIVERSITY	ERS #21446-44249	\$61,260	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		TULANE UNIVERSITY	TUL-HSC-553788-15/16	\$61,346	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-120561-01			\$62,271	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-116519-01A1			\$62,863	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF MIAMI	SPC-001391	\$62,989	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA	3200370521 PO# 962245 - RSUB	\$68,189	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		PENNSYLVANIA STATE UNIVERSITY	5821-UP-DHHS-4888	\$69,082	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-F32-DK-116528-01A1			\$69,591	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA	3209280512-P	\$74,208	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R25-DK-066028-16			\$74,869	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-107910-01A1			\$79,031	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-088383-05			\$80,102	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ALASKA FAIRBANKS	SUB TO R01DK109946	\$82,357	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-102667-01A1			\$84,645	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R25-DK-108711-01A1			\$85,335	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	201010	\$86,440	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		AUGUSTA UNIVERSITY	32307-15	\$90,117	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K01-DK-117970-01			\$93,997	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		NEW YORK UNIVERSITY GROSSMAN SCHOOL OF MEDICINE	SUB TO DP3DK114812	\$94,005	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R03-DK-122191-01			\$94,622	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-087635-11A1			\$97,476	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-106478-01			\$102,088	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		EMORY UNIVERSITY	T674972	\$103,958	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-123252-01			\$104,051	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		TEMPLE UNIVERSITY	258377-UPENN	\$114,724	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		TULANE UNIVERSITY	TUL-HSC-556921-18/19	\$117,933	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		MASSACHUSETTS GENERAL HOSPITAL	SUB TO U01DK106981	\$118,027	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7-K01-DK-102868-02			\$122,885	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-060455-11A1			\$126,242	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		WINTHROP-UNIVERSITY HOSPITAL	3500-07429 (PENN)	\$128,070	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		AUGUSTA UNIVERSITY	30835-61	\$134,412	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-102533-01A1			\$138,416	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF ILLINOIS AT CHICAGO	16587-00	\$148,245	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K01-DK-111715-01			\$151,010	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		INDIANA UNIVERSITY	IN4689868 PENN	\$154,894	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-117013-01			\$157,686	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-122099-01			\$159,070	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA	FP21401_A1_SUB02_01	\$162,175	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-119475-01			\$162,480	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	K23-DK118198			\$165,513	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		TULANE UNIVERSITY	TUL-HSC-556923-18/19	\$170,244	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA	3200040820	\$171,307	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7-K23-DK-114526-02			\$178,242	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K23-DK-116935-01A1			\$183,397	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	107905C	\$185,624	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CASE WESTERN RESERVE UNIVERSITY	RES512857	\$186,236	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-106457-01A1			\$191,146	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-DP3-DK-108220-01			\$194,145	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K08-DK-106489-01			\$198,284	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-K23-DK-115897-01			\$199,519	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	50578.914951.6560	\$225,692	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-122039-01			\$227,427	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007785-19			\$229,300	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-121175-01			\$236,107	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-104796-01A1			\$236,712	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-101478-02			\$241,716	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-114104-01			\$251,202	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-123528-01			\$256,240	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R56-DK-101478-06			\$257,614	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-107453-01A1			\$264,827	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	96445C	\$274,496	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-123356-01			\$286,027	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		CHILDREN'S HOSPITAL OF PHILADELPHIA	3200400817	\$291,425	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-087635-06			\$300,776	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-110183-01A1			\$304,120	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007314-36			\$307,013	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-091331-06			\$308,703	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-107667-01A1			\$316,761	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		ICAGEN INC	ICA-0422501120000-01	\$338,100	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-119314-01			\$343,366	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007740-21A1		\$345,511	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-109979-01		\$350,165	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-119290-01A1		\$350,795	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-106309-01A1		\$352,474	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U01-DK-057135-17		\$361,445	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-120757-01A1		\$367,705	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007780-16		\$378,536	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-111547-01A1		\$411,091	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK045586-24		\$437,978	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007006-42		\$440,325	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2--23		\$453,467	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-021397-40A1		\$456,843	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-105821-01A1		\$503,475	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-T32-DK-007066-41		\$513,123	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-045416-23A1		\$518,859	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK114291-01A1		\$543,802	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	4-R37-DK-053839-20		\$552,698	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2R01DK043806-28		\$570,791	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-114103-01A1		\$623,806	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-R01-DK-076077-10		\$636,149	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U01-DK-060984-18		\$685,614	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-UG3-DK-122644-01		\$695,578	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-P30-DK-050306-21		\$907,002	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-R01-DK-120982-01		\$934,727	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-U01-DK-123594-01		\$1,118,201	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U24-DK-082316-12		\$1,404,188	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2-U24-DK-060990-18		\$2,529,044	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1-UC4-DK-112217-01		\$3,218,357	\$46,876,665	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-099348-01		\$411,219	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-102838-01	\$3,484	\$395,983	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-042645-11A1	\$4,029	\$41,950	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-102324-01	\$14,101	\$294,373	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	4-R01-NS-085211-04	\$14,666	\$22,010	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U01-NS-103799-01	\$19,830	\$468,198	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	7-R01-NS-063399-09	\$24,341	\$317,808	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U24-NS-107199-01	\$25,912	\$220,428	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U54-NS-115322-01	\$27,792	\$247,694	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-083702-06A1	\$30,254	\$441,623	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-090998-01A1			\$33,347	\$266,096	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-101629-01A1			\$52,455	\$78,327	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R24-NS-092986-01			\$58,903	\$72,162	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-099129-01A1			\$59,340	\$867,426	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-038104-15A1			\$77,808	\$613,154	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-102731-01A1			\$81,364	\$228,191	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-106611-01A1			\$92,939	\$340,240	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-107969-01A1			\$116,820	\$305,130	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-029436-26A1			\$135,738	\$485,055	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-100949-01			\$149,656	\$581,376	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-111115-01			\$155,485	\$351,326	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-094003-01A1			\$160,608	\$549,997	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-094224-01A1			\$163,856	\$446,539	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-096720-01A1			\$207,176	\$323,387	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-094705-01			\$339,507	\$719,265	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1U01NS113198-01			\$348,207	\$669,969	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	7-P01-NS-097206-02			\$402,677	\$686,733	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U19-NS-110456-01A1			\$655,435	\$2,286,797	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA	3200071216		-\$79,056	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	GMO 181204		-\$15,927	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MAYO CLINIC ROCHESTER	THE-213453		-\$11,926	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MICHIGAN	3004674950-PNT		-\$11,400	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-102687-01				-\$10,138	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K23-NS-088341-01				-\$9,827	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		COGNIZANCE BIOMARKERS	PENN CTA#10039935		-\$6,528	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MAYO CLINIC ROCHESTER	THE-214838		-\$1,416	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MIAMI	SPC-00091		-\$434	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-039421-15				\$172	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-113241-01				\$193	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	011337-135731		\$249	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U01-NS-103799-01				\$413	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U54-NS-115322-01				\$439	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MIAMI	668005 SPC-000425		\$517	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R03NS116301-01				\$672	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA	20479-10-01 / PO #951200RSUB		\$1,787	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MICHIGAN	SUBK00004105-ESETT		\$1,952	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-116999-01				\$2,110	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-112742-01A1			\$2,937	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MAYO CLINIC JACKSONVILLE	SUB TO 5-U01NS080168-02	\$3,010	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	012043-135731	\$3,156	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CLEVELAND CLINIC	SUB TO U01NS116776	\$3,645	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	7-U01-NS-094248-03	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	8567	\$4,017	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-113481-01A1			\$4,220	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MAYO CLINIC JACKSONVILLE	THE-232483	\$4,550	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	011266-135731	\$4,802	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS101762-01A1			\$5,312	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-T32-NS-061779-06			\$7,026	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-115995			\$7,328	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U01-NS-114140-01			\$7,962	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF VERMONT	33121SUB52663	\$8,048	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MICHIGAN STATE UNIVERSITY	RC110062UP	\$11,157	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF ALABAMA AT BIRMINGHAM	000523825-SC001	\$11,353	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		FOX CHASE CANCER CENTER	FCCC 15099-01	\$11,990	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U01-NS-097056-01A1			\$12,083	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MASSACHUSETTS GENERAL HOSPITAL	SUB TO U01NS095388 / NN108	\$13,343	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF IOWA	W000750292	\$13,389	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-116315-01			\$13,545	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MASSACHUSETTS GENERAL HOSPITAL	SUB TO 1U01NS090259	\$14,096	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MICHIGAN	SUBK00009898	\$14,674	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MEDICAL UNIVERSITY OF SOUTH CAROLINA	A20-0051-S005	\$15,668	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		ASURAGEN, INC.	C90RF72	\$17,786	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K08-NS-090461-01			\$18,280	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		DUQUESNE UNIVERSITY	G1900015	\$19,965	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-101863-01			\$19,994	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201310623	\$21,038	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CALIFORNIA, DAVIS	A19-0451-S001	\$21,634	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		TUFTS MEDICAL CENTER	5017157-SERV	\$22,348	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MICHIGAN STATE UNIVERSITY	RC107677UP	\$22,466	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-115256-01			\$23,201	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-115345-01			\$23,201	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-106754-01			\$23,418	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF IOWA	S01314-01	\$26,887	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F30-NS-100595-01			\$28,258	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		DUKE UNIVERSITY	A030443	\$29,526	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K01-NS-097519-01			\$30,257	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MOSS REHABILITATION RESEARCH INSTITUTE	491401	\$31,767	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R35-NS-116843-01			\$32,511	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-101807-01A1			\$34,008	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-108622-01			\$34,126	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		AXONOVA MEDICAL, LLC	SUB TO R43NS108869	\$36,770	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-111803-01A1			\$38,025	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-111868-01			\$38,214	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	98195C	\$39,739	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-111870-01			\$40,190	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201190720	\$41,832	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F31-NS-103445-01A1			\$43,309	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201620321	\$43,658	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F32-NS-108511-01A1			\$43,806	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		NORTHWESTERN UNIVERSITY	SP0046269-PROJ0013110	\$44,175	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CINCINNATI	010785-135731	\$44,414	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K99-NS-105942-01			\$45,634	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-110716-01A1			\$45,936	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F32-NS-108598-01A1			\$46,962	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-104874-01			\$49,120	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U24-NS-115691-01			\$50,667	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF ROCHESTER	1417584G/UR FAQ GR10929	\$54,532	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F32-NS-103219-01			\$56,158	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-F32-NS-103253-01			\$57,581	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF ALABAMA AT BIRMINGHAM	000510297-006	\$59,614	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201870620	\$60,069	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-082309-01A1			\$61,482	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-088176-01A1			\$65,066	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K99-NS-111736-01A1			\$65,462	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		JOHNS HOPKINS UNIVERSITY	2003724400	\$67,799	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-112274-01A1			\$69,066	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K08-NS-110929-01A1			\$74,693	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF IOWA	501108-01	\$75,330	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MASSACHUSETTS GENERAL HOSPITAL	226626	\$75,853	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CLEVELAND CLINIC FOUNDATION	718-SUB	\$75,974	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-082265-06A1			\$78,238	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1U01NS114143-01			\$79,597	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K99-NS-109286-01			\$82,730	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		DARTMOUTH COLLEGE	R837	\$83,194	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-105437-01A1			\$89,795	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R37-NS-115439-01A1			\$89,983	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CALIFORNIA, LOS ANGELES	2000 G VK 398	\$93,363	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-T32-NS-007180-32			\$102,467	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K08-NS-093127-01			\$103,963	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		MAYO CLINIC ROCHESTER	THE-214838-04	\$105,289	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-109763-01A1			\$108,091	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R01NS114226-01			\$109,609	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-088432-01A1			\$121,588	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA	RSUB/ACTIVITY NO. 3201700420	\$121,741	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-T32-NS-091008-01			\$122,017	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K23-NS-110993-01A1			\$125,919	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R21-NS-100182-01			\$133,185	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K08-NS-112576-01			\$142,984	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201060520	\$163,071	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-092398-01			\$163,455	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R25-NS-065745-06			\$166,593	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-087516-01			\$169,538	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R25-NS-065745-11			\$173,824	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-088322-01A1			\$185,083	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K23-NS-104239-01			\$191,288	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-T32-NS-091006-01			\$202,996	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-103873-01A1			\$203,777	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF MICHIGAN	SUBK00007465	\$212,747	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-K23-NS-092973-01A1			\$218,394	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-110865-01			\$232,559	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-094533-01			\$233,681	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-T32-NS-061779-11A1			\$243,628	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-T32-NS-043126-16			\$257,082	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2R01NS042645-16A1			\$261,861	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-101108-01			\$263,683	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-081054-06			\$288,208	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201590324	\$295,601	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		DUKE UNIVERSITY	2034906	\$298,501	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853		UNIVERSITY OF CALIFORNIA, LOS ANGELES	2301 G WE215	\$302,823	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-096087-01			\$313,518	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-097914-01A1			\$315,167	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-101156-01A1			\$327,715	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R56-NS-109435-01A1			\$336,827	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R37-NS-048471-10			\$338,194	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-095793-01			\$338,619	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-110688-01			\$344,536	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-U24-NS-107224-01			\$371,043	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-100892-01A1			\$388,154	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-096606-01			\$408,616	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-021229-33A1			\$424,365	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	4-R01-NS-055293-09			\$449,170	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-101106-01			\$452,826	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-106108-01A1			\$459,887	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	4-R37-NS-047344-14			\$469,716	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R01NS115139-01			\$472,387	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-060698-06A1			\$472,435	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-113241-01			\$477,619	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-060653-06			\$525,061	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-102435-01A1			\$531,674	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2-R01-NS-039421-19			\$536,532	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-T32-NS-105607-01			\$544,177	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R35-NS-097275-01			\$569,368	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-109260-01A			\$610,045	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-DP2-NS-111996-01			\$646,215	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R35-NS-097340-01			\$673,035	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1-R01-NS-107550-01A1			\$740,133	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	7-R35-NS-097370-02			\$824,588	\$34,871,221	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-R01-AI-091627-08			\$467,685	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI133261-01		\$2,230	\$2,230	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI133261-01			\$-830	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI150246-01			\$2,614	\$246,848	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-150556-01A1			\$2,670	\$35,207	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-082020-05A1			\$5,278	\$7,299	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-128530-01			\$11,658	\$278,533	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139618-01A1			\$12,386	\$675,543	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		FHI 360	SUB TO UM1 A1068619	\$13,823	\$716,260	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139240-01			\$16,528	\$29,069	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-136626-01			\$17,211	\$521,425	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-143564-01A1			\$17,777	\$270,986	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-120489-01A1			\$25,304	\$379,465	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-138564-01			\$26,769	\$141,081	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-U19-AI-117950-01			\$28,156	\$1,672,303	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-118691-01			\$31,871	\$262,400	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-143790-01			\$35,640	\$833,854	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-120821-01			\$38,331	\$206,268	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-091595-04A1			\$40,018	\$248,473	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI130115-01A1			\$40,728	\$520,766	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-108686-06			\$48,513	\$389,472	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	4-R01-AI-101229-04			\$52,476	\$128,369	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-P30-AI-045008-16			\$63,259	\$89,626	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-150590-01			\$65,529	\$444,487	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-125524-01			\$68,821	\$68,821	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-125524-01					-\$3,528	\$62,719,888	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-140442-01			\$74,075	\$399,430	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-137433-01			\$87,908	\$135,542	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-139392-01			\$92,524	\$221,165	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139188-01			\$94,513	\$657,711	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-U01-AI-088650-06			\$102,327	\$183,415	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-142572-01			\$102,451	\$265,345	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-146129-01			\$125,902	\$470,914	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-146101-01			\$142,209	\$325,545	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-140539-01			\$152,741	\$511,603	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-120011-01			\$193,300	\$637,317	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-118891-01			\$227,691	\$427,573	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-120810-01A1			\$228,103	\$563,341	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-118549-01A1			\$228,638	\$488,558	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-123539-01A1			\$254,808	\$694,660	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-138782-01			\$275,902	\$426,951	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-P30-AI-045008-21			\$294,710	\$2,533,459	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-124429-01			\$298,162	\$463,777	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-114266-01			\$317,736	\$491,303	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-R01-AI127271-03			\$342,549	\$586,185	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-104887-06A1			\$363,729	\$694,735	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-118694-01A1			\$382,552	\$760,324	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R61-AI-133696-01			\$557,754	\$980,777	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-P01-AI-131338-01			\$802,020	\$1,515,209	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-U19-AI-131130-01			\$1,048,276	\$1,374,997	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-P01-AI-131251-01			\$1,498,352	\$2,368,406	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-126042-01				-\$31,355	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-106842-01A1				-\$22,685	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-007324-21A1				-\$6,730	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	4-R01-AI0-74951-09				-\$6,701	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HARVARD MEDICAL SCHOOL	116543-5079901		-\$6,643	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-U01-AI-102430-01				-\$4,913	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-083284-06				-\$3,033	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	4-R33-AI-102104-01				-\$2,838	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F31-AI-126673-01A1				-\$1,641	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DANA-FARBER CANCER INSTITUTE	1300401		-\$1,593	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	2036288		-\$1,451	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-070077-06				-\$559	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HARVARD MEDICAL SCHOOL	152384.5077707.0006		-\$306	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F30-AI-114475-01A1				-\$164	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-F32-AI-124518-02				-\$143	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-125814-01				-\$77	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-115688-01A1				-\$68	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	4-R01-AI-103062-04				-\$41	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WINDTREE THERAPEUTICS, INC.	SUB TO 1-R43-AI-102308		\$2	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-128530-01				\$72	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF COLORADO DENVER	FY17.600.001		\$90	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI139890-01A1				\$90	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-124182-01A1				\$94	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-149487-01				\$94	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-144572-01				\$125	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139060-01				\$157	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139102-01A1				\$159	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-139982-01A1				\$196	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		JOHNS HOPKINS UNIVERSITY	2003649380		\$207	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		BENAROYA RESEARCH INSTITUTE	FY17IN224		\$287	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		JOHNS HOPKINS UNIVERSITY	2003548218		\$305	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-R01-AI-127798-02				\$316	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF HOUSTON	R-17-0049		\$316	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-120011-01				\$325	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-112427-07				\$354	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WASHINGTON UNIVERSITY IN ST. LOUIS	WU-19-433		\$372	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-138078-01A1				\$382	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		EMORY UNIVERSITY	T6836910		\$513	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		BENAROYA RESEARCH INSTITUTE	FY16ITN191		\$550	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-151882-01				\$731	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	4-R01-AI-076066-09				\$1,059	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		FAMILY HEALTH INTERNATIONAL	FCO 790/D 0080.0224		\$1,238	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-117100-01				\$1,396	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		RUTGERS UNIVERSITY	1382		\$1,405	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-R01-AI-112427-05				\$1,691	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	2031969		\$2,089	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, IRVINE	2018-3550	\$3,561	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-124057-01			\$6,010	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MASSACHUSETTS GENERAL HOSPITAL	SUB TO U01AI136816	\$6,594	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI154022-01			\$6,884	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF MASSACHUSETTS	OSP30517-01	\$6,926	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		FHI 360	SUB TO UM1 A1068619	\$7,315	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		EMORY UNIVERSITY	A291031	\$7,626	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, SAN DIEGO	114143023	\$9,151	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		NATIONAL JEWISH HEALTH	1-U01-AI-097073-01A1	\$9,527	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-148431-01A1			\$9,572	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MASSACHUSETTS GENERAL HOSPITAL	234447	\$10,209	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139123-01			\$10,812	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		AMERICAN GASTROENTEROLOGICAL ASSOCIATION	2016002	\$10,836	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0000866273	\$12,567	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MAGEE-WOMENS RESEARCH INSTITUTE & FOUNDATION	9440	\$13,214	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-143185-01A1			\$14,198	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-127832-01			\$14,280	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, LOS ANGELES	1560 G WB030	\$14,343	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		AMERICAN GASTROENTEROLOGICAL ASSOCIATION	2016003	\$14,942	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		PARABON NANOLABS, INC.	20190927-UPENN-SBIR1-MRNA	\$15,095	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC78982	\$16,857	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MASSACHUSETTS GENERAL HOSPITAL	234438	\$17,059	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		YALE UNIVERSITY	M17Q12603 (Q01414)	\$17,341	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-085596-05A1			\$18,808	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-152362-01			\$19,694	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		FLORIDA ATLANTIC UNIVERSITY	UR-K152	\$19,918	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-128569-01A1			\$20,751	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	86595C	\$21,643	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-113543-01			\$23,553	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-K08-AI-114852-01			\$23,748	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		ROCKEFELLER UNIVERSITY	SU01AI129825-02	\$23,966	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		NATIONAL JEWISH HEALTH	20098204	\$24,491	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-055435-11A1			\$24,865	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI152765-01			\$26,069	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WEILL CORNELL MEDICAL COLLEGE	183723-13	\$27,324	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MAGEE-WOMENS RESEARCH INSTITUTE & FOUNDATION	9496	\$29,477	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F31-AI-140508-01A1			\$30,534	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		JOHNS HOPKINS UNIVERSITY	2003898728	\$30,776	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	3021174	\$32,156	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	103525C	\$32,343	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF ALABAMA AT BIRMINGHAM	000515868-002	\$32,401	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI144522-01A1			\$32,579	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MAGEE-WOMENS RESEARCH INSTITUTE & FOUNDATION	9436	\$33,152	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5112310	\$34,722	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI149761-01A1			\$35,707	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI142638-01A1			\$36,175	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5112626	\$36,691	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		ROCKEFELLER UNIVERSITY	1 U01AI145921	\$38,528	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		EMORY UNIVERSITY	98905C	\$38,549	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201750624	\$39,237	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		HUTCHINSON (FRED) CANCER RESEARCH CENTER	0000851168	\$40,029	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F31-AI-143387-01A1			\$40,158	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	203-9727	\$40,690	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F31-AI-133871-01A1			\$40,879	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-F31-AI-147415-01			\$42,905	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-105343-01A1			\$45,193	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		LOYOLA UNIVERSITY OF CHICAGO	1-210155	\$47,253	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			CLEVELAND CLINIC LERNER COLLEGE					
			OF MEDICINE	959-SUB	\$50,983	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		RUTGERS UNIVERSITY	1382	\$55,303	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-149771-01A1			\$57,115	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		NOTA LABORATORIES LLC	SUB TO 2R44A120443	\$57,592	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1K23AI143925-01A1			\$57,820	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-K99-AI-137442-01			\$59,626	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF CALIFORNIA, LOS ANGELES	1560 G WA905	\$60,198	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-U19-AI-149680-01			\$60,985	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WISTAR INSTITUTE	25281-18-324	\$61,037	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	4-R33-AI-104280-03			\$64,096	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-129890-01A1			\$66,663	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-137283-01			\$67,047	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			MAGEE-WOMENS RESEARCH INSTITUTE & FOUNDATION	9629	\$67,322	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-134594-01A1			\$69,764	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		LIGNAMED	SUB TO R42AI132012	\$74,805	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	92605C	\$75,113	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF HOUSTON	R-17-0049	\$81,218	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI149456-01			\$83,089	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-018289-34			\$84,029	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			OREGON HEALTH & SCIENCE UNIVERSITY	1007881_UPA	\$86,282	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-137484-01			\$88,277	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MICHIGAN STATE UNIVERSITY	RC108563PENN	\$92,725	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-130665-01A1			\$93,374	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-R01-AI-113047-04			\$94,564	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-117410-01			\$95,104	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			CHILDREN'S HOSPITAL OF PHILADELPHIA	3201540224	\$98,172	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5105566	\$100,402	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R56AI132329-01A1			\$101,868	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WISTAR INSTITUTE	25281-17-324	\$104,599	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-K24-AI-146137-01			\$104,635	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-128059-01A1			\$104,855	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-143676-01A1			\$108,190	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		STEALTH BIOLOGICS LLC	1R41AI142940-S2	\$108,432	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			HUTCHINSON (FRED) CANCER RESEARCH CENTER	0000853385	\$108,860	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		ARIZONA STATE UNIVERSITY	SUB TO R01AI117011	\$113,323	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-055400-16			\$113,863	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-152195-01			\$114,835	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-132912-01			\$117,025	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			MASSACHUSETTS GENERAL HOSPITAL	234443	\$117,994	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-055428-11A1			\$118,337	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			FOX CHASE CHEMICAL DIVERSITY CENTER	R41AI138630-UP	\$119,028	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-K01-AI-137317-01A1			\$120,857	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			MAGEE-WOMENS RESEARCH INSTITUTE & FOUNDATION	9492	\$122,015	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-041158-15			\$123,825	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-138052-01			\$123,903	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-K01-AI-139284-01A1			\$124,328	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			CASE WESTERN RESERVE UNIVERSITY	RES508678	\$130,095	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		BENAROYA RESEARCH INSTITUTE	0112701501	\$132,107	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF CALIFORNIA, LOS ANGELES	1560 BW487	\$132,180	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CHILDREN'S HOSPITAL BOSTON	GENFD0001487482	\$133,818	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		JOHNS HOPKINS UNIVERSITY	2002973536	\$137,935	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	112775C	\$138,197	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		EMORY UNIVERSITY	T860086	\$140,414	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
			DANA-FARBER CANCER INSTITUTE	1280903	\$142,315	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-148249-01			\$144,662	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-K23-AI-121485-01A1			\$147,644	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-133998-01			\$148,403	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC65908	\$151,803	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-129531-01			\$153,842	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WEILL CORNELL MEDICAL COLLEGE HUTCHINSON (FRED) CANCER RESEARCH CENTER	183723-13	\$157,108	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855			0000852931	\$158,849	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-135421-01A1			\$165,615	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-149487-01			\$166,003	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-150606-01			\$166,598	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI139890-01A1			\$168,590	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-007324-26A1			\$168,839	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF PITTSBURGH	9011702 (126206-1)	\$169,326	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-K08-AI-130365-01A1			\$172,072	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-142162-01A1			\$176,954	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-139895-01A1			\$177,497	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	A030469	\$182,175	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-UM1-AI-144288-01			\$188,474	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-145905-01			\$196,844	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-132971-01A1			\$203,692	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-T32-AI-118684-01A1			\$205,603	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-144732-01			\$205,771	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF COLORADO DENVER	FY17.600.001	\$207,693	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DANA-FARBER CANCER INSTITUTE	SUB TO R01-AI-115712-01	\$208,309	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-070077-11			\$213,706	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-144838-01			\$213,943	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-135359-01			\$215,626	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-125563-01			\$215,894	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CHILDREN'S HOSPITAL OF PHILADELPHIA	3200280521-PP00019478-SUB01-01	\$218,447	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-139982-01A1			\$219,478	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WISTAR INSTITUTE	25281-07-324	\$219,906	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	0012501A	\$220,399	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC64583	\$221,405	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-T32-AI-141393-01			\$225,009	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-U01-AI-125940-01			\$232,332	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-007532-21			\$243,636	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	SUB TO R01-AI-145840	\$249,655	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		UNIVERSITY OF PITTSBURGH	9011707 (126211-1)	\$252,554	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-138078-01A1			\$252,650	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-118861-01A1			\$257,240	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WISTAR INSTITUTE	252841-16-324	\$261,558	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-129661-01A1			\$265,996	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	4-R00-AI-125786-03			\$267,926	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R21-AI-144572-01			\$273,226	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		MASSACHUSETTS GENERAL HOSPITAL	234447	\$276,871	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	R01-AI-143850			\$285,404	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R61-AI-147406-01			\$286,238	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-R01-AI-127798-02			\$287,512	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	1UM1-AI144371-01	\$334,173	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-123243-01			\$345,347	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-124182-01A1			\$346,069	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-055435-16A1			\$352,125	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-050668-14			\$353,191	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-122749-01			\$357,471	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-125265-01			\$358,437	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-137062-01			\$359,483	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-123173-01A1			\$369,509	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WISTAR INSTITUTE	25281-12-324	\$369,854	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	2036421	\$373,472	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-047833-16A1			\$375,972	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	1UM1-AI144371-01	\$396,877	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	1UM1-AI144371-01	\$400,879	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139060-01			\$408,936	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-116794-01A1			\$413,937	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	2037104	\$421,191	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7-R01-AI-123738-02			\$424,413	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-134879-01			\$430,533	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-T32-AI-007632-16			\$452,936	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-134862-01A1			\$461,723	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-125284-01A1			\$462,241	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-079002-06			\$464,807	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-121166-01			\$475,631	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139102-01A1			\$484,996	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		COLUMBIA UNIVERSITY	3(GG013567-03)	\$490,250	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-136945-01			\$498,979	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-134834-01A1			\$508,543	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-131331-01			\$510,699	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-112427-07			\$519,700	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		DUKE UNIVERSITY	A030915	\$523,962	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-R01-AI-050529-17			\$621,824	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1-R01-AI-139123-01			\$660,112	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-P01-AI-068730-06			\$893,633	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		WISTAR INSTITUTE	25281-10-324	\$1,023,356	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2-UM1-AI-069534-08			\$2,808,201	\$62,719,888	RESEARCH AND DEVELOPMENT	\$710,017,793
MICROBIOLOGY AND INFECTIOUS DISEASES RESEARCH	93.856	HHSN272201400030C			\$1,969,200	\$1,969,200	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	4-P01-GM-055876-17			-\$64,562	-\$64,325	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-071339-11			\$1,296	\$185,672	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-095977-05			\$3,389	\$268,418	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-084979-06A1			\$4,576	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-084979-06A1				-\$13,217	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R01GM125301-01			\$14,190	\$383,405	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-034883-27A1			\$15,247	\$89,518	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-103899-07			\$21,912	\$395,629	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-124091-01A1			\$24,205	\$370,446	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-118139-01			\$31,109	\$715,388	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-124111-01			\$38,233	\$366,308	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R37-GM-057247-18			\$55,587	\$427,613	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-K12-GM-081259			\$69,473	\$1,023,011	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-129357-01			\$74,084	\$569,480	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-123019-01			\$85,281	\$286,021	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-085207-09			\$124,907	\$393,094	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-111384-01				-\$55,747	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-056326-18				-\$36,033	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	4-R01-GM-104003-04				-\$22,695	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-117981-01				-\$5,063	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-082989-10				-\$964	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-008076-30				-\$795	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F31-GM-123644-01A1				-\$50	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F32-GM-128265-01				-\$16	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-108744-01				-\$3	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-083030-06A1				\$1	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-055560-18A1				\$27	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-121375-01				\$232	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-125811-01A1				\$405	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-P01-GM-087253-11				\$445	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R37-GM-057247-18				\$582	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	4-R37-GM-056328-18				\$667	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-007229-38A1				\$681	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-133842-01A1				\$729	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-008216-28				\$1,361	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-118139-01				\$1,464	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM031847				\$2,124	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F31-GM-136073-01				\$4,851	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-108751-01				\$5,504	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-076201-08A1				\$6,131	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-110174-01				\$6,252	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F31-GM-123737-01A1				\$6,364	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		ABZYME THERAPEUTICS, LLC	SUB TO R43GM122126	\$6,511	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		CASE WESTERN RESERVE UNIVERSITY	RES513926	\$8,615	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-107117-01A1				\$8,630	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-112684-01A1				\$10,079	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-097478-05				\$11,674	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		SAINT LOUIS UNIVERSITY	ERS #21441-43869	\$12,569	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-072777-10				\$13,907	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R35GM136270-01				\$14,073	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	7-R01-GM-103899-06				\$17,048	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF COLORADO DENVER	FY18.575.005	\$20,889	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		SAINT LOUIS UNIVERSITY	ERS#22288-45656	\$22,439	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F31-GM-123633-01A1				\$23,818	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1RM1GM136511-01				\$24,194	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R35GM134957-01				\$24,557	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		COLUMBIA UNIVERSITY	1(GG011920)	\$24,795	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-105654-01A1				\$24,939	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		PENNSYLVANIA STATE UNIVERSITY	6093-UP-DHHS-2653	\$26,308	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF PITTSBURGH	0047527 (125989-2)	\$34,162	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-008275-26			\$36,916	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		PARADIGM SURGICAL, LLC	SUB TO R44GM123789	\$37,703	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		PARADIGM SURGICAL, LLC	SUB TO R41GM130213	\$38,836	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F31-GM-133161-01			\$45,094	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F32-GM-120933-01A1			\$47,872	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF MIAMI	SPC-000658	\$48,483	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F32-GM-133162-01			\$58,483	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F32-GM-126639-01			\$60,030	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-F32-GM-125123-01A1			\$62,359	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-108600-01A1			\$65,114	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-115420-01			\$77,653	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		ANDAMIO GAMES	7006-001-001-004	\$86,771	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-111942-01A1			\$90,903	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-K99-GM-131028-01			\$95,095	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1R01GM135633-01			\$101,962	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	SUB TO P50GM115318	\$104,275	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-T32-GM-112596-01			\$105,228	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	7-R01-GM-083204-09			\$111,096	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-112923-01			\$116,367	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-036477-37			\$121,665	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-133172-01			\$121,870	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		CHILDREN'S HOSPITAL OAKLAND RESEARCH INSTITUTE	12_8036_03	\$156,165	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-111421-01			\$164,108	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		UNIVERSITY OF CALIFORNIA, LOS ANGELES	0830 G UA376	\$167,448	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-K23-GM-120630-01A1			\$172,998	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-118501-01A1			\$181,594	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-K08-GM-123317-01			\$186,695	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-058540-14			\$187,296	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-038237-27A1			\$190,699	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-118510-01			\$197,896	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R21-GM-132831-01			\$201,110	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R21-GM-133060-01			\$205,126	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-111128-05			\$225,626	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-114042-01A1			\$233,941	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-055560-18A1			\$241,876	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM087605-04A1			\$242,623	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-101149-05			\$243,343	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-115517-01A1			\$255,172	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-049758-24			\$270,090	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-060804-17			\$270,933	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-133842-01A1			\$279,468	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		NORTHWESTERN UNIVERSITY	60051124 UPENN	\$282,390	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-127374-01			\$283,590	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-124143-01			\$285,521	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-123512-01A1			\$286,962	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-124023-01A1			\$287,133	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R25-GM-071745-14A1			\$289,441	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-133380-01			\$291,010	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-133154-01			\$291,879	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-125811-01A1			\$297,705	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-073791-14			\$298,653	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-051893-20			\$303,659	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-099836-05			\$307,948	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-097552-06			\$311,989	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-133708-01			\$317,562	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-T32-GM-132039-01			\$324,242	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-124684-01			\$342,097	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-123783-01A1			\$343,037	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-124749-01			\$347,608	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-127593-01			\$355,314	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-056838-21			\$358,281	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-133425-01			\$364,520	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-115420-05			\$365,301	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-131902-01			\$366,899	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-100366-05			\$366,943	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-052302-21			\$373,859	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-008216-33			\$375,723	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-127408-01			\$381,792	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-127093-01			\$383,993	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

			UNIVERSITY OF CALIFORNIA, LOS ANGELES	1445 G UE023					
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859					\$387,437	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-133721-01			\$399,268	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-123233-01			\$402,157	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-119735-01			\$406,424	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-128794-01			\$410,367	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-116876-01A1			\$411,842	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-125959-01A1			\$413,809	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	4-R37-GM-051279-23			\$423,885	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-085146-09A1			\$426,130	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM080279-09			\$428,954	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-128903-01			\$434,933	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-118052-01			\$443,515	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-118048-01			\$448,798	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-007229-43			\$452,754	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-088156-06			\$460,874	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-128748-01			\$472,788	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-129781-01			\$477,652	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-113657-01			\$503,308	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-036477-33			\$508,562	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-122475-01			\$532,125	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-118090-01			\$537,262	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	4-R37-GM-056328-18			\$538,653	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-131680-01			\$542,597	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-121375-01			\$545,526	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-123056-01A1			\$549,764	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R01-GM-128096-01			\$550,444	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-130302-01			\$554,828	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-126950-01			\$555,755	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-131907-01			\$562,339	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-008076-35			\$563,802	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-R01-GM-098389-06			\$571,913	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-075766-11			\$621,449	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-122505-01			\$747,487	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1-R35-GM-131908-01			\$762,212	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-P01-GM-087253-11			\$931,364	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2-T32-GM-007170-44			\$2,574,172	\$41,295,880	RESEARCH AND DEVELOPMENT	\$710,017,793	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	4-R01-HD-049681-09			\$79,623	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	4-R01-HD-073221-04		\$2,325	\$2,325	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R21-HD-088941-01A1		\$11,080	\$93,602	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793	
<i>CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH</i>	<i>93.865</i>		<i>RESEARCH TRIANGLE INSTITUTE</i>	<i>MOU SUB TO U24HD095254</i>					
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-097686-01A1			\$12,867	\$340,343	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R21-HD-091330-01A1			\$13,365	\$316,379	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	7R21HD083628-02			\$14,455	\$96,733	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-U01-HD-087180-01			\$15,282	\$68,862	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-U01-HD-079475-01A1			\$19,554	\$1,016,309	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-079475-01A1			\$20,511	\$69,881	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	4-R01-HD-071920-05 PREFAIR			\$25,934	\$131,006	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-076279-01A1							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	ECTOPIC			\$40,484	\$107,170	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-089390-01A1			\$49,547	\$507,420	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R21-HD-093369-01			\$65,255	\$120,772	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-K12-HD-085848-01			\$86,663	\$567,571	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-075869-01A1			\$94,255	\$210,728	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-087485-01A1			\$129,574	\$320,520	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-P50-HD-068157-06A1			\$175,438	\$1,612,214	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-UG1-HD-068244-06			\$192,659	\$192,659	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-091350-01			\$225,185	\$524,941	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-087391-01A1			\$317,531	\$572,002	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-090082-01			\$464,492	\$949,075	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
<i>CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH</i>	<i>93.865</i>		<i>UNIVERSITY OF DELAWARE</i>	<i>44252</i>					
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R21-HD-094006-01				\$94,393	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	4-R01-HD-037507-18				\$2,815	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	4-R13-HD-074468-05				\$598	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	7-R03-HD-086497-03				\$350	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		<i>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</i>	<i>0255-3971-4609</i>					
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		<i>WASHINGTON UNIVERSITY IN ST. LOUIS</i>	<i>WU-18-39</i>					
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		<i>CHILDREN'S HOSPITAL OF PHILADELPHIA</i>	<i>321098 PO #961914RSUB</i>					
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865								
COVID-19 - CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R21-HD-091330-01A1				\$25	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

COVID-19 - CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-T32-HD-007242-36A1			\$500	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		RESEARCH TRIANGLE INSTITUTE	MOU SUB TO U10HD036790	\$923	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F31-HD-095579-01			\$1,586	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA	321098 (PO#962254 RSUB)	\$3,160	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		GEORGE WASHINGTON UNIVERSITY	SUB TO U10HD036801/MFMU TOPS	\$3,245	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		MEDIA REZ, LLC	UPO03	\$4,011	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		GEORGE WASHINGTON UNIVERSITY	SUB TO U10HD036801/MFMU40C PROSPECT	\$4,339	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	7-R00-HD-074649-05			\$5,226	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R13-HD-089669-01A1			\$6,000	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-U10-HD-027049-21			\$8,437	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		WASHINGTON UNIVERSITY IN ST. LOUIS	WU-15-54	\$9,078	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F31-HD-095583-01A1			\$11,988	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		JOHNS HOPKINS UNIVERSITY	2004462188	\$13,796	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201440523	\$15,161	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5106229	\$17,172	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF MICHIGAN	SUBK00012813	\$17,923	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF MICHIGAN	SUBK00010144	\$19,791	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5113143	\$20,288	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		MOSS REHABILITATION RESEARCH INSTITUTE	4934	\$20,361	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201340523	\$21,031	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5116605	\$22,560	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		COLUMBIA UNIVERSITY	4(GG011848-01)	\$27,220	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-076032-01A1			\$28,304	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F30-HD-098015-01			\$33,537	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		NORTHWESTERN UNIVERSITY	60046347 PENN	\$34,678	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF TEXAS AT AUSTIN	UTA20-000200	\$37,095	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F31-HD-098764-01			\$42,878	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		MEDICAL UNIVERSITY OF SOUTH CAROLINA	A00-2240-S004	\$44,640	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF MICHIGAN	SUBK00011494	\$44,888	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F30-HD-098803-01			\$50,140	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		YALE UNIVERSITY	GR107889 (CON-80002064)	\$50,326	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		WASHINGTON STATE UNIVERSITY	123853-G003469	\$50,490	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CENTRAL MICHIGAN UNIVERSITY	F63374	\$53,174	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA	8233030620	\$55,442	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-F32-HD-089623-01A1			\$57,549	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CAPRISA (CENTER FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA)	SUB TO 1-R01-HD083343	\$60,356	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5113142	\$61,342	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF PITTSBURGH	0061510 (1312261)	\$66,318	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-K99-HD-096115-01			\$67,194	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA	3200880522	\$68,524	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA	203661015-51	\$69,821	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201990721	\$73,681	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA	ACTIVITY 321098 (PO#961915RSUB)	\$84,749	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-K99-HD-098329-01			\$88,986	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-U01-HD-084007-01			\$90,629	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		JOHNS HOPKINS UNIVERSITY	2004123438	\$96,813	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		RESEARCH TRIANGLE INSTITUTE	PFDN CAPITATION FUNDING	\$100,845	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201860524	\$102,483	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		GEORGE WASHINGTON UNIVERSITY	SUB TO U10HD036801 (CMV)MFMU	\$115,516	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R21-HD087674-01			\$125,063	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		STATE UNIVERSITY OF NEW YORK CHILDREN'S HOSPITAL OF PHILADELPHIA	77545-1138238-2	\$136,329	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201250522	\$143,143	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		CHILDREN'S HOSPITAL OF PHILADELPHIA	3200830522	\$147,679	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		GEORGE WASHINGTON UNIVERSITY	SUB TO U10HD036801	\$148,312	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-086888-01			\$152,310	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		GEORGE WASHINGTON UNIVERSITY	SUB TO U10HD036801	\$153,436	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	7-R01-HD-079106-02			\$155,140	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-K23-HD-090272-01A1			\$161,393	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-K23-HD-084727-01A1			\$169,363	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R61-HD-101937-01A1			\$176,903	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-T32-HD-007242-36A1			\$275,190	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5106045	\$278,676	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-UG1-HD-069010-06			\$282,803	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-R01-HD-058730-06A1			\$289,370	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-UG1-HD-087192-01			\$290,359	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-T32-HD-083185-01			\$305,216	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1-R01-HD-092266-01			\$312,833	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-R01-HD-069592-06A1			\$327,785	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	K12-HD-001265			\$336,850	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	T32-HD-007440			\$418,212	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2-P2C-HD-044964-16			\$547,287	\$15,119,635	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	7-R01-AG-048388-03			\$2,879	\$192,440	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-RF1-AG-063481-01A1			\$8,432	\$347,895	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-049757-01A1			\$9,305	\$12,046	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-UF1-AG-047133-01			\$11,132	\$11,132	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-UF1-AG-047133-01				-\$350	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R56-AG-063344-01			\$16,844	\$358,381	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R03-AG-052117-01A1			\$19,428	\$19,428	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	2-P30-AG-034546-06			\$22,239	\$52,182	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R21-AG-053638-01A1			\$24,260	\$111,188	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-P30-AG-059302-01			\$27,060	\$758,629	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-064589-01			\$30,557	\$358,204	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-054521-01A1			\$32,465	\$487,866	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-UH2-AG-050311-01			\$37,220	\$243,636	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-062595-01			\$46,704	\$309,813	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	2-P01-AG-017586-16			\$47,533	\$1,930,816	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R56-AG-061867-01			\$60,445	\$397,994	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	2-P30-AG-034546-11			\$70,226	\$425,851	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	2-R01-AG-025152-11			\$98,253	\$421,795	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-056014-01			\$112,884	\$732,363	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	2-P30-AG-012836-21			\$165,000	\$471,952	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-054060-01			\$193,103	\$460,226	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-060115-01			\$210,877	\$386,799	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-061945-01			\$214,446	\$526,412	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-058718-01			\$220,465	\$435,667	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	7-R01-AG-049815-04			\$242,383	\$592,744	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-057501-01			\$243,909	\$678,898	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-RF1-AG-053951			\$272,457	\$593,624	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-U01-AG-061173-01			\$314,914	\$646,184	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	2-P01-AG-031862-11			\$833,557	\$2,076,061	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-U01-AG-052943-01			\$933,600	\$1,338,382	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-U54-AG-052427-01			\$1,175,681	\$2,972,781	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-054435-01A1			\$1,197,215	\$2,369,393	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	5-U01-AG-032984-07			\$1,219,901	\$3,468,840	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		VISITING NURSE SERVICE OF NEW YORK	4614	-\$384	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		BOSTON MEDICAL CENTER	SUB TO R01AG066892	\$48	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - AGING RESEARCH	93.866	1-R21-AG-052905-01			\$51	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - AGING RESEARCH	93.866	2-P01-AG-017586-16			\$227	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

COVID-19 - AGING RESEARCH	93.866	7-R01-AG-048388-03			\$262	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
COVID-19 - AGING RESEARCH	93.866	1-R01-AG-054435-01A1			\$537	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	4-R01-AG-043483-04			\$623	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA, SAN DIEGO	47180199	\$2,133	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		WAKE FOREST UNIVERSITY HEALTH SCIENCES	101720-114750	\$2,354	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF PITTSBURGH	AWD00000729 (133049-01)	\$3,822	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-065276-01			\$3,869	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		DUKE UNIVERSITY	1 (GG012937-01)	\$3,999	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001337	\$4,072	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		WAKE FOREST UNIVERSITY	101720-114751	\$5,876	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MISSOURI-COLUMBIA	C00065785-1	\$6,302	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-K99-AG-065500-01A1			\$6,717	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		BOSTON MEDICAL CENTER	5-U01-AG-023755-08	\$7,200	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1F31AG060672-01			\$8,418	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	110645C	\$9,765	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-F30-AG-058409-01			\$10,655	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R03-AG-053277-01			\$10,773	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		DUKE UNIVERSITY	A030456	\$11,197	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001347	\$11,236	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	2004442257	\$13,666	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		BROWN UNIVERSITY	00001384	\$14,312	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		DUKE UNIVERSITY	2036654	\$15,339	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		DUKE UNIVERSITY	2036653	\$16,031	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		CASE WESTERN RESERVE UNIVERSITY	RESS14121	\$18,715	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	NIH-Q22 A4 75697387	\$19,079	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		PENNSYLVANIA STATE UNIVERSITY	5714-UP-DHHS-01A1	\$19,724	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		OREGON HEALTH & SCIENCE UNIVERSITY	1014486_UPENN	\$20,011	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		STANFORD UNIVERSITY	61927487-133778	\$20,032	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001376	\$20,918	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	4-K24-AG-042765-03			\$21,087	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-F32-AG-056081-01			\$21,249	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	2K24AG047908-06			\$22,098	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	122133383	\$23,574	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF WASHINGTON	762205	\$26,393	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-000772	\$26,794	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R03-AG-055724-01			\$28,853	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-F30-AG-058317-01			\$28,895	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		ALBERT EINSTEIN COLLEGE OF MEDICINE, INC	SUB TO R01AG055527	\$29,978	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	2003755014	\$31,368	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	2004105740	\$32,860	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		MAYO CLINIC ROCHESTER	UOP-263134	\$33,122	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		DREXEL UNIVERSITY	800167	\$33,818	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-F31-AG-057171-01			\$34,621	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001173	\$35,044	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		DUKE UNIVERSITY	203-6989	\$36,719	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MARYLAND	1600268	\$37,392	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF TEXAS AT AUSTIN	UTA17-000231	\$38,592	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-1544-4609	\$39,124	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MARYLAND, BALTIMORE	1200011D REQUEST-2765	\$39,159	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF PITTSBURGH	0058745 131435-2	\$39,990	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC001222	\$40,082	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-F31-AG-063470-01A1			\$40,198	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-F32-AG-053036-01A1			\$40,518	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	79634962	\$43,020	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001202	\$43,951	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		CASE WESTERN RESERVE UNIVERSITY	RESS14122	\$44,748	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1R01AG065659-01			\$45,884	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		BOSTON UNIVERSITY	4500003108	\$46,578	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001233	\$47,098	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001049	\$48,339	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		STANFORD UNIVERSITY	61927487-133778	\$49,132	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-001223	\$50,449	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	117340690	\$55,576	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-F32-AG-060630-01A1			\$59,161	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		NATIONAL BUREAU OF ECONOMIC RESEARCH, INC.	41218.10.02.00_PENN	\$60,000	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-F32-AG-054032-01A1			\$62,500	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		BANNER HEALTH	0435-06-102819	\$64,701	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MICHIGAN	SUBK00007532	\$64,711	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		BRIGHAM AND WOMEN'S HOSPITAL	121337	\$67,648	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION	WEI-2015-17	\$68,875	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MICHIGAN	SUBK00009919	\$70,487	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	107888795	\$77,219	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF WASHINGTON	UWSC10653/BPO33606	\$80,474	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R21-AG-065854-01			\$82,829	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R56-AG-062665-01			\$84,310	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF WISCONSIN-MADISON	785K492	\$91,093	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		VANDERBILT UNIVERSITY	VUMC71547	\$91,205	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		WAKE FOREST UNIVERSITY	WFUHS 552702	\$93,404	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	107890382	\$96,419	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		CHILDREN'S HOSPITAL OF PHILADELPHIA	ACTIVITY # 3200620420	\$100,563	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	7-K23-AG-045338-05			\$101,033	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		BANNER HEALTH	0435-02-71562	\$101,138	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R21-AG-052905-01			\$103,184	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1U01AG066100-01			\$104,074	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		BANNER HEALTH	0435-06-08001	\$110,066	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		WAKE FOREST UNIVERSITY	WFUHS-551083	\$110,374	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		WAKE FOREST UNIVERSITY	WFUHS 112971	\$111,061	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-K01-AG-055691-01A1			\$119,570	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		INDIANA UNIVERSITY	IN4683234UPEN CS	\$120,248	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R56-AG-050620-01A1			\$122,153	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-K01-AG-064123-01			\$122,960	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R21-AG-055142-01A1			\$123,337	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-1544-4609	\$123,826	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		CASE WESTERN RESERVE UNIVERSITY	RESS14120	\$124,936	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		EMDRY UNIVERSITY	A175663	\$125,691	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		IFIT PROSTHETICS	SUB TO 2-SB1-AG-050430-06	\$126,906	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-K01-AG-061277-01			\$127,692	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		WAKE FOREST UNIVERSITY HEALTH SCIENCES	WFUHS 551083	\$129,070	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-K24-AG-055602-01			\$135,205	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-K08-AG-052572-01			\$146,217	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R56-AG-062293-01			\$146,388	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		BROWN UNIVERSITY	00001361	\$148,712	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R21-AG-051981-01A1			\$149,764	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R03-AG-063213-01			\$150,394	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-T32-AG-051090-01			\$155,323	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF SOUTHERN CALIFORNIA	105710197	\$168,272	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-047373-01			\$173,640	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-K24-AG-047908-01			\$176,013	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	2004028077	\$180,475	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		JOHNS HOPKINS UNIVERSITY	2003994874	\$197,653	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		ADVANCED MEDICAL ELECTRONICS	SUB TO 1R32AG049524	\$200,206	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF WASHINGTON	UWSC10172	\$200,937	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-062819-01A1			\$208,695	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		BRIGHAM AND WOMEN'S HOSPITAL	113049	\$212,196	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R01-AG-066114-01			\$215,220	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF WASHINGTON	UWSC10710	\$230,419	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		DUKE UNIVERSITY	2034990	\$230,719	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R21-AG-064618-01			\$232,017	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	4-R00-AG-056054-03			\$233,540	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-000516	\$234,130	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	2-U01-AG-032984-11			\$235,768	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793
AGING RESEARCH	93.866	1-R21-AG-047915-01A1			\$247,281	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	103875C		\$248,651	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-R21-AG-057380-01				\$259,837	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866		MAYO CLINIC ROCHESTER	PO #63788299		\$260,676	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	2-R01-AG-041099-04				\$264,102	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	7-K76-AG-057016-02				\$272,167	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-R21-AG-061784-01A1				\$275,919	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-P30-AG-064105-01				\$280,114	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-0P2-AG-067511-01				\$288,494	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1R01AG061447-01				\$295,465	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-R01-AG-066152-01				\$306,482	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-R01-AG-059763-01A1				\$344,257	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-R01-AG-060612-01A1				\$375,770	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866		COGNITION THERAPEUTICS, INC.	SUB TO R42AG052249		\$382,288	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-R01-AG-062140-01A1				\$431,013	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-R56-AG-058732-01A1				\$443,840	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-R01-AG-060975-01				\$445,366	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-R01-AG-055570-01				\$451,746	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	94095C		\$455,569	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-RF1-AG-058065-01				\$504,898	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-RF1-AG-057197-01A1				\$516,671	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	2-T32-AG-000255-21				\$526,853	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-RF1-AG-055477-01				\$531,514	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-R56-AG-061057-01				\$548,174	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-RF1-AG-054104-01				\$594,950	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-RF1-AG-054409-01				\$627,797	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866		NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION	WEI2015-14		\$690,941	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-R01-AG-055005-01				\$707,214	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866		UNIVERSITY OF MIAMI	SPC-000472		\$715,358	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-0P2-AG-067492-01				\$795,577	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1-R01-AG-054519-01A1				\$945,224	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	1U19AG062418-01A1				\$2,201,061	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	2-U24-AG-041689-06				\$2,387,199	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
AGING RESEARCH	93.866	P30-AG-010124				\$3,034,391	\$55,174,834	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867	2-R01-EY-014943-07				-\$14,454	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867	1-R01-EY-025287-01A1				\$16,171	\$512,103	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R21-EY-028998-01A1				\$44,194	\$240,533	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R21-EY-029776-01				\$87,254	\$194,419	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R01-EY-026972-01				\$99,736	\$385,356	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R01-EY-026525-01				\$104,479	\$247,595	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-017549-10				\$112,741	\$669,088	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R01-EY-030192-01				\$117,918	\$322,153	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-022070-05A1				\$197,042	\$449,676	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-015537-08A1				-\$32,975	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867		WASHINGTON UNIVERSITY IN ST. LOUIS	WU-16-125		-\$9,515	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867	2-R01-EY-010016-21A1				-\$618	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867		PENNSYLVANIA STATE UNIVERSITY	UPA023533		-\$212	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
COVID-19 - VISION RESEARCH	93.867	2-R01-EY-017549-10				\$45	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
COVID-19 - VISION RESEARCH	93.867	2-R01-EY-006855-34				\$143	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
COVID-19 - VISION RESEARCH	93.867		CHILDREN'S HOSPITAL OF PHILADELPHIA	3201360819		\$230	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
COVID-19 - VISION RESEARCH	93.867	2-R01-EY-105537-12A1				\$581	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
COVID-19 - VISION RESEARCH	93.867	2-R01-EY-013434-12A1				\$2,127	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867		JAEB CENTER FOR HEALTH RESEARCH	DRCR.NET		\$2,544	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	0255-3312-4605		\$3,394	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867		NANOSCOPE TECHNOLOGIES, LLC	N/A		\$3,931	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867		JOHNS HOPKINS UNIVERSITY	2004433095		\$4,700	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867		PENNSYLVANIA STATE UNIVERSITY	UPAEY023533		\$5,300	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867		JOHNS HOPKINS UNIVERSITY	2002565177		\$7,551	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867		NEW ENGLAND COLLEGE OF OPTOMETRY	3708-01-01-16UP		\$8,351	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867		UNIVERSITY OF TEXAS AT AUSTIN	UT17-000180		\$11,126	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867		UNIVERSITY OF FLORIDA	UFDSPO0010918		\$11,522	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867	1R01EY030227-01A1				\$13,805	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867	1-R21-EY-027562-01				\$16,590	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867	1-R21-EY-027047-01				\$17,260	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	
VISION RESEARCH	93.867		NEW YORK UNIVERSITY	SUB TO 1U10EY026869		\$19,597	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793	

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

		JAEB CENTER FOR HEALTH RESEARCH						
VISION RESEARCH	93.867		RESEARCH	EY 14231	\$27,086	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-F30-EY-029931-01A1			\$28,695	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-T32-EY-007035-36			\$31,591	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R21-EY-031338-01			\$33,279	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
		MASSACHUSETTS EYE AND EAR INSTITUTE						
VISION RESEARCH	93.867			2300165-01	\$36,266	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-026525-05			\$39,282	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
		CHILDREN'S HOSPITAL OF PHILADELPHIA						
VISION RESEARCH	93.867			3201580224	\$41,627	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867			15050678	\$50,101	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867			A031038	\$51,177	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
		BRIGHAM AND WOMEN'S HOSPITAL						
VISION RESEARCH	93.867			119243	\$56,351	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R21-EY-027936-01A1			\$67,785	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
		WASHINGTON UNIVERSITY IN ST. LOUIS						
VISION RESEARCH	93.867			WU-16-30	\$68,309	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867			61637952-131084	\$74,430	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
		UNIVERSITY OF SOUTHERN CALIFORNIA						
VISION RESEARCH	93.867			67228549	\$82,624	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-022411-05A1			\$105,910	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-T35-OD-010919-21			\$110,974	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
		UNIVERSITY OF WASHINGTON						
VISION RESEARCH	93.867			762671	\$111,085	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-006855-29			\$114,040	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-T32-EY-007035-41			\$119,286	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
		NORTHWESTERN UNIVERSITY						
VISION RESEARCH	93.867			SP0039783-PROJ0013665	\$120,645	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867			1(GG013355-01)	\$130,567	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R01-EY-024681-01A1			\$141,094	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
		MASSACHUSETTS EYE AND EAR INSTITUTE						
VISION RESEARCH	93.867			530636	\$141,098	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R21-EY-028273-01A1			\$143,492	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-K08-EY-029765-01A1			\$146,939	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1UG1EY030419-01			\$176,268	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-U10-EY-022879-01			\$205,623	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R21-EY-029091-01			\$211,198	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-K08-EY-025742-01			\$211,768	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R01-EY-024861-01			\$219,806	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-K23-EY-025729-01			\$247,459	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-K12-EY-015398-11A1			\$254,301	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-K08-EY-030163-01			\$255,539	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R21-EY-029826-01			\$261,164	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-020851-06			\$266,008	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-013434-12A1			\$308,981	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R01-EY-030599-01			\$315,237	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R01-EY-028601-01A1			\$349,234	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-019014-06A1			\$352,160	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-015240-13A1			\$358,051	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-006855-34			\$404,256	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-105537-12A1			\$404,417	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R01-EY-028916-01A1			\$413,923	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R01-EY-028571-01A1			\$417,740	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-R01-EY-022350-04A1			\$445,654	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R01-EY-023557-01			\$467,932	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	1-R01-EY-027205-01A1			\$577,746	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
VISION RESEARCH	93.867	2-P30-EY-001583-41			\$655,570	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
		CHILDREN'S HOSPITAL OF PHILADELPHIA						
VISION RESEARCH	93.867			3201360819	\$666,624	\$13,612,338	RESEARCH AND DEVELOPMENT	\$710,017,793
MEDICAL LIBRARY ASSISTANCE	93.879	2-R01-LM-011176-06A1			\$8,150	\$768,964	RESEARCH AND DEVELOPMENT	\$710,017,793
MEDICAL LIBRARY ASSISTANCE	93.879	1-R01-LM012601-01			\$55,137	\$638,566	RESEARCH AND DEVELOPMENT	\$710,017,793
MEDICAL LIBRARY ASSISTANCE	93.879	2-R01-LM-010098-10			\$79,013	\$400,159	RESEARCH AND DEVELOPMENT	\$710,017,793
MEDICAL LIBRARY ASSISTANCE	93.879			CNVA00050256 (132448-22)	\$11,715	\$2,611,336	RESEARCH AND DEVELOPMENT	\$710,017,793
		UNIVERSITY OF PITTSBURGH MEDSTAR HEALTH RESEARCH INSTITUTE						
MEDICAL LIBRARY ASSISTANCE	93.879			5001371840	\$20,047	\$2,611,336	RESEARCH AND DEVELOPMENT	\$710,017,793
MEDICAL LIBRARY ASSISTANCE	93.879	1-K99-LM-012926-01A1			\$69,626	\$2,611,336	RESEARCH AND DEVELOPMENT	\$710,017,793
MEDICAL LIBRARY ASSISTANCE	93.879	1-R21-LM-012763-01A1			\$74,499	\$2,611,336	RESEARCH AND DEVELOPMENT	\$710,017,793
MEDICAL LIBRARY ASSISTANCE	93.879	1-K01-LM-012870-01			\$138,777	\$2,611,336	RESEARCH AND DEVELOPMENT	\$710,017,793
		INDIANA UNIVERSITY						
MEDICAL LIBRARY ASSISTANCE	93.879			IN-4687289-UP	\$175,020	\$2,611,336	RESEARCH AND DEVELOPMENT	\$710,017,793
MEDICAL LIBRARY ASSISTANCE	93.879	1-R01-LM-012607-01			\$313,963	\$2,611,336	RESEARCH AND DEVELOPMENT	\$710,017,793
GRANTS FOR PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	1 UH1HP29964-01-00			\$5,220	\$195,831	RESEARCH AND DEVELOPMENT	\$710,017,793
GRANTS FOR PRIMARY CARE TRAINING AND ENHANCEMENT	93.884			MAYO CLINIC ROCHESTER THE-268163/PO #67322769	\$15,477	\$254,890	RESEARCH AND DEVELOPMENT	\$710,017,793
GRANTS FOR PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	1 T13HP32112-01-00			\$253,409	\$704,130	RESEARCH AND DEVELOPMENT	\$710,017,793
		CITY OF PHILADELPHIA						
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914			1720665-02/RW0965	\$23,716	\$1,456,463	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914			1720666-03/RS0944	\$35,850	\$1,456,463	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914			1720665-02/RW9965	\$48,271	\$1,456,463	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914			1720666-03/RW0866	\$50,282	\$1,456,463	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914			1720668-03/RW0969	\$50,540	\$1,456,463	OTHER PROGRAMS	\$15,539,552

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS**

Fiscal Period 7/1/2019 - 6/30/2020

HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720666-02/RS9944	\$63,665	\$1,456,463	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720668-03/RS0668	\$100,586	\$1,456,463	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720667-03	\$101,655	\$1,456,463	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720666-03/RW0968	\$102,381	\$1,456,463	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720666-02/RW9866	\$108,738	\$1,456,463	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720668-02/RW9866	\$119,019	\$1,456,463	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720667-02	\$211,902	\$1,456,463	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720666-02/RW9668	\$216,944	\$1,456,463	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914		CITY OF PHILADELPHIA	1720668-02/RW9668	\$222,914	\$1,456,463	OTHER PROGRAMS	\$15,539,552
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	H7CHA37319			\$38,152	\$672,632	OTHER PROGRAMS	\$15,539,552
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918		DREXEL UNIVERSITY	800100	\$41,312	\$672,632	OTHER PROGRAMS	\$15,539,552
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918		CITY OF PHILADELPHIA	1820058-02	\$75,000	\$672,632	OTHER PROGRAMS	\$15,539,552
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	H76HA00556			\$518,168	\$672,632	OTHER PROGRAMS	\$15,539,552
COOPERATIVE AGREEMENTS FOR STATE-BASED COMPREHENSIVE BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAMS	93.919		FAMILY HEALTH COUNCIL OF CENTRAL PA	4100066441	\$59,264	\$59,264	OTHER PROGRAMS	\$15,539,552
RYAN WHITE HIV/AIDS DENTAL REIMBURSEMENT AND COMMUNITY BASED DENTAL PARTNERSHIP GRANTS	93.924	1 T22HA336950100			\$19,745	\$19,745	OTHER PROGRAMS	\$15,539,552
REDUCING MORTALITY ATTRIBUTABLE TO CARDIAC ARREST AFTER INJURY: LEVERA	93.937	1-R03-HL-141521-01			\$17,132	\$74,329	RESEARCH AND DEVELOPMENT	\$710,017,793
ALVEOLAR EPITHELIAL CELL DYSFUNCTION IN PULMONARY FIBROSIS: LEVERAGING	93.937	1-R01-HL-145408-01A1			\$550,062	\$624,391	RESEARCH AND DEVELOPMENT	\$710,017,793
HIV EMERGENCY RELIEF PROJECT GRANTS	93.940		CITY OF PHILADELPHIA	1820469-02/CP0023	\$34,739	\$73,126	OTHER PROGRAMS	\$15,539,552
HIV EMERGENCY RELIEF PROJECT GRANTS	93.940		CITY OF PHILADELPHIA	1820469-01/CP9023	\$38,387	\$73,126	OTHER PROGRAMS	\$15,539,552
HIV DEMONSTRATION, RESEARCH, PUBLIC AND PROFESSIONAL EDUCATION PROJECTS	93.941		EMORY UNIVERSITY	T652427	\$13,511	\$13,511	RESEARCH AND DEVELOPMENT	\$710,017,793
ASSISTANCE PROGRAMS FOR CHRONIC DISEASE PREVENTION AND CONTROL	93.945		CROHN'S & COLITIS FOUNDATION OF AMERICA	1-U01-DP-006369-01-00	\$454,179	\$454,179	RESEARCH AND DEVELOPMENT	\$710,017,793
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958		ADAMS COUNTY, PENNSYLVANIA	SUB TO SAMHSA	\$19,132	\$312,373	OTHER PROGRAMS	\$15,539,552
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958		CITY OF PHILADELPHIA	1720597-003 SAMHSA-PERC	-\$3,287	\$1,056,915	OTHER PROGRAMS	\$15,539,552
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958		CITY OF PHILADELPHIA	PAC 0100-0294	\$254,118	\$1,056,915	OTHER PROGRAMS	\$15,539,552
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958		ADAMS COUNTY, PENNSYLVANIA	SUB TO SAMHSA	\$493,711	\$1,056,915	OTHER PROGRAMS	\$15,539,552
PPHF GERIATRIC EDUCATION CENTERS	93.969	1 U1QHP282720-01-00			\$5,867	\$88,116	OTHER PROGRAMS	\$15,539,552
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-R25-TW-009738-01			\$9,831	\$59,464	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-D43-TW-010448-01			\$24,221	\$467,350	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1R21TW011260-01			\$44,954	\$178,286	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.	25941	\$381	\$1,301,234	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		UNIVERSITY OF CONNECTICUT HEALTH CENTER	UCHC7-117322154	\$1,966	\$1,301,234	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		DUKE UNIVERSITY	3880535	\$3,980	\$1,301,234	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		DARTMOUTH-HITCHECOCK MEDICAL CENTER	GC10054-00-02	\$48,862	\$1,301,234	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		NEW YORK UNIVERSITY	1-R21-TW-011084-01	\$71,617	\$1,301,234	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-R21-TW-010837-01			\$77,491	\$1,301,234	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-R21-TW-011496-01A1			\$85,675	\$1,301,234	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-K01-TW-011190-01A1			\$99,814	\$1,301,234	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-D43-TW-009781-01			\$102,039	\$1,301,234	RESEARCH AND DEVELOPMENT	\$710,017,793
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1-K01-TW-011481-01			\$104,309	\$1,301,234	RESEARCH AND DEVELOPMENT	\$710,017,793
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994		SHADYSIDE HOSPITAL FOUNDATION	4100080264	\$100,861	\$729,748	OTHER PROGRAMS	\$15,539,552
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994		COMMONWEALTH OF PENNSYLVANIA	4100065681	\$178,887	\$729,748	OTHER PROGRAMS	\$15,539,552
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994		COMMONWEALTH OF PENNSYLVANIA	4100074035	\$450,000	\$729,748	OTHER PROGRAMS	\$15,539,552
CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES	93.RD	HHSN275201300020I			\$3,150	\$237,681	RESEARCH AND DEVELOPMENT	\$710,017,793
POPULATION HEALTH RESEARCH SUPPORT (START)	93.RD	HHSN275201800012I			\$5,734	\$11,905	RESEARCH AND DEVELOPMENT	\$710,017,793
CENTERS OF EXCELLENCE FOR PAIN EDUCATION (COEPE)	93.RD	HHSN271201500067C			\$6,031	\$26,923	RESEARCH AND DEVELOPMENT	\$710,017,793
METAGENOMIC AND WHOLE-GENOME SEQUENCING TO DEFINE RESISTOME EVOLUTION	93.RD	75D3 01 18C029 19			\$16,408	\$164,731	RESEARCH AND DEVELOPMENT	\$710,017,793
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY (AHRQ) REQUEST FOR PROPOSAL	93.RD	HHS2490201500051	ECRI	SUB TO HHS2490201500051	\$46,132	\$197,123	RESEARCH AND DEVELOPMENT	\$710,017,793
INTEGRATED INFORMATICS RESOURCES FOR EUKARYOTIC MICROBIAL PATHOGENS AN	93.RD	75N93019C00077			\$1,326,222	\$3,684,666	RESEARCH AND DEVELOPMENT	\$710,017,793
MRNA SYNTHESIS AND PURIFICATION FOR FLAVIVIRUS VACCINE A PHASE 1, SINGLE DOSE STUDY OF THE SAFETY AND VIROLOGIC EFFECT OF A H	93.RD	HHSN26100029	LEIDOS BIOMEDICAL RESEARCH, INC	16X273Q	-\$25,787	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793
OPTION 16C	93.RD	HHSN272201000049I	EMMES CORPORATION	VRC 607 SUB TO HHSN272201000049I	\$81	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793
CLINICAL EVALUATION OF NESTORONE (NES) AND TESTOSTERONE (T) COMBINATIO	93.RD	HHSN272201400005C	UNIVERSITY OF ROCHESTER	417173	\$871	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793
OPTION 16F	93.RD	HHSN275201300025I/HHSN27500006	UNIVERSITY OF WASHINGTON	UWSC11767	\$1,552	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793
	93.RD	HHSN272201400005C	UNIVERSITY OF ROCHESTER	417175	\$2,329	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793

**UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020**

ASSESSING AND TRAINING EVERYDAY FUNCTION IN OLDER ADULTS WITH THE VIRT	93.RD	(BLANK)	TEMPLE UNIVERSITY	SUB TO NIH ADV ACCT	\$6,032	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
PRESERVING CANCER STEM CELLS IN CANINE BLOOD SPECIMENS	93.RD	HHSN261200800001E	LEIDOS BIOMEDICAL RESEARCH, INC	18X011	\$6,698	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
DETECTION AND ANALYSIS OF ADVERSE EVENTS RELATED TO REGULATED PRODUCTS	93.RD	HHSF22320140030I	HARVARD PILGRIM HEALTH CARE	HHSF22320140030I	\$6,875	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
SECURE DATA MANAGEMENT SYSTEM TO FACILITATE PROSPECTIVE FOLLOW UP OF P	93.RD	HHSN261201400010/HHSN26100006	SOCIAL & SCIENTIFIC SYSTEMS, INC.	PHR-SS5-S-16-004996	\$7,250	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
SAFETY AND FEASIBILITY OF CULTIVATED AUTOLOGOUS LIMBAL EPITHELIAL CELL	93.RD	(BLANK)	JAEB CENTER FOR HEALTH RESEARCH	CALEC	\$8,192	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
A REUSABLE, GENERALIZABLE METHOD TO LINK HEALTH PLAN CLAIMS DATA WITH	93.RD	(BLANK)	HARVARD PILGRIM HEALTH CARE	HHSF223201710132C	\$12,047	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
HEALTH ECONOMICS OF SUBSTANCE USE DISORDER, HCV, AND HIV TREATMENT: EV	93.RD	(BLANK)	WEILL CORNELL MEDICAL COLLEGE	SUB TO NIH ADV ACCT	\$16,537	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
EVALUATION OF SDG AS COUNTERMEASURE TO RADIATION-INDUCED LUNG DAMAGE	93.RD	HHSN27220150000	LIGNAMED	LGM-2605	\$16,992	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA FOR WILLIAM LA CAVA	93.RD	IPA AGREEMENT	JAEB CENTER FOR HEALTH RESEARCH	N/A	\$19,237	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
CONTRACTOR SERVICES - FEDERAL	93.RD	N/A	JAEB CENTER FOR HEALTH RESEARCH	N/A	\$34,587	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
UTILIZATION OF DATA INDICATORS IN THE ESRD SURVEY PROCESS	93.RD	HHSN-500-2016-00085C	UNIVERSITY OF MICHIGAN	SUBK00011951	\$35,283	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
IPA FOR HAOCHANG SHOU	93.RD	IPA	UNIVERSITY OF MICHIGAN	SUBK00011951	\$39,673	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
CIRCULATING ANTIBODIES TO ORAL MICROBIOTA AND COLON CANCER RISK	93.RD	(BLANK)	TUFTS UNIVERSITY	N/A	\$41,948	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
BACTERIAL INTERFERENCE TO PREVENT STAPHYLOCOCCUS AUREUS INFECTION	93.RD	(BLANK)	CHILDREN'S HOSPITAL OF PHILADELPHIA	3201270822	\$45,963	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
ASSESSMENT OF CONTINUED OPIOID EFFICACY IN PATIENTS ON CHRONIC OPIOIDS	93.RD	HHSF223201710131C	UNIVERSITY OF MICHIGAN	SUBK00011951	\$49,545	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
PK AND SAFETY OF COMMONLY USED DRUGS IN LACTATING WOMEN AND BREASTFED	93.RD	HHSN- 275201000003I	DUKE UNIVERSITY	T051 / SUB TO HHSN-275201000003I	\$65,514	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
EARLY MARKERS OF ALZHEIMER'S DISEASE (AD) IN BLSA PARTICIPANTS - STRUC	93.RD	HHSN271201600059C	UNIVERSITY OF MICHIGAN	SUBK00011951	\$85,128	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
PROMOTING AND SUPPORTING INNOVATION IN TANF DATA	93.RD	HHSF233201500059I	MDRC	HHSF23337005T	\$126,226	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
DEVELOPING ASSAYS TO CHARACTERIZE ANTIBODIES ELICITED BY NEW UNIVERSAL	93.RD	HHSN272201400005C	UNIVERSITY OF ROCHESTER	417638G/UR FAO GRS10969	\$126,622	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
CEIRS OPTION 16C EA "HT" (2018-20)	93.RD	HHSN272201400005C	UNIVERSITY OF ROCHESTER	417427G/UR FAO GRS10845	\$143,495	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
VALIDATION OF SERIOUS INFECTIONS AMONG AN IMMUNOCOMPROMISED POPULATION	93.RD	HHSF22301002T	HARVARD PILGRIM HEALTH CARE	SUB TO HHSF22301002T	\$147,637	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
COVID-19 - A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SA	93.RD	75N91019D00024	LEIDOS BIOMEDICAL RESEARCH, INC	20CTA-DM0009	\$167,128	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
PAN-INFLUENZA MRNA VACCINE	93.RD	HHSN272201400006C	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	112106011-7856437	\$172,521	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
QUANTITATIVE ANALYSIS OF LONGITUDINAL MR IMAGES IN BLSA PARTICIPANTS	93.RD	75N95019C00022	UNIVERSITY OF MICHIGAN	SUBK00011951	\$203,468	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
CLINICAL EVALUATION OF NOVEL PRODUCTS FOR FEMALE CONTRACEPTION (MAIN 5	93.RD	HHSN275201300020I	UNIVERSITY OF ROCHESTER	417428G/GRS10848	\$219,025	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
CEIRS OPTION 16C EA "HSH" (2018-20)	93.RD	HHSN272201400005C	UNIVERSITY OF ROCHESTER	417428G/GRS10848	\$251,760	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
CEIRS OPTION 12 (2018-19)	93.RD	HHSN272201400005C	UNIVERSITY OF ROCHESTER	417427G/UR FAD GRS10845	\$353,538	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
A SCALABLE, PATIENT-CENTERED APPROACH FOR "RIGHT-SIZING" OPIOID PRESCR	93.RD	HHSF223201810209C	UNIVERSITY OF MICHIGAN	SUBK00011951	\$370,051	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
ASSESSMENT OF THE EFFICACY OF ACUTE PAIN TREATMENTS: AN RTC RE-ANALYSI	93.RD	75F40119C10099	UNIVERSITY OF MICHIGAN	SUBK00011951	\$457,458	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
CIVICS COMPONENT A	93.RD	75N93019C00050	DUKE UNIVERSITY	A032640	\$531,595	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
KENTUCKY HEALTH ANALYSIS	93.RD	FAP111-44-00	COMMONWEALTH OF KENTUCKY	FAP111-44-00	\$592,268	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
PRECLINICAL VECTOR PRODUCTION CORE LABORATORY	93.RD	75N92019D00016	UNIVERSITY OF MICHIGAN	SUBK00011951	\$637,636	\$9,300,004	RESEARCH AND DEVELOPMENT	\$710,017,793	
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES					\$61,163,974	\$616,322,577			
CORPORATION FOR NATIONAL AND COMMUNITY SERVICE									
AMERICORPS	94.006		COMMONWEALTH OF PENNSYLVANIA	4100084201	\$25	\$109,614	\$142,043	OTHER PROGRAMS	\$15,539,552
AMERICORPS	94.006		COMMONWEALTH OF PENNSYLVANIA	4100081392		\$32,429	\$142,043	OTHER PROGRAMS	\$15,539,552
COVID-19 - VOLUNTEERS IN SERVICE TO AMERICA	94.013	18VSAPA005				\$1,271	\$714,378	OTHER PROGRAMS	\$15,539,552
VOLUNTEERS IN SERVICE TO AMERICA	94.013	18VSAPA005				\$335,077	\$714,378	OTHER PROGRAMS	\$15,539,552
VOLUNTEERS IN SERVICE TO AMERICA	94.013	18VSAPA005				\$378,030	\$714,378	OTHER PROGRAMS	\$15,539,552
PFS PROJECT	94.RD	2016-2019	THIRD SECTOR CAPITAL PARTNERS	N/A		-\$791	-\$791	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL CORPORATION FOR NATIONAL AND COMMUNITY SERVICE						\$25	\$855,630		
SOCIAL SECURITY ADMINISTRATION									
SOCIAL SECURITY RESEARCH AND DEMONSTRATION	96.007		UNIVERSITY OF WISCONSIN-MADISON	0000000419		\$73,580	\$180,272	RESEARCH AND DEVELOPMENT	\$710,017,793

UNIVERSITY OF PENNSYLVANIA
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 7/1/2019 - 6/30/2020

<i>SOCIAL SECURITY RESEARCH AND DEMONSTRATION</i>	96.007		<i>UNIVERSITY OF MICHIGAN</i>	<i>SUBK00011189</i>	\$106,692	\$180,272	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL SOCIAL SECURITY ADMINISTRATION					<u>\$180,272</u>			
DEPARTMENT OF HOMELAND SECURITY								
EVALUATING THE PRIVATE FLOOD INSURANCE MARKET	97.RD	HSHQDC-17-C-B0032			\$321,893	\$321,893	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL DEPARTMENT OF HOMELAND SECURITY					<u>\$321,893</u>			
U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT								
<i>OPTIMIZATION OF AUTOPHAGY INHIBITION AS A CLINICAL TARGET FOR BRAIN TUMOR</i>	98.853		<i>UNIVERSITY OF COLORADO DENVER</i>	<i>FY19.996.001</i>	\$7,968	\$7,968	RESEARCH AND DEVELOPMENT	\$710,017,793
TOTAL U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT					<u>\$7,968</u>			
TOTAL EXPENDITURE OF FEDERAL AWARDS					<u>\$82,598,019</u>	<u>\$978,490,559</u>		

Please Note:

Italicized award lines indicate pass-through funding

University of Pennsylvania
Notes to Schedule of Expenditures of Federal Awards
June 30, 2020

1. Basis of Presentation

The Schedule of Expenditures of Federal Awards (the “Schedule”) has been prepared to present a summary of those activities of the University of Pennsylvania for the year ended June 30, 2020, which have been financed by the U.S. Government (“Federal awards”) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance).

For purposes of the Schedule, Federal awards include all Federal assistance entered into directly between the University of Pennsylvania and the Federal government and sub-awards from non-Federal organizations made under federally sponsored agreements. Because the Schedule presents only a selected portion of the activities of the University of Pennsylvania, it is not intended to and does not present the financial position or the revenues, expenses or changes in net assets of the University of Pennsylvania.

The University applies its predetermined approved facilities and administrative rate when charging indirect costs to federal awards rather than the 10% de minimis cost rate as described in Section 200.414 of the Uniform Guidance.

Negative amounts on the schedule represent adjustments in the normal course of business to amounts reported in previous years. Catalog of Federal Domestic Assistance (“CFDA”) and pass-through award numbers are present where available.

2. Federal Student Financial Assistance

The federal student loan programs included within the Student Financial Aid Cluster on the Schedule of Expenditures of Federal Awards above, with the exception of Federal Direct Loans, are administered directly by the University and balances and transactions relating to these programs are included in the University’s consolidated financial statements. Loans outstanding at the beginning of the year and loans made during the year are included in the federal expenditures presented in the Schedule. The amounts of Federal Loans outstanding at June 30, 2020 are shown on below.

Federal Grantor/Program	CFDA Number	Outstanding Balance as of 6/30/2020
Department of Education		
Perkins Loan	84.038	27,312,446
Department of Health and Human Services		
Health Professions Student Loans - Dental	93.342	9,319,464
Health Professions Student Loans - Medical	93.342	165,278
Health Professions Student Loans - Vet	93.342	2,775,204
Loans for Disadvantaged Students - Dental	93.342	3,243
Loans for Disadvantaged Students - Medical	93.342	2,145,750
Nursing Student Loan - Graduate	93.364	417,050
Nurse Faculty Loan Program	93.264	2,212,888
Nursing Student Loan - Undergraduate	93.364	2,770,248

II. Internal Control and Compliance



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

To the Trustees of the University of Pennsylvania:

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of the University of Pennsylvania ("the University"), which comprise the consolidated statement of financial position as of June 30, 2020, and the related consolidated statements of activities and of cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 7, 2020, which includes an emphasis of matter paragraph as the University changed the manner in which it accounts for leases.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the University's internal control over financial reporting ("internal control") as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

A handwritten signature in cursive script that reads "PricewaterhouseCoopers LLP".

Philadelphia, Pennsylvania
October 7, 2020



**Report of Independent Auditors on Compliance with Requirements
That Could Have a Direct and Material Effect on Each Major Program and on Internal
Control Over Compliance in Accordance with the Uniform Guidance**

To the Trustees of the University of Pennsylvania:

Report on Compliance for Each Major Federal Program

We have audited the University of Pennsylvania’s (the “University”) compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of the University’s major federal programs for the year ended June 30, 2020. The University’s major federal programs are identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs.

Management’s Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditors’ Responsibility

Our responsibility is to express an opinion on compliance for each of the University’s major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the University’s compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the University’s compliance.

Opinion on Each Major Federal Program

In our opinion, the University complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2020.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule



of findings and questioned costs as item 2020-001. Our opinion on each major federal program is not modified with respect to this matter.

The University's response to the noncompliance finding identified in our audit is described in the accompanying Management's View and Corrective Action Plan. The University's response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control over Compliance

Management of the University is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the University's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the University's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Philadelphia, Pennsylvania
February 5, 2021

III. Schedule of Findings and Questioned Costs

University of Pennsylvania
Schedule of Findings and Questioned Costs
June 30, 2020

Section I – Summary of Auditor’s Results

Consolidated Financial Statements

- (i) Type of auditor’s report issued: Unmodified
- (ii) Internal control over financial reporting:
 Material weakness(es) identified? ___ yes X no
 Significant deficiency(ies) identified that are not considered to be material weaknesses? ___ yes X none reported
- (iii) Noncompliance material to financial statements noted? ___ yes X no

Federal Awards

- (iv) Internal control over major programs:
 Material weakness(es) identified? ___ yes X no
 Significant deficiency(ies) identified that are not considered to be material weaknesses? ___ yes X none reported
- (v) Type of auditor’s report issued on compliance for major programs: Unmodified
- (vi) Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? X yes ___ no
- (vii) Identification of major programs:

CFDA Number(s)	Name of Federal Program or Cluster
Various	Research and Development Cluster
84.287	Twenty-First Century Community Learning Centers

- (viii) Dollar threshold used to distinguish between Type A and Type B programs: \$3,000,000
- (ix) Auditee qualified as low-risk auditee? X yes ___ no

Section II – Financial Statement Findings

None noted.

**University of Pennsylvania
Schedule of Findings and Questioned Costs
June 30, 2020**

Section III – Federal Awards Findings and Questioned Costs

Finding 2020-001 Cash Management

Grantor: National Institute of Aging, National Institute of Health (NIH), Department of Health and Human Services (DHHS); National Institute of Diabetes and Digestive and Kidney Diseases, NIH, DHHS; National Center for Advancing Translational Sciences, NIH, DHHS; National Cancer Institute, NIH, DHHS; National Science Foundation; Department of Education

Program: Research and Development Cluster; Twenty-First Century Community Learning Centers

CFDA#: 93.866; 93.847; 93.350; 93.397; 47.041; 84.287

Title: Coordinating Center for Genetics and Genomics of Alzheimer's Disease (CGAD); Penn integrated Human Pancreas procurement and Analysis Program; Institutional Clinical and Translational Science Award; Abramson Cancer Center Support Grant; Science and Technology Center for Mechano-Biology; Twenty-First Century Community Learning Centers

Award Year: 07/1/2019 – 06/30/2020

Award Number: 1-U54-AG-052427-01; 1-UC4-DK-112217-01; 1-UL1-TR-001879-01; 2-P30-CA-016520-40; CMMI-1548571; 4100068078; FC #4100071658; SUB TO S287C170038

Criteria

2 CFR 200.305 (b3): Reimbursement is the preferred method when the requirements in paragraph (b) cannot be met, when the Federal awarding agency sets a specific condition per §200.207 Specific conditions, or when the non-Federal entity requests payment by reimbursement.

Per the OMB Compliance Supplement, the non-Federal entity must disburse funds for program purposes before requesting payment from the Federal awarding agency or pass-through entity.

Condition

In testing compliance with the cash management compliance requirement, specifically the reimbursement-method, 40 individual expenditures were tested to compare the date the University made payment to a vendor for a selected expense transaction to the date the University requested sponsor reimbursement for the same transaction. Twenty-six instances were noted in which the University paid the vendor after requesting and receiving reimbursement from the government, as shown in the chart below.

CFDA Number	Award Number	Expenditure Amount	Date of Payment to Vendor	Date of Government Reimbursement	Days Variance
47.041	CMMI-1548571	107,785	9/6/2019	8/16/2019	21
47.041	CMMI-1548571	100,251	11/12/2019	10/29/2019	14
93.866	1-U54-AG-052427-01	48,661	3/13/2020	2/19/2020	23
93.847	1-UC4-DK-112217-01	18,067	2/6/2020	1/16/2020	21
47.041	CMMI-1548571	30,205	11/14/2019	10/22/2019	23
93.866	1-U54-AG-052427-01	24,836	12/16/2019	12/11/2019	5
47.041	CMMI-1548571	22,175	9/4/2019	8/28/2019	7
93.866	1-U54-AG-052427-01	17,472	9/19/2019	9/12/2019	7
93.866	1-U54-AG-052427-01	16,014	2/14/2020	1/8/2020	37
93.847	1-UC4-DK-112217-01	14,940	10/25/2019	9/18/2019	37
93.397	2-P30-CA-016520-40	12,482	10/15/2019	9/24/2019	21
93.847	1-UC4-DK-112217-01	12,072	10/15/2019	9/24/2019	21
93.397	2-P30-CA-016520-40	6,143	10/3/2019	9/18/2019	15
93.866	1-U54-AG-052427-01	4,210	3/24/2020	3/16/2020	8
93.866	1-U54-AG-052427-01	21,802	7/24/2019	7/23/2019	1

**University of Pennsylvania
Schedule of Findings and Questioned Costs
June 30, 2020**

93.847	1-UC4-DK-112217-01	11,636	8/27/2019	7/30/2019	28
47.041	CMMI-1548571	70	10/11/2019	9/9/2019	32
93.350	1-UL1-TR-001879-01	91	1/2/2020	12/11/2019	22
93.397	2-P30-CA-016520-40	1,600	5/12/2020	4/15/2020	27
84.287	SUB TO S287C170038	228	9/6/2019	8/12/2019	25
84.287	4100068078	150	12/5/2019	12/1/2019	4
84.287	4100068078	10,500	11/22/2019	10/29/2019	24
84.287	4100068078	2,000	11/6/2019	10/29/2019	8
84.287	SUB TO S287C170038	1,410	9/13/2019	9/10/2019	3
84.287	FC #4100071658	390	4/17/2020	4/3/2020	14
84.287	SUB TO S287C170038	228	9/6/2019	8/12/2019	25

This is a repeat of finding 2019-001, 2018-002 and 2017-002 in prior year audit reports.

Cause

Management's current process to ensure that the reimbursement of expenditures occurs only after paying the vendor utilizes the assumption that vendors will be paid within 30 days, on average, of incurring the expense.

Effect

The University received Federal reimbursement prior to paying the vendors for the selected expenses. The reliance of the 30 day average time-frame allowed certain expenditures to be included in requests for reimbursement prior to being liquidated.

Questioned Costs

None as reimbursement was request for allowable costs

Recommendation

The University should revisit existing internal control procedures to ensure expenditures are paid in compliance with the Federal reimbursement requirements. We also recommend management discuss current cash management requirements with the OMB and the University's cognizant agency to determine a solution that meets the needs of both parties.

Management's View and Corrective Action Plan

Following these findings are management's view and corrective action plan.

University of Pennsylvania
Summary Schedule of Prior Audit Findings
June 30, 2020

Section IV – Summary Schedule of Prior Audit Findings

Finding 2019-001 Cash Management

Grantor: National Science Foundation (NSF), Directorate for Biological Sciences; Department of Health and Human Services (DHHS), National Institute of Health (NIH), National Center for Advancing Translational Sciences; DHHS, NIH, National Institute on Minority Health and Health Disparities; DHHS, NIH, National Institute on Aging; DHHS, NIH, National Cancer Institute; DHHS, NIH, National Institute of Allergy and Infectious Diseases

Program: Research and Development Cluster

CFDA#: 47.041, 93.350, 93.307, 93.866, 93.397, 93.855

Title: Science and Technology Center for Mechano-Biology; Institutional Clinical and Translational Science Award; Reducing HIV vulnerability through a multilevel life skills intervention for adolescent men; Epigenetics of Aging and Age-Associated Diseases; Alzheimer's Disease Genetics Consortium; Abramson Cancer Center Support Grant; Targeting Blys/Baff in Non-Human Primate Islet Transplantation

Award Year: 07/1/2018 – 06/30/2019

Award Number: CMMI-1548571; 5-UL1-TR-001878-03; 5-U01-MD-011274-03; 5-P01-AG-031862-12; 5-U01-AG-032984-09; 5-P30-CA-016520-42; 1-U01-AI-102430-01

Summary

Per the OMB Compliance Supplement, the non-Federal entity must disburse funds for program purposes before requesting payment from the Federal awarding agency or pass-through entity. In testing conformity with the cash management reimbursement-method, 40 individual expenditures were tested to compare the date of University payment to the vendor to the date of Government reimbursement to the University. Twelve instances were noted in which the University paid the vendor after requesting and receiving reimbursement from the government.

Status Update

The University continues to follow and believes it is in compliance with the cash management regulations as written in 2 CFR Part 200.305(b) which require the organization to minimize the time lapse between request for reimbursement from sponsoring agencies and vendor payment.

The University will continue to monitor the OMB interpretation of the Cash Management requirements until a resolution by OMB or change to the requirement in the Compliance Supplement has been reached.

In addition, the Director of Cost Analysis in the Office of Research Services actively reached out to PMS/DHHS from January through July 2020 on a monthly basis to discuss a resolution to cash management audit findings from previous years and to obtain a management decision. As of the date of this audit report, the University of Pennsylvania is still awaiting a response from PMS.

**University of Pennsylvania
Summary Schedule of Prior Audit Findings
June 30, 2020**

Finding 2019-002 Period of Performance

Grantor: Department of Health and Human Services, National Institute of Allergy and Infectious Diseases; Department of Health and Human Services, National Institute of Neurological Disorders and Stroke
Program: Research and Development Cluster
CFDA#: 93.855; 93.853
Title: Targeting Blys/Baff in Non-Human Primate Islet Transplantation; Paraneoplastic Disorders of the CNS: Autoantigen Profiling
Award Year: 07/1/2018 – 06/30/2019
Award Number: 4-U01-AI-102430-05; 5-R01-NS-077851-08

Summary

Of twenty-five awards tested with a period of performance ending within the fiscal year, one award was noted with an expense totaling \$1,148 in which the invoice date of 8/27/2018 was after the award period end date of 7/31/2018. Additionally, one award was noted with an expense totaling \$84,459 in which the University paid the vendor on 1/8/2019, which was 161 days after the award period end date of 7/31/2018.

Status Update

The questioned cost of \$1,148 on award 4-U01-AI-102430-05 was removed from the fund and refunded to the sponsor in March 2020, and the department was instructed on the period of performance compliance standard. Following the issuance of the FY19 audit report, the Period of Performance finding was also discussed in the Research Shared Governance Board meeting among school representatives.

University of Pennsylvania
Summary Schedule of Prior Audit Findings
June 30, 2020

2019-003 Eligibility

Grantor: Department of Health and Human Services, Pass-through City of Philadelphia, AIDS Activity Coordinating Office (AACO)

Program: Ryan White HIV/AIDS

Title: HIV Emergency Relief Project Grants

CFDA: 93.914

Award Year: 2018-2019, 2019-2020

Award Number: 1720668-01 (RW8668, RW8969); 1720668-02 (RW9668, RW9969)

Summary

Health Resources and Services Administration of the Department of Health and Human Services standards require service providers who receive Ryan White funding to screen clients and collect documentation to support the patient's eligibility for Ryan White funded services, including but not limited to an HIV positive diagnosis, identity, residency, insurance status, and income level. These requirements were sent to the University of Pennsylvania ("the University") by the City of Philadelphia as part of its contract to provide services. For the AACO Medical awards, 3 of a sample of 60 patient files selected for eligibility testing did not contain sufficient evidence of income level to support the Provider's eligibility determination.

Status Update

Since the prior year audit, the clinic staff, especially the social workers performing Ryan White certifications, have worked to improve awareness, training and processes to retain Ryan White eligibility documentation in patient files.



Office of Research Services

Management View and Corrective Action Plan

Finding 2020-001 Cash Management

Grantor: National Institute of Aging, National Institute of Health (NIH), Department of Health and Human Services (DHHS); National Institute of Diabetes and Digestive and Kidney Diseases, NIH, DHHS; National Center for Advancing Translational Sciences, NIH, DHHS; National Cancer Institute, NIH, DHHS; National Science Foundation; Department of Education

Program: Research and Development Cluster; Twenty-First Century Community Learning Centers

CFDA#: 93.866; 93.847; 93.350; 93.397; 47.041; 84.287

Title: Coordinating Center for Genetics and Genomics of Alzheimer's Disease (CGAD); Penn integrated Human Pancreas procurement and Analysis Program; Institutional Clinical and Translational Science Award; Abramson Cancer Center Support Grant; Science and Technology Center for Mechano-Biology; Twenty-First Century Community Learning Centers

Award Year: 07/1/2019 – 06/30/2020

Award Number: 1-U54-AG-052427-01; 1-UC4-DK-112217-01; 1-UL1-TR-001879-01; 2-P30-CA-016520-40; CMMI-1548571; 4100068078; FC #4100071658; SUB TO S287C170038

The University is currently following and believes it is in compliance with the cash management regulations as written in 2 CFR Part 200.305(b) which require the organization to minimize the time lapse between request for reimbursement from sponsoring agencies and vendor payment.


We understand that variations remain in the interpretation of the cash management compliance requirement. For example, on October 20, 2017, the Council On Governmental Relations (COGR) wrote a letter to the Office of Financial Management expressing concern that the cash management requirement language in the 2017 Compliance Supplement was not aligned with the requirements for cash management as currently written in 2 CFR Part 200.305(b). COGR's position is that the Compliance Supplement should be revised to conform with the cash management requirements as written in 2 CFR 200.305(b). The University agrees with COGR's position and believes the language in the Compliance supplement leads to an unrealistic and unreasonable administrative burden for universities and possibly a reconfiguration of smoothly running electronic process or a complete replacement of electronic processes with an inefficient, manual one in efforts to ensure each vendor has been paid prior to requesting reimbursement from the sponsoring agency.

The University will continue to monitor the OMB interpretation of the Cash Management requirements. If there is no resolution by OMB or change to the requirement in the Compliance Supplement we will work with our cognizant agency to arrive at a solution that fits the interests of all parties. During 2020, the Director of Cost Analysis in the Office of Research Services (ORS) repeatedly contacted PMS/DHHS to discuss a resolution to cash management audit findings from previous years and to obtain a management decision but has yet to receive a response. ORS will continue to seek Management Decision letters from PMS on the cash management findings.

Again, for FY20, we note that these only relate to payables transactions. Payables account for approximately 20% of costs across all federal awards (the other 80% of costs are payroll and fringe,

indirect costs, and other internal billings and journals for which cash management is not an issue). Also, the payments identified as exceptions in the audit were all made to vendors within our institutional standard terms of net 45 days.

Lastly, for the cash management exceptions related to the Twenty-First Century Community Learning Centers program, we note that although the University of Pennsylvania requested reimbursement from the non-federal prime sponsor prior to issuing payment on the vendor invoices, we received the reimbursements well after the vendor invoices were paid.



Elizabeth D. Peloso

Associate Vice President / Associate Vice Provost Research Services

epeloso@upenn.edu

215-898-7293